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Calvin and Hobbs, by Bill Watterson 
Abstract 1 
The proportion of the world population aged over 60 yrs is steadily increasing. Non-2 
communicable disease and cognitive decline are prevalent in the elderly population 3 
which present a significant burden for national health care systems and economies. 4 
Malnutrition is prevalent in many longterm care unit-residing older people and 5 
importantly, it is also common among community-living elderly people. The 6 
deficiency in the aged population in certain nutrients, such as vitamins and proteins, 7 
may be associated with dementia and loss of bone and muscular health. Importantly, 8 
frailty that is accompanied by sarcopenia (i.e. deregulation of muscular homeostasis) 9 
is prevalent among older adults and may gradually lead to functional disability. 10 
Many studies have shown the importance of dietary management of aged-related 11 
conditions.  12 
In the last decade, our knowledge of the importance of the gut microbiota in health 13 
and disease has significantly increased. Importantly, shifts in the composition and 14 
diversity of the gut microbiota of older people compared to healthy young adults are 15 
being identified and associated with ageing and age-related conditions, such as 16 
frailty. Similarly to other conditions for which gut microbiota modulation may lead 17 
to significant improvement of health, microbiota modulation may be a novel strategy 18 
for preventing or ameliorating ageing. This proposed gut microbiota modulation 19 
could be achieved through the use of prebiotics, probiotics or live bacteriotherapy 20 
among others. Importantly, diet can be a means of general (not targeted) gut 21 
microbiota modulation due to its documented significance in the shaping of the gut 22 
microbiota and to the fact that common dietary components may be a source of novel 23 
prebiotics.  24 
xxvii 
 
In the ElderFood project, we investigated the prebiotic potential of milk and milk-25 
derived components to modulate the gut microbiota of older subjects. Using in vitro 26 
and in vivo colon models, we generated an in-depth insight into the effect of 27 
glycomacropeptide (GMP), a milk-derived peptide that contains mucin-type glycans, 28 
and milk (whole and lactose free) on the elderly gut microbiota. We also performed 29 
exploratory work for the investigation of fibre and polyphenol-rich foods on the 30 
elderly gut microbiota and on artificial bacterial communities. The use of artificial 31 
bacterial communities can increase our understanding of the microbiota dynamics 32 
and how microbiota members respond to diet. 33 
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1 Chapter 1 – Literature Review 
 
 
Chapter 1 34 
Literature Review  35 
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1.1 From birth to old age: Factors that shape the human gut 36 
microbiome 37 
 
Chapter 1 was published as a book chapter:  38 
Ntemiri, A., Stanton, C., Ross, R. P., O’Toole, P. W. From birth to old age: Factors 39 
that shape the human gut microbiome. In “The Human Microbiome Handbook” 40 
Tetro JA, Allen-Vercoe E, eds. Lancaster, PA, 2016. pp 35-72.   41 
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1.1.1 Abstract 42 
The term microbiome generally refers to the microbiota and the collective genetic 43 
information those organisms carry. This genetic information supplements the 44 
genomic and metabolic potential of the host. A common approach to analysing the 45 
microbiome is to monitor compositional and functional changes in the microbiota 46 
and then attempting to correlate those changes with health or disease symptoms. This 47 
is usually a prelude to attempting to identify mechanisms and effectors. 48 
Largely based on culture-independent techniques, the core composition of the 49 
intestinal microbiota has recently been identified. The same phyla, taxa and genera 50 
are generally found in the microbiota of the gastrointestinal tract of humans 51 
irrespective of the condition of the subjects under testing, that is, healthy or non-52 
healthy young or older subjects. Thus, selective pressure and co-evolution between 53 
the host and the intestinal commensals have apparently established a functionally 54 
stable microbiota composition in the gut. Differences in the relative abundance of 55 
bacterial subgroups in the gut microbiota, i.e. dysbiosis, indicate changes in the 56 
health status of the host, or major environmental perturbations such as diet or 57 
antibiotics.  58 
The changes in the microbiota from early colonisation events to those that occur 59 
during ageing are summarised here. Habitual diet is postulated to be the most 60 
determinative factor in shaping the human gut microbiome. “Westernised diet” has 61 
been identified as a major link between nutrient and gut microbiota signalling, 62 
inflammation and metabolic disease. Dysbiosis also characterises functional 63 
disorders of the gastrointestinal track like irritable bowel syndrome and 64 
inflammatory bowel disease. The microbiota of the gastrointestinal tract of older 65 
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subjects differs from that of young healthy adults. A key aspect in future research is 66 
to identify the exact molecular mechanisms that link dysbiosis and disease in order 67 
to develop therapeutic strategies based on microbiota manipulation or administration 68 
of microbial products.  69 
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1.1.2 Introduction 70 
The term microbiome refers to the microbiota collection of microorganisms or in a 71 
particular site and more specifically to the collective genetic information of those 72 
organisms. Investigation of the association of gut microbiota to phenotypes of health 73 
or disease is a major feature of contemporary microbiome research (Cho and Blaser, 74 
2012). Culture-independent techniques and massive parallel next-generation 75 
sequencing has generated data that enabled the profiling of the gut microbiota of 76 
various healthy and disease cohorts ranging from infancy to the extremities of life 77 
span as discussed in following chapters. 78 
The phyla Firmicutes and Bacteroidetes are the most predominant in the healthy 79 
adult gut microbiota and around 90 % of the bacterial groups found in the intestine 80 
typically belong to these phyla, whereas Actinobacteria, Proteobacteria and 81 
Verrucomicrobia comprise up to around 2 %, 1 % and 0.1 % respectively of the 82 
intestinal microbiota composition (Hold et al., 2002; Wang et al., 2003; Eckburg et 83 
al., 2005; Rajilic-Stojanovic et al., 2009; Tap et al., 2009; Qin et al., 2010). 84 
Dominant bacterial groups in the gut microbiota belong to the genera 85 
Faecalibacterium, Ruminococcus, Eubacterium, Dorea, Bacteroides, Alistipes and 86 
Bifidobacterium (Tap et al., 2009). Eckburg et al (2005) also identified substantial 87 
representation of butyrate–producing Firmicutes belonging mostly to clostridia 88 
(clusters IV, XIVa) and of Bacteroides thetaiotaomicron in the intestinal microbiota, 89 
both subgroups known for exerting beneficial effects upon the host (Wrzosek et al., 90 
2013). 91 
The gut microbiota composition as described above is based on studies on the 92 
intestinal microbiota of westernised urban cohorts. There are exceptions to this 93 
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general picture of the composition of the gut microbiota. A recent study on the gut 94 
microbiota of healthy hunter-gatherers in Hadza of Tanzania revealed the absence of 95 
bifidobacteria and other major compositional differences compared to a European 96 
urban cohort (Schnorr et al, 2014). Strong selective pressure during co-evolution of 97 
commensal gut bacteria and the mammalian host (Ley et al., 2009) apparently 98 
resulted in the establishment of symbiotic relationships that allow the host to extract 99 
the maximum energy from the available habitual diet sources. It seems that the gut 100 
microbiota of the Hadza cohort is adapted to a certain diet which is significantly 101 
different to the westernised urban diet.  102 
Host genetics seems to play an important role in shaping the microbiome profile 103 
(approximately 2% contribution of genetics; Rothschild et al., 2018) and potentially 104 
explains some of the inter-individual variations in predominant species, subgroups 105 
and phylotypes (Eckburg et al., 2005; Benson et al., 2010). However, a more 106 
determinative role in the composition of the gut microbiota has been attributed to 107 
habitual diet compared to host-genetics (Zhang et al., 2010). Rothschild et al. (2018) 108 
reported that environmental factors such as diet and lifestyle contribute over 20% to 109 
the microbiota variability observed between individuals. Recently, bacterial groups 110 
have been identified that are stably either absent or abundant over time in most 111 
individuals (based on a cohort of a thousand western adults) without being affected 112 
by short-term diet intervention and which correlated to health status such as 113 
overweight and ageing (Lahti et al., 2014). 114 
It is becoming accepted that there is a functional redundancy in the gut microbiota 115 
(Mahowald et al., 2009; Lozupone et al., 2012) which explains how variant bacterial 116 
groups can result in the same functional core of the human gut microbiome 117 
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(Turnbaugh et al., 2009; Qin et al., 2010) Lessons from microbial ecology support 118 
the notion that bacterial community structure is rather explained from the point of 119 
functional genes than by species composition (Burke et al., 2011). 120 
The gut microbiome shifts that occur throughout the lifespan and the factors driving 121 
these changes are reviewed here, including the early colonisation events of the 122 
gastrointestinal track and the changes observed during ageing. The important role of 123 
diet in modulating the intestinal microbiota is also discussed, summarising the 124 
existing evidence indicating that diet can underpin metabolic disorders and 125 
inflammation via the microbiota. Furthermore, we present the existing evidence 126 
linking gut microbiota and exercise. Finally, dysbiosis associated with antibiotic 127 
intake and functional disorders of the gastrointestinal track are reviewed. In figure 1 128 
an overview of the factors affecting the composition of the gut microbiota 129 




Figure 1 Overview of the Overview of the factors affecting the composition of 132 
the gut microbiota throughout life. C-section: Caesarean section, E. coli: 133 
Escherichia coli. 134 
1.1.3 Establishment of the gut microbiota 135 
Several studies on germ-free (GF) mice demonstrate the importance of the gut 136 
microbiota in the development of gut physiology and the priming of the innate and 137 
adaptive immune systems (reviewed in Sekirov et al., 2010; Sommer and Backhead, 138 
2013). Disrupted colonisation patterns of the GIT in early life may have an 139 
immediate or future impact on health (Salminen et al., 2004; Penders et al., 2007; 140 
Cahenzli et al., 2013; El Aidy et al., 2013; Penders et al., 2013; Ardeshir et al., 141 
2014). 142 
In utero, the foetus is generally considered sterile although some recent studies 143 
suggest the opposite. Bacteria such as Escherichia coli, Enterococcus faecium and 144 
Streptococcus epidermidis have been isolated from the meconium of healthy term 145 
infants (Jimenez et al., 2008). Bacteria have also been isolated from the amniotic 146 
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fluid of preterm neonates which could however be indicative of a hidden infection 147 
and preterm delivery risk (DiGiulio et al., 2008). In a first study on the placental 148 
microbiome, Aagaard et al. (2014) conducted 16S rRNA sequencing and shot-gun 149 
metagenomics on placental samples from 320 individuals. Comparing the findings to 150 
other body microbiota data they reported the presence of a distinct community 151 
comprised of non-pathogenic Firmicutes, Tennericutes, Proteobacteria, Bacteroidetes 152 
and Fusobacteria. The placental microbiota was found to be similar to the microbiota 153 
of the oral cavity. Importantly, an association between placental microbiota and 154 
infection during the first pregnancy months and risk of preterm birth was observed. 155 
Despite data suggestive of prenatal presence of bacteria in the uterus environment, 156 
the role of these bacteria in the colonisation of the gastrointestinal track (GIT) 157 
remains largely unclear and debateable (Matamoros et al., 2013). Recently, Perez-158 
Muñoz (2017) concluded that the existing data connot support the pre-birth existence 159 
of fetal microbiota.  160 
Colonisation of the human GIT is a dynamic and complex event and begins with 161 
facultative anaerobes that prime the niche for the strict anaerobes that will follow 162 
and ultimately prevail in the healthy adult microbiota. After birth the first bacteria 163 
that colonise the infant gut are Enterococci, Enterobacteria (E. coli, E. faecium, 164 
Enterococcus faecalis) and some staphylococci, and when these organisms deplete 165 
the gut of oxygen anaerobes such as bifidobacteria, lactobacilli, clostridia and 166 
Bacteroidetes emerge (Palmer et al., 2007; Alderberth et al., 2009). In the 167 
repopulation of a GF murine model with normal murine gut microbiota, fermentation 168 
metabolites and cross-feeding between early colonising bacteria and successors 169 
facilitated the establishment of the latter (El Aidy et al., 2013). The colonisation 170 
event is regarded as leading to a dynamic eubiotic balance between the commensal 171 
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bacteria and the host inhibiting the growth of pathobionts, a phenomenon called 172 
colonization resistance (Lawley and Walker, 2012). 173 
It has been observed that in the first days of life the microbiota not only in the gut 174 
but in all body niches (skin, oral mucosa, nasopharyngeal cavity) is similar and 175 
reflects the mode of delivery (Dominguez-Bello et al., 2010). Samples taken from 176 
new-borns within 24 h of birth showed that vaginally born neonates harboured a 177 
microbiota close to the maternal vaginal microbiota with Lactobacillus, Prevotella, 178 
Atopobium and Sneathia spp. as prevalent taxa, whereas in neonates delivered by 179 
Caesarean section (C-section) the microbiota of various body niches including the 180 
gut resembled that of maternal skin (Dominguez-Bello et al., 2010). A few days after 181 
birth bifidobacteria are among the most dominant taxa in the gut of naturally 182 
delivered babies (Biasucci et al., 2008) but they seem to be absent or in low 183 
representation in the gut of new-borns delivered by C-section (Aires et al., 2011).  184 
Jost et al. (2012) found that from the fourth day of life till the end of the first month 185 
the gut microbiota of vaginally delivered breast-fed babies was dominated by 186 
bifidobacteria. It was also reported that Bacteroides species showed variant patterns 187 
of establishment that correlated to low counts of Bifidobacterium species, that 188 
clostridia of the clusters IV and XIV were undetectable and that the presence of 189 
Lactobacillus was not stable (Jost et al., 2012). Other studies also confirm that 190 
Bifidobacterium and Lactobacillus dominate the infant gut (Turroni et al., 2012). 191 
Aspects of the colonisation of the human gut by bifidobacteria have been 192 
comprehensively reviewed in Ventura et al. (2012). 193 
Interestingly, gestation time seems to affect the colonisation patterns of the GIT. 194 
Vaginally delivered preterm babies seem to have an intestinal microbiota of low 195 
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phylogenetic diversity compared to full-term infants (Arboleya et al., 2012). In 196 
comparison to full-term babies preterm children were found to harbour more 197 
facultative and fewer strict anaerobes and these differences could be attributed to 198 
exposure to intensive medical treatment, hospitalisation and insufficient organ 199 
function (Arboleya et al., 2012). 200 
The gut microbiota of preterm infants seems to be a risk factor for the development 201 
of necrotising enterocolitis (NEC) / late onset sepsis (LOS). Both culture and non-202 
culture based analysis of stool samples from infants born around the 27
th
 week of 203 
pregnancy showed that those diagnosed with NEC and LOS had higher faecal 204 
abundance of Enterobacteria and coagulase negative staphylococci (CONS) 205 
respectively (Stewart et al., 2012). As observed in another study on the gut 206 
microbiota of preterm babies (Mshvildadze et al., 2010) meconium was not sterile. 207 
Dysbiosis rather than the presence of pathobionts, for example CONS, was 208 
postulated to be significant in the onset of LOS in preterm patients (Mai et al., 2013). 209 
The group also observed low abundance of bifidobacteria in stool samples of LOS 210 
patients. Interestingly, it has been recently suggested that irrespective of mode of 211 
birth, feeding and antibiotic treatment the colonisation of the preterm GIT follows a 212 
certain pattern from Bacilli to γ-Proteobacteria to Clostridia mainly influenced by 213 
time of birth (La Rosa et al., 2014).  214 
It has been controversially proposed that during the final pregnancy stages maternal 215 
symbiotic gut bacteria could translocate to the mammary gland (Fernandez et al., 216 
2013). Studies identified Streptococcus, Staphylococcus and Corynebacterium, and 217 
lactic acid bacteria and bifidobacteria as dominant bacteria in the breast-milk 218 
microbiota which however, seems to change with lactation towards a community 219 
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composition more rich in Veillonella, Leptotrichia and Prevotella (Hunt et al., 2010; 220 
Cabrera-Rubio et al., 2012; Soto et al., 2014). The same strains of bifidobacteria, 221 
lactobacilli and staphylococci have been isolated from both the faeces of new-borns 222 
and the maternal breast-milk of their mothers (Martin et al., 2012) demonstrating 223 
that the two bacterial communities are interrelated. 224 
Many studies have confirmed that the intestinal microbiota of breast-fed new-born 225 
children harbours more bifidobacteria than formula-fed e.g. Harmsen et al. (2000), 226 
Martin et al. (2008), Roger et al. (2010), Bezirtzoglou et al. (2011). Others failed to 227 
report significant differences in the bifidobacteria population in infant stool samples 228 
between breastfed and formula-fed babies but abundance of E. coli and Clostridium 229 
difficile was higher in formula-fed subjects (Penders et al., 2005).  230 
Breast milk contains human milk oligosaccharides (HMO). New-born babies are not 231 
able to fully digest those oligosaccharides but infant-type bifidobacteria like 232 
Bifidobacterium longum subsp. infantis are genetically endowed with the ability to 233 
efficiently metabolise various short chain HMOs, an ability not detected in adult-234 
type bifidobacteria like B. longum subsp. longum (LoCassio et al., 2010; Sela and 235 
Mills, 2010; Garrido et al., 2011). A variety of pathways for HMO metabolism are 236 
distributed among the infant-type bifidobacteria revealing the selective pressure 237 
breast feeding has put on certain bacteria groups (Zivkovic et al., 2011). In all cases, 238 
research agrees that after weaning, the introduction of solid food marks clear 239 
changes in the microbiota although pre-weaning colonisation patterns are still 240 
detectable (Fallani et al., 2011; Koening et al., 2011).  241 
As discussed below, antibiotics have an impact on the gut microbiota at every age. 242 
Analysis of faecal microbiota of infants exposed to antibiotic treatment during the 243 
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first days after birth showed that the microbiota had limited numbers of 244 
bifidobacteria and high abundance of Enterobacteria and Proteobacteria (Brunser et 245 
al., 2006; Tanaka et al., 2009; Persaud et al., 2014). In early life antibiotics can 246 
disturb normal colonisation patterns which in turn can affect mammalian immunity 247 
and metabolism in later life (reviewed in Rautava et al., 2012). Cho et al. (2012) 248 
observed that infant mice treated with antibiotics developed a gut microbiota that 249 
was correlated to increased body fat. Cox et al. (2014) showed that in weaning mice 250 
antibiotic treatment resulted in an altered gut microbiota capable of inducing obesity, 251 
a permanent trait of the microbiota that could be transmitted through faecal transfer 252 
to GF mice. The group postulated that the microbiota-related obesity was a result of 253 
the altered gut microbiota composition due to antibiotic treatment. This has profound 254 
implications for human weight management at population levels because paediatric 255 
antibiotic usage is very frequent.  256 
Studies suggest that the microbiota begins to stabilise to a more adult-like profile 257 
from year one till 2.5 years of age (Palmer et al., 2007; Koening et al., 2011). More 258 
recent research shows that the microbiota undergoes changes till the 36
th
 month of 259 
age and that an enterotype establishment can be observed between the 9
th 
month and 260 
the third year of age (Yatsunenko et al., 2012; Bergstrom et al., 2014). 261 
1.1.4 Shaping factors of gut microbiota composition  262 
1.1.4.1 Diet 263 
Habitual diet plays a significant role in the development of the composition of the 264 
intestinal microbiota (Scott et al., 2013, Simoes et al., 2013). The intestinal 265 
microbiota rapidly responds to diet variations which is a characteristic of the gut 266 
microbiota of many mammalian groups (Muegge et al., 2011; David et al., 2014). 267 
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Most of the dietary nutrient absorption occurs in the duodenum and small intestine 268 
whereas undigested molecules like complex polysaccharides reach the large intestine 269 
(reviewed in Wong and Jenkins, 2007). In the colon a phylogenetically diverse and 270 
metabolically active bacterial community salvages energy from the undigested food 271 
particles which is subsequently used for the maintenance of the microbiota and by 272 
the host (Blaut and Clavel, 2007). 273 
Fermentation of undigested polysaccharides as well as dietary and endogenous 274 
proteinaceous substrates and polyphenols results in various end-products with 275 
tremendous impact on colonic health and homeostasis (Cummings and Macfarlane, 276 
1997; Nyangale et al., 2012, Windey et al., 2012). These fermentation compounds 277 
are predominantly the short chain fatty acids (SCFA) propionate, acetate and 278 
butyrate, and gasses like H2, H2S and CO2 as well as potentially toxic phenolic and 279 
indolic compounds, ammonia, amines and sulphur molecules (reviewed in 280 
Macfarlane and Macfarlane, 2012).  281 
Different non-digestible carbohydrates like resistant starch (RS), non-starch 282 
polysaccharides (NSP) and prebiotics can selectively enhance the growth of certain 283 
bacterial groups in the GIT (Martinez et al., 2010; Walker et al., 2011). Modulated 284 
microbial fermentation can yield beneficial end-products for the host. One such 285 
fermentation product is butyrate that is extensively studied for the beneficial effect it 286 
exerts on colonic epithelial cells (reviewed in Hamer et al. 2008). Clostridium 287 
clusters XIVa and IV, with representatives like Eubacterium / Roseburia species and 288 
F. prausnitzii respectively, are major saccharolytic players in butyrate generation in 289 
the colon (reviewed in Louis and Flint, 2009) and potentially prominent regulators of 290 
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innate immunity through the production of SCFAs (Atarashi et al., 2011; Atarashi et 291 
al., 2013; Smith et al., 2013).  292 
A statistical model was generated by Faith et al. (2011) that allowed for up to 60% 293 
accuracy in the prediction of shifts in species abundance as a response to host diet. 294 
The team isolated ten bacteria species from the human colon, sequenced their 295 
genomes and introduced them in gnotobiotic mice. They subsequently conducted 296 
detailed measurements on species abundance and gene expression in response to host 297 
diet, from which the statistical model was developed. Animal models are valuable 298 
tools in studying shifts in the microbiome but there is need for more extensive 299 
human studies to better simulate the complex conditions occurring naturally in the 300 
GIT (Walker et al., 2010; Muegge et al., 2011). Importantly, a recent study by 301 
Korpela et al. (2014) developed models to predict the gut microbiota responses to 302 
diet intervention based on the intestinal microbiota composition, predominantly on 303 
the Firmicutes abundance, of certain obese individuals.  304 
A summary of culture-independent studies correlating habitual diet to gut microbiota 305 
is presented in Table 1. From metagenomic studies on human faecal data sets from 306 
different countries Arumugam et al. (2011) observed that collectively, the grouping 307 
of the data formed three clusters called “enterotypes”. Analytically, enterotype 308 
number 1 was Bacteroides-dominated and positively co-related with 309 
Parabacteroides, Lactobacillus, Clostridiales and Alkaliphilus species, and was 310 
characterised by enrichment in metabolism of a broad spectrum of carbohydrate 311 
utilization and proteolytic activity. In enterotype 2 Prevotella was predominant and 312 
co-occurred with Desulfovibrio probably in a synergistic consortium for mucin 313 
degradation. The Ruminococcus enterotype correlated with Akkermansia abundance 314 
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which is a mucin-degrading bacterium. The “enterotype” classification was based on 315 
the high abundances of certain genera and this grouping should be regarded as 316 
metabolic variations in the way gut microbiota utilises available nutrients. 317 
Consumption of a vegetarian diet leads to changes in the microbiota of the GIT. Low 318 
abundance of Clostridium cluster IV and higher but not significant abundance of 319 
Bacteroides was observed by qPCR analysis of faecal samples of vegetarians 320 
compared to omnivores (Liszt et al., 2008). Another culture-independent study 321 
reported low abundance of Clostridium cluster XIVa and the Roseburia / E. rectale 322 
group in the faecal samples of vegetarians compared to omnivores (Kabberdoss et al., 323 
2012). Diet intervention with strict vegetarian diet on obese individuals for one 324 
month led to changes in the intestinal microbiota composition of patients without 325 
any impact on enterotypes and improved inflammatory markers in blood (Kim et al., 326 
2013). In that study, the diet intervention reduced the Firmicutes / Bacteroides ratio 327 
and the proportion of Enterobacteria in the intestinal microbiota, and increased the 328 
abundances of Clostridium cluster XIVa and IV. 329 
Based on diet interventions and habitual diet of 98 individuals Wu et al. (2011) 330 
reported that colonic communities clustered according to the aforementioned 331 
enterotypes 1 and 2 and that number 3 demonstrated a tendency to fuse with 332 
enterotype 1. The Bacteroides-dominated cluster co-occurred with Alistipes and 333 
Parabacteroides and associated with an animal protein and saturated fat-based 334 
habitual diet. In contrast, the Prevotella-cluster correlated with Paraprevotella and 335 
Catenibacterium and was related to fibre intake. Importantly, enterotypes as 336 
monitored by Wu et al. (2011) were driven by habitual diet and overall, remained 337 
stable during the diet intervention, although changes in the microbiome did occur as 338 
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a response to the new diet. The group also concluded that the two clusters mirrored a 339 
westernised and a more agrarian kind of diet respectively.  340 
Similar conclusions were drawn when high-through put sequencing was conducted 341 
on 16S rDNA from faecal samples of children of two geographically distinct areas: 342 
urban in Florence, Italy and rural in Boulpon, Burkina Faso (De Filippo et al., 2010). 343 
The rural diet was almost vegetarian and enriched in starch, fibre and plant 344 
polysaccharides and low in animal fat and protein. The faecal microbiota of subjects 345 
residing in rural areas was enriched in bacteria enabling maximum energy harvest 346 
from fibre and high rates of SCFAs production. Genera like Xylanibacter, Prevotella, 347 
Butyrivibrio and Treponema were characteristic of the intestinal microbiota of 348 
people living in rural areas and indicative of the potential to harvest energy from 349 
complex polysaccharides. By contrast, the urban diet sustained a much less diverse 350 
microbiota.  351 
Taken together, the results of the two studies above reveal the impact on gut 352 
microbiota of two kinds of diet, one “rural” enriched in fibre and low in fat and the 353 
other more “westernised”, rich in animal protein and saturated fat. The global 354 
convergence of dietary habits towards a westernised high fat / low fibre diet is an 355 
increasing phenomenon in modern society and is accompanied by the escalating 356 
prevalence of inflammatory and metabolic disease. The interplay between 357 
Westernised dietary habits, commensal bacteria and inflammation are 358 
comprehensively reviewed by Thorburn et al. (2014). 359 
1.1.4.2 Exercise 360 
No extensive studies have been dedicated so far to the exploration of the effect of 361 
exercise on the human microbiota. There are however some indications that exercise 362 
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affects the gut environment based on a murine model. Matsumoto et al. (2008) 363 
observed that rats that regularly exercise on the wheel-run had an intestinal 364 
microbiota distinct from the microbiota of sedentary animals and notably the former 365 
had higher colonic butyrate concentration compared to sedentary littermates. Choi et 366 
al. (2013) observed exercise-induced changes in the intestinal microbiota of healthy 367 
mice. Another study showed that exercise can lead to shifts in the gut microbiota of 368 
obese mice (Evans et al 2013). Recently, Clarke et al. (2014) studied the effect of 369 
exercise on the intestinal microbiota of the members of a professional rugby team. 370 
The study showed that athletes had a distinct faecal microbiota and lower 371 
inflammatory status in blood compared to controls. Athletes and low body mass 372 
index (BMI) controls had higher abundance of Akkermansia in the faecal samples 373 
compared to high BMI controls. The group correlated the gut microbiota changes not 374 
only with regular intense exercise but with the high protein diet regime the athletes 375 
consumed. However, it was impossible to rule out the effect of potential confounding 376 
factors. The existing evidence indicate that gut-microbiota is responsive to exercise 377 
but more research including intervention studies is necessary to elucidate the 378 
mechanisms of such responses. Recently, Barton et al. (2018) reported that after 379 
reexaminig the microbiome of the Clarke et al. (2014) study-participants using 380 
shotgun metagenomics analysis, the microbiome of athletes at taxonomic and mostly 381 
at metabolomic level had significant differences compared to the more sendetary 382 
controls; the athletes’ microbiome profile was associated with high fibre and protein 383 
diet and exercise.  384 
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Table 1 Culture-independent studies associating changes in gut microbiota to diet.  385 
Cohort Analysis Method Diet Main findings Reference 
29 healthy adults qPCR, PCR-DGGE Habitual vegetarians, 
omnivores 
↓Clostridium cluster IV 
↑Bacteroides spp. (non-significant ) 
Liszt et al. 
(2009) 
 
46 healthy adults qPCR Habitual vegetarians, 
omnivores 
↓Clostridium cluster XIVa 




6 obese with type 2 
diabetes (T2D) 
16S rRNA sequencing, 
biochemical analysis 
Strict vegetarian diet/ 
1 month 
↓Firmicutes/Bacteroides ratio 
↓No effect on enterotypes 
↓Pathobionts, Enterobacteria 
↑Bacteroides fragilis, Clostridium cluster 
XIVa, IV species 
↓Body weight, blood triglycerides, 
cholesterol 
 
Kim et al. 
(2013) 
 
14 healthy Mossi ethnic 
group children (rural 
community), 15 healthy 
Europeans (urban 
community) 
16S rRNA sequencing -Habitual rural diet: low 
fat, protein, sugar, high 
fibre 
 
-Habitual urban diet: high 




unique presence of Xylanibacter, 









Cohort Analysis Method Diet Main findings Reference 




-10 healthy Bacteroides 
enterotype 
16S rRNA sequencing -Habitual fat-rich diet 
 









-Bacteroides enterotype correlated 
-Prevotella enterotype related 
-No permanent enterotype switch 
 
Wu et al. 
(2011) 
14 overweight subjects 16S rRNA sequencing, 
qPCR 





-↑Roseburia / E. rectale related 
Firmicutes 
 
-↓Roseburia / E. rectale related 
Firmicutes 
Walker et al. 
(2011) 
18 lean subjects, 33  
mammalian species 
 
16S rRNA sequencing, 
qPCR 
Proteins, insoluble fibre -Similar enzymatic activity and 
adaptation to diet across species 
Muegge et al. 
(2011) 
178 older subject: 
community, long-stay 
16S rRNA sequencing -Community: moderate 




fibre, less diverse diet 
-↑Phylogenetic diversity,  







Claesson et al. 
(2012) 
20 monozygotic twins  16S rRNA sequencing, 
DGGE 
Habitual diet Bacteroides spp. and bifidobacteria most 
affected by habitual diet 
 




Cohort Analysis Method Diet Main findings Reference 
40 professional athletes  16S rRNA sequencing, 
biochemical 
Strict habitual diet, high 
protein 
↑Akkermansia sp., 
↓inflammatory markers in blood  
 
Clarke et al. 
(2014) 
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1.1.4.3 Antibiotics 386 
Antibiotic treatment can reduce the compositional diversity and the metabolic 387 
potential of the gut microbiome, with an effect that attenuates with treatment 388 
cessation (Pérez-Cobas et al., 2013). Jakobsson et al. (2010) studied subjects 389 
receiving clarithromycin and metronidazole treatment and monitored microbiota 390 
over a period of four years. After a week of treatment distinct changes in the 391 
composition of the intestinal microbiota of all subjects were observed. Interestingly, 392 
the group also observed that although the general trend was gut microbiota recovery 393 
in individuals after completion of treatment, some cases failed to fully recover the 394 
pre-treatment microbiota. The same pattern of inter-individual responses to 395 
antibiotics, recovery after cessation of treatment but with cases among subjects 396 
studied with reduced to absent restoration of taxa in the intestinal microbiota, was 397 
reported in other studies (Jernberg et al., 2007; Dethlefsen et al., 2008; Dethlefsen 398 
and Relman, 2011). Inter-individual responses reflected the variations of the healthy 399 
status microbiota among individuals. The faecal metabolome associated with the 400 
microbiota seems to be affected. Streptomycin was shown to exert multiple effects 401 
on murine intestinal metabolic activity (Caetano et al., 2011) implying a potential 402 
effect on the microbiota involved in certain metabolic pathways 403 
Low diversity of the gut microbiota makes the intestinal environment susceptible to 404 
entro-pathogens. In a murine model after two days of treatment with 405 
vancomycin/streptomycin a dose-dependent effect was apparent upon the 406 
composition of the gut microbiota (Sekirov et al., 2008). The group observed that 407 
although total bacterial numbers were not affected, the composition of the microbiota 408 




Another common example of infection susceptibility and breach in the colonisation 411 
resistance phenomenon is that of Clostridium difficile infection (CDI). C. difficile is 412 
a common nosocomial pathogen, causing antibiotic-associated diarrhoea (AAD) and 413 
affecting mostly hospitalised older patients. Epidemiology and risk factors of CDI 414 
were reviewed by Ananthakrishnan (2011). Cephalosporins, macrolides, clindamycin 415 
and predominantly fluoroquinolones are some of the associated infection-risk 416 
antibiotics (Pépin et al., 2005). The successful treatment of CDI in a mouse model 417 
with a mixture of bacteria isolated from healthy subjects (Lawley et al., 2012), and 418 
in humans with a stool substitute (Petrof et al., 2013) showed that a phylogenetically 419 
diverse mix of faecal bacteria is sufficient to displace C. difficile from the gut more 420 
effectively than any known antibiotic.  421 
Overall, antibiotic administration results in mostly short-term disturbances in the 422 
microbiota and these disturbances tend to revert with the end of antibiotic use. The 423 
dominant taxa in the gut microbiota tend to recover soon after short-term 424 
administration ends showing that balancing ecological mechanisms drive the 425 
microbiota back to its pre-treatment status whereas long-term use may result in 426 
permanent alterations in the intestinal microbiota (De La Cochetiere et al., 2005) and 427 
increase risk of AAD. 428 
1.1.4.4 Extra-intestinal disorders: Metabolic syndrome and related obesity, 429 
type 2 diabetes, liver disease 430 
The metabolic syndrome is mainly characterised by insulin resistance and visceral 431 
obesity as well as raised blood pressure, atherogenic dyslipidaemia and pro-432 
inflammatory status (Grundy et al., 2004). The syndrome is a risk factor for the 433 
interrelated development of cardiovascular disease (CDV) and type 2 diabetes (T2D) 434 
(Huang, 2009). Dysbiosis seems to play a role in this syndrome. The intermediate 435 
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step is the interplay between the gut microbiota, nutrient absorption, fat storage and 436 
host metabolism (reviewed in Musso et al., 2011). The metabolic syndrome also 437 
affects hepatic physiology with the potential for development of the non-alcoholic 438 
fatty liver disease (NAFLD) and the more severe non-alcoholic steatohepatitis 439 
(NASH) (Abu-Shanab and Quigley, 2010).  440 
Obesity and type 2 diabetes  441 
There is an accumulation of evidence that commensal bacteria play a significant role 442 
in modulating fat storage. When lean GF mice were conventionalised with normal 443 
gut microbiota they gained body fat although food intake was not increased 444 
(Backhed et al., 2004). Cani et al. (2007; 2008) used a murine model to propose a 445 
sequence of events leading from high-fat diet to gut microbiota-controlled metabolic 446 
disorders. High-fat feeding was correlated with increased intestinal permeability and 447 
high lipopolysaccharides (LPS) plasma concentrations leading to metabolic 448 
endotoxemia, inflammation and eventually metabolic conditions. Obesity and 449 
diabetes reflecting the metabolic deregulation were attenuated in a mouse strain 450 
lacking the main LPS-receptor CD14, demonstrating the importance of LPS in the 451 
initiation of the metabolic deregulation (Cani et al., 2007). In humans, plasma LPS 452 
levels increase after increase of fat intake (Erridge et al., 2007) and translocation of 453 
bacterial components across the gut barrier seem to occur in obese and diabetic 454 
subjects (Gummesson, et al., 2011; Hawkesworth et al., 2013).  455 
Importantly, LPS interacts with the endocannabinoid system (eCB) which emerges 456 
as an important player in the metabolic deregulation in obesity (Lamber and 457 
Muccioli, 2007). The endocannabinoid system is implicated in gut barrier integrity 458 
as blocking the G protein-coupled receptor of eCB CB1 resulted in reduced plasma 459 
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LPS and an increase in tight-junction proteins in murine model (Muccioli et al. 460 
2010).  461 
Ley et al. (2005) showed that the establishment of the diet-induced obesity 462 
phenotype in mice was accompanied by low intestinal microbiota diversity and 463 
altered relative abundances of the major taxa with increased abundance of Firmicutes 464 
and reduction to 50% of phylum Bacteroidetes compared to lean mice. The group 465 
also demonstrated that the potential to gain energy from nutrients was improved in 466 
this “obese microbiome”: more enzymes involved in starch and carbohydrate 467 
metabolism, more fermentation-end products like butyrate and reduced energy load 468 
in faeces compared to lean littermates (Turnbaugh et al., 2006). Importantly, the 469 
increased energy uptake trait could be transmitted to germ-free mice by faecal 470 
transplantation (Turnbaugh et al., 2006). Studying obesity-associated shifts in gut 471 
microbiota in humans, Ley et al (2006) obtained results analogous to data from the 472 
mouse studies. Accordingly, in obese humans Bacteroidetes relative abundance was 473 
lower compared to Firmicutes. However, studies by other groups in humans have 474 
been contradictory and report different changes in the ratios of the Firmicutes and 475 
Bacteroidetes (Duncan et al., 2008; Schwiertz et al., 2010). In a Danish cohort of 476 
obese and non-obese people, metagenomics analysis showed that the number of the 477 
gut microbiota genes used as a measure of bacterial richness in the microbiota, was 478 
associated with obesity phenotypes (Le Chatelier et al. 2013). In individuals with 479 
low gene counts demonstrated associated obesity phenotypes such adiposity and 480 
insulin resistance, and had increased abundance of Bacteroides, Parabacteroides, 481 
certain Ruminocccus taxa and Proteobacteria among others, whereas in the gut 482 
microbiota of individuals with high gene counts “anti-inflammatory” taxa such as 483 
Faecalibacterium were dominant (Le Chatelier et al. 2013). Cotillard et al. (2013) 484 
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reported that low gene richness in obese and overweight individuals was associated 485 
with higher low-grade inflammation and deregulated metabolism.   486 
Like in obesity, research on the microbiota of patients with type 2 diabetes (T2D) 487 
reveals significant alterations compared to healthy controls. The “diabetic microbiota” 488 
had high proportions of Bacteroidetes-Prevotella group whereas the abundance of 489 
the butyrate-producer group C. coccoides-E. rectale was reduced (Larsen et al., 490 
2010). A metagenomic analysis on the faecal microbiome of Chinese T2D patients 491 
showed decreased butyrate biosynthesis and metabolism of vitamins, enrichment in 492 
metabolism of xenobiotics, branched chain amino acids (BCAA) and methane, and 493 
sulphate reduction to mention some (Qin et al., 2012). The group also reported 494 
opportunistic pathogens, the mucin-degrader Akkermansia municiphila and sulphur 495 
reducers like Desulfovibrio sp. to be higher in abundance in T2D faecal microbiota. 496 
A metagenome-wide study on a cohort of 145 healthy and with risk for diabetes 497 
European women also revealed composition and function alterations in the gut 498 
microbiota of the at-risk subjects (Karlsson et al., 2013). The group developed a 499 
diabetes risk predicting tool which however failed to predict diabetes when applied 500 
on the aforementioned Chinese cohort suggesting that the metagenomic markers for 501 
T2D between the two cohorts were cohort-specific and could not be generalised. 502 
Importantly, Forslund et al. (2015) reported that when controlling for the use of 503 
antidiabetes drug use i.e. metformin, a certain “diabetic” gut microbiota profile 504 
emerged characterised by significant reduction in butyrate producers. Metformin is 505 
widely used for T2D treatment and there is data supporting that part of its 506 
antidiabetic activity is mediated by acting on the gut micorbiota (Wu et al., 2017).  507 
Non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) 508 
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A range of hepatic conditions related to obesity are grouped under the term NAFLD 509 
including the inflammatory steatosis NASH (Brunt and Tiniakos, 2010). In obesity 510 
accompanied by co-morbidity the NAFLD prevalence is 95% and prevalence for 511 
NASH is 25%, whereas in diabetic patients NASH may reach 63% prevalence (Bajaj 512 
et al., 2012). The gut microbiota of patients with either NAFLD or NASH have not 513 
yet been extensively studied. 514 
Mouzaki et al (2013) conducted one of the first culture-independent studies on 50 515 
adults with steatosis, non-alcoholic steatohepatitis and healthy controls. The group 516 
observed a diet-independent reduced relative abundance of Bacteroidetes in the stool 517 
of NASH patients. A previous study on the intestinal microbiota of obese, healthy 518 
children and children with NASH showed that obese and NASH microbiomes could 519 
cluster in a Prevotella-enriched enterotype diversifying from the healthy controls 520 
(Zhu et al., 2012). Bacteroides abundance was higher in obese and NASH subjects 521 
compared to healthy controls, Actinobacteria had relatively lower abundance in non-522 
healthy subjects and Proteobacteria abundance increased significantly from healthy 523 
to obese individuals with higher scores in NASH subjects (Zhu et al., 2012). The 524 
study also associated the elevated ethanol measurements in NASH patients blood 525 
samples to a gut microbiota enriched in ethanol-producing bacteria like Escherichia 526 
coli.  527 
Data on the gut microbiota of NAFLD patients is still limited. A clear link between 528 
gut microbiota, diet and metabolic disorders exist. However, these two studies on 529 
NAFLD and intestinal microbiota yielded diet-independent results implying a causal 530 
role of the gut microbiota in the pathogenesis of the condition. Serino et al. (2012) 531 
investigating metabolic disorders and gut microbiota in a murine model showed that 532 
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irrespective of diet and host genetics gut microbiota and the naturally occurring 533 
metabolic variations of the intestinal microbiome among individuals predisposed the 534 
animals for metabolic conditions. Future work is expected to further elucidate both 535 
the mechanisms through which diet controls gut microbiota-driven host metabolism 536 
disorders and the existence of a diet-independent role of the gut microbiota in the 537 
progression of metabolic conditions.  538 
1.1.4.5 Functional gastrointestinal disorders: Inflammatory bowel disease 539 
(IBD), Irritable bowel syndrome (IBS) 540 
Functional gastrointestinal disorders (FGIDs) are a broad group of commonly 541 
occurring gastrointestinal conditions with irritable bowel syndrome (IBS) being the 542 
most prevalent (Talley, 2008). Using Rome III criteria similar symptoms in IBS and 543 
IBD could be identified (Bryant et al., 2011). 544 
Inflammatory bowel disease (IBD) 545 
The two major forms of IBD are ulcerative colitis (UC) and Crohn’s disease (CD) 546 
and both are influenced by host genetics and deregulated immunological response to 547 
the intestinal microbiota (Abraham and Cho, 2009). Culture-independent studies 548 
show abnormalities in the microbiome of individuals with IBD. Frank et al. (2007) 549 
compared the microbiota in biopsies of UC and CD to those of healthy controls. 550 
Although the abundances of the predominant taxa were not altered, significant 551 
variations in the relative abundances of subgroups distinguished the healthy from the 552 
non-healthy microbiotas and health-promoting butyrate-producers belonging to 553 
Bacteroidetes and Lachnospiraceae were significantly reduced in abundance in the 554 
IBD samples. Conversely, Proteobacteria and Bacillus species were increased in 555 
proportion.  556 
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Manichah et al (2006) applied metagenomics to the faecal microbiota of CD patients 557 
and observed reduced phylogenetic diversity. Patient faecal samples demonstrated 558 
low abundance of the butyrate-producer groups Clostridium leptum and Clostridium 559 
coccoides and were enriched in Gram negative species and the family 560 
Porphyromonadaceae. F. prausnitzii is a major butyrate-producer and the dysbiosis 561 
and symptomology characterized by the significant reduction of this Firmicutes in 562 
CD could be reversed by oral administration of this organism in a murine model 563 
(Sokol et al., 2008).  564 
Another bacterium implicated in IBD is Bacteroides fragilis. Transcriptional 565 
analysis of colonic mucosal biopsies showed that the phylum Bacteroidetes was the 566 
most active based on rRNA gene libraries and B. fragilis was dominant in CD based 567 
on proportion of sequences in rRNA library/percentage of sequences in rRNA gene 568 
library (AIR) (Rehman et al. 2010). Previously, Swidsinski et al. (2005) had 569 
demonstrated the prevalence of this species in gut microbiota of IBD patients and 570 
especially CD and they suggested the potential role of the high abundance of this 571 
bacterium in increased barrier permeability.  572 
Risk factors for IBD have been identified, and host genetics and dysbiosis have been 573 
associated to the progression of the condition. However, the exact mechanisms 574 
leading to IBD remain elusive thus making the unravelling of IBD causation a 575 
paradigm for the understanding of the complex interplay between microbiota, host 576 
and inflammation (Huttenhower et al., 2014). Furthermore, the complex cross-talk 577 
between the causative factors of the condition, the inter-individual variations in gut 578 
microbiota and the fact that no universal colitogenic bacteria have been identified 579 
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indicate the need for more personalised IBD therapeutic strategies (Stephens and 580 
Round, 2014). 581 
Irritable bowel syndrome (IBS) 582 
A common FGID disorder is IBS and unlike IBD it is not associated with 583 
histopathological conditions and it is believed to be related to the deregulation of the 584 
gut-brain axis (GBA) (Ringel and Maharshak, 2013). The cross-talk between gut and 585 
brain and the association with intestinal homeostasis and progression of FGID have 586 
been recently comprehensively reviewed by Collins and Bercik (2009) and Collins 587 
(2014). IBS progression can be outlined as follows: extrinsically-induced dysbiosis, 588 
for example after severe infection, triggers mucosal immunity in genetically 589 
predisposed subjects resulting in enteric nervous system deregulation caused by 590 
intestinal permeability (Collins et al., 2009; Simren et al. 2009; Steck et al., 2013).  591 
The diagnostic criteria set by the Rome Foundation, Rome criteria III 592 
(http://www.theromefoundation.org/criteria/), are widely used for FGID diagnosis 593 
(Soares, 2014); outlined here in Table 2. Three subtypes of the condition exist based 594 
on stool appearance: diarrhoea-predominant (IBS-D), constipation-predominant 595 
(IBS-C), mixed (IBS-M) (Longstreth et al., 2006). 596 
Using culture-based techniques and PCR - denaturing gradient gel electrophoresis 597 
(PCR-DGGE) analysis Matto et al. (2005) observed temporal instability of the gut 598 
microbiota of IBS patients but failed to associate shifts in bacterial groups with 599 
symptoms of the condition. Other culture-independent studies also showed temporal 600 
instability of the intestinal microbiota of IBS subjects, lower abundance of 601 
Lactobacillus species in stool samples of patients with IBS-D, increase in abundance 602 
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of Veillonella species in IBS-C individuals and a reduction in Clostridia species 603 
abundance (Malinen et al., 2005; Kassinen et al., 2007).  604 
Other culture-independent studies showed that in the faecal microbiota of IBS 605 
patients compared to controls, the Firmicutes to Bacteroidetes ratio was increased, 606 
Actinobacteria had lower abundance and Proteobacteria were more abundant 607 
(Krogius-Kurikka et al., 2009; Rajilic-Stojanovic et al., 2011). Similar results were 608 
published by Jeffrey et al. (2012), that is, significant differences between gut 609 
microbiota of IBS patients and healthy controls and increased Firmicutes to 610 
Bacteroidetes ratio. Subgroups were formed based on the faecal microbiota of 611 
patients and importantly, one of these was characterised by normal-resembling faecal 612 
microbiota. These patients had high scores for anxiety and depression, suggesting a 613 
subclass of IBS on non-microbial aetiology.  614 
In stool samples of IBS-C patients the fermentation potential of the microbiota was 615 
altered: fluorescent in situ hybridisation (FISH) revealed that the abundance of H2-616 
consuming sulphur-reducing bacteria and butyrate producing Roseburia / E. rectale 617 
group was significantly higher and lower respectively compared to control subjects 618 
(Chassard et al. 2012). The altered fermentation activity of the intestinal microbiota 619 
in IBS patients was also indicated by abnormal hydrogen and methane breath 620 
measurements in patients (King et al., 1998). Interestingly, the commensal 621 
methanogenic Achaea with the production of H2 may have a role in IBS 622 
pathogenesis (Triantafyllou et al., 2014) but studies to date yield contradictory 623 
results (Rajilic-Stojanovic et al., 2011; Kim et al. 2012). 624 
Studies so far have not fully revealed the exact mechanism through which the 625 
microbiota influences the onset and progression of IBS. The fact that probiotics seem 626 
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to ameliorate the symptoms of the dysbiotic condition of this multifaceted syndrome 627 
further promotes the idea of microbiota disturbances implicated in the disease 628 
(Santos and Whorwell, 2014). IBS is an interesting field of research as the 629 
unravelling of the disease mechanisms will enable further insight in the brain-gut 630 
axis communication and how mediators from the intestinal microbiota can influence 631 
cognitive function in subjects with intestinal disorders (Bercik et al., 2011). 632 
Table 2 Diagnostic criteria for IBS adapted from Rome III 633 
(http://www.theromefoundation.org/criteria/). 634 
Criteria for diagnosis of IBS 
 Intermittent abdominal pain and 
discomfort related to at least two 
of the conditions below: 
1. Improvement with defecation 
2. Alterations in the defecation 
habits 
3. Alterations in stool form 
 Frequency of symptoms: 3 days 
per month for the last 3 months 
 
 Symptom detection at least 6 
months before diagnosis. 
1.1.5 Ageing and microbiota alterations 635 
There is growing scientific interest in the connection between low-grade 636 
inflammation observed in older age and the role of gut microbiota. According to this 637 
concept, accumulation of antigenic stimulation and stressors throughout life leads to 638 
declined immune responses and low immune adaptiveness resulting in inflamm-639 
ageing (Franceschi et al., 2000). An overview of how the protective activity of the 640 
immune system (IS) is deregulated with immuno-senescence, that is the ageing of 641 
the IS, is presented by De Martinis et al. (2005). The Nuclear Factor κΒ (NF-κΒ) 642 
seems to be at the core of this process by being the major signalling pathway in the 643 
innate IS (Salminen et al., 2008). 644 
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It is now accepted that this low-grade inflammatory status with characteristic 645 
markers circulating in the plasma of older people is associated with the degenerative 646 
conditions that characterise old age (Howcroft et al., 2013). Among the most usual 647 
pro-inflammatory markers correlated with muscle tissue damage and sarcopenia, 648 
neuro-degeneration and obesity are C-reactive protein (CRP), tumour necrosis 649 
factor-α (TNF-α), IL-6 and IL-18 (Howcroft et al., 2013). 650 
Antigenic stimuli associated with the microbiota composition shifts observed in 651 
older age may contribute to inflamm-ageing. The exact correlation and mechanisms 652 
that link the microbiome to ageing remain unclear and this presents a promising field 653 
for future research and new therapeutic strategies. 654 
Changes in the gut microbiota in older age 655 
Changes in the GIT physiology, in the functionality of the IS, in lifestyle and 656 
nutritional habits, and hospitalisation and medical treatment can impact the 657 
composition of the gut microbiota in older age and consequently health status 658 
(reviewed in Cusack and O’Toole, 2013). 659 
The combined data from older mainly culture-dependent studies suggest that age is 660 
accompanied by an increase in the proportion of facultative anaerobes, with a 661 
simultaneous decline of beneficial anaerobes such as bifidobacterial and lactobacilli 662 
and importantly, an overall decline in species diversity in several bacterial groups 663 
(Woodmansey, 2007). During inflammation pathobionts - potentially harmful 664 
bacteria that are in low abundance in the healthy gut, increase in abundance 665 
displacing commensals (Pédron and Sansonetti, 2008). The example of the 666 
proliferation of the pathogenic Salmonella enterica serotype Typhimurium in the gut 667 
shows how a pathogen can compete with commensals and prevail in the dysbiotic 668 
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condition of the inflamed ecosystem and further promote inflammation (Winter et al., 669 
2010). Furthermore, an alarming correlation exists between the low diversity profile 670 
of the intestinal microbiota of older subjects and infection or non-symptomatic 671 
colonization by the common nosocomial pathogen C. difficile (Rea et al., 2012). 672 
Studies based on culture-independent techniques offered more comprehensive 673 
information about the shifts occurring in the gut microbiome of older subjects. 674 
Overall, studies do not yield homogenous results and there are variations based on 675 
the cohorts and the methods employed. However, it seems that compared to controls, 676 
the intestinal microbiota of older people is characterised by differences in the 677 
abundance of specific bacterial groups and the composition and species diversity of 678 
these groups is altered (Tiihonen et al., 2010). Variations in the reported composition 679 
and significant inter-individual variability in the microbiota could be attributed to the 680 
fact that ageing alone is not enough to alter the generally stable microbiota (Brussow, 681 
2013) and the alterations should be viewed and explained accompanied by data on 682 
the cohort diet, physical activity, drug and antibiotic intake, and even geographical 683 
and socio-economical profile.  684 
When the faecal bacterial population of older community-dwellers, hospitalised and 685 
hospitalised on antibiotic treatment were compared, Bartosch et al. (2004) noted that 686 
the basic difference in the faecal microbiota between healthy and hospitalized 687 
subjects was the significant reduction in the Bacteroides / Prevotella group. In the 688 
same study, bifidobacteria, Desulfovibrio spp., Clostridium clostridioforme and F. 689 
prausnitzii also declined in abundance after hospitalisation. However, the relative 690 
abundance of the aforementioned bacteria remained stable as the total bacterial load 691 
in stool of hospitalised subjects also decreased. Antibiotic treatment had an 692 
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additional negative impact on the faecal microbiota. Antibiotics lowered the 693 
diversity in the stool microbiota and even eliminated certain bacterial groups, 694 
promoting the growth of opportunistic species and enterococci like E. faecalis 695 
(Bartosch et al., 2004). 696 
Mueller et al. (2006) studied the gut microbiota composition of 230 healthy 697 
individuals from four European countries. A significant increase in Enterobacteria 698 
abundance in the stool samples of the older volunteers was observed irrespective of 699 
country of origin whereas for most of the other dominant bacterial groups like F. 700 
prausnitzii, bifidobacteria, Bacteroides / Prevotella no generalised conclusions could 701 
be made that would unify the results from the stool samples of all individuals tested. 702 
However, the Bacteroides / Prevotella group was more abundant in male subjects 703 
compared to female. Zwielehner et al. (2009) comparing the faecal microbiota of 704 
long-term residential elderly to healthy adults reported an overall decline in diversity 705 
of the dominant phyla and significantly low representation of Clostridium cluster IV 706 
and bifidobacteria along with inter-individual variations in Bacteroides. Comparing 707 
the faecal microbiota of 161 Irish subjects aged >65 years and 9 younger controls 708 
identified significant differences and remarkable inter-individual variability was 709 
reported for Bacteroidetes and Firmicutes abundances (Claesson et al., 2011) 710 
When faecal microbiota of healthy adults (around 30 years), older (around 70 years) 711 
and centenarian subjects was analysed the intestinal microbiota of centenarians was 712 
distinct from the other subject categories (Biagi et al., 2010). With Firmicutes and 713 
Bacteroidetes remaining the major phyla throughout life, certain re-arrangements 714 
were observed in the microbiota of centenarians with extensive remodelling in the 715 
population of Clostridium cluster XIVa (Biagi et al., 2010).  716 
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Data from the ELDERMET project was able to demonstrate a clear correlation 717 
between diet, gut microbiota and health status in a large cohort of older subjects. The 718 
participants were stratified in community-dwelling and short-term and long-term 719 
hospitalized. The profiling of the intestinal microbiota was accompanied by data 720 
collection on habitual diet, inflammation status, cognitive function and frailty. 721 
Overall, subjects frequenting or residing in long-stay care units had poor diet which 722 
correlated with higher frailty scores, higher inflammation indicators like IL-6, IL-8, 723 
TNFα and CRP in the serum and a distinct microbiota in comparison to community-724 
dwellers of the same ethno-geographic region (Claesson et al., 2012). Bacteroidetes-725 
related operational taxonomic units (OTUs) were more abundant in faecal samples of 726 
long-stay subjects whereas in community-residing subjects the phylum Firmicutes 727 
was at higher levels with dominant genera Coprococcus and Roseburia for the latter 728 
group of subjects and Parabacteroides, Eubacterium, Anaerotruncus, Lactonifactor 729 
and Coprobacillus for the former (Claesson et al., 2012).  730 
The gut microbiota in older age is characterised by both compositional and 731 
functional alterations expressed in centenarians in the marked shift from a 732 
saccharolytic metabolism towards putrefaction with significant loss of genes 733 
involved in SCFA production (Rampelli et al., 2013). Given the importance of these 734 
metabolites in gut homeostasis (Smith et al., 2013) this shift could increase the risk 735 
for disease. Protein fermentation metabolites can also be detrimental for health by 736 
affecting gut homeostasis (Windey et al., 2012). However, in people reaching the 737 
hundredth decade of life changes in the microbiome could be seen as an evolutionary 738 
advantage. In centenarians high phenylacetyglutamine (PAG) and p-cresol sulphate 739 
(PCS) secretion indicates shifts in the microbiome which could reflect an overall 740 
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remodelling of structure and functionality in order for the human organism to survive 741 
in the extremities of life-spam (Collino et al., 2013). 742 
1.1.6 Concluding remarks 743 
As summarised here there is accumulating evidence predominantly from studies 744 
based on high throughput parallel sequencing which underlines the significance of 745 
gut microbiota in modulating health and disease. The gut microbiota is affected by 746 
the host life-style, with a major factor being habitual diet. Intestinal microbiota 747 
profiling conducted on faecal samples of various cohorts ranging from the Hazda 748 
hunter-gatherers of Tanzania to subjects residing in westernised urban areas has 749 
revealed how diet shapes the composition and function of the mammalian 750 
microbiome. Nutrient products generated by commensal bacterial fermentation in the 751 
colon affect fat storage, metabolism and even the gut-brain axis. In Figure 2 a 752 
schematic overview of how extrinsic factors like diet and antibiotics influence 753 
normal gut microbiota leading to dysbiosis is presented. Interestingly, the gut 754 
microbiota is significantly associated with the rate of ageing of the human organism 755 
(Heintz and Mair, 2014).  756 
Thus the gut microbiota is a promising target for novel therapeutics for a wide range 757 
of conditions and for the manipulation of the progression of ageing itself (Foxx-758 
Orenstein et al., 2010; Cani and Delzenne, 2011; Candela et al., 2014). Culturomics 759 
and phylogeny are indispensable for the development of novel microbial therapeutics 760 
as they offer a tool for a more detailed study of bacterial physiology and metabolism 761 
(Walker et al., 2014). Understanding gut bacterial physiology will also facilitate the 762 
development of in silico simulation models of the host-microbe / microbe-microbe 763 




Figure 2 A schematic representation of how extrinsic factors like diet and 766 
antibiotics influence normal gut microbiota leading to dysbiosis. The Wiggum 767 
plots at the bottom represent normal gut microbiota and gut microbiota in dysbiosis. 768 
Coloured circles represent correlated genera and their interactions are schematically 769 
indicated by lines. T2D: Type-2 diabetes, NAFLD: non-alcoholic fatty liver disease, 770 
NASH: non-alcoholic steatohepatitis, IBS: irritable bowel syndrome, IBD: 771 
inflammatory bowel disease.   772 
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1.2 The gut microbiota is a modifiable factor for maintaining 1394 
health 1395 
1.2.1 Introduction 1396 
In the previous section I reviwed the factors that shape the human gut microbiome 1397 
throughout life and I discussed how GIT and extra-intestinal disease, and ageing 1398 
affect and are affected by the gut microbiota. The colonisation process of the GIT 1399 
tract begins shortly after birth; the first colonisers are facultative anaerobes 1400 
originating from vaginal or skin microbiota depending on delivery mode, and are 1401 
gradually succeeded by anaerobic microorganisms selected by host genetics, diet and 1402 
the natural environment of the individual, including other people such as family 1403 
members (Messer et al., 2017). The gut microbiota of individuals can be viewed as 1404 
part of a wider “local metacommunity” due to the microbial exchange that occurs 1405 
among individuals and with their envoronment (Adair and Douglas, 2017).  1406 
Although host-associated factors such as immunity and GIT physiology remain 1407 
important (Kurilshikov et al., 2017), environment is emerging as the most 1408 
determinant one in the long-term shaping of the microbiome. Recently, Rothschild et 1409 
al. (2018) showed that in spite of some degree of heritability, the gut microbiome is 1410 
largely shaped by external environmental factors that prevail on host traits.  1411 
Studies on the gut microbiota of urban and pre-agricultural modern populations have 1412 
shown the significant impact of the environment (that is, an array of environmental 1413 
factors including diet and life-style) on the shaping of the gut microbiota (reviewed 1414 
in Mancabelli et al., 2017). A clear example of environmental impact (available diet, 1415 
microbial communitites of their habitat) on the microbiota is that of the microbiota 1416 
(gut, skin, oral) of the highly isolated Yanomami Ameridians (Clemente et al., 2015). 1417 
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Isolation and lack of communication with external microbial communities 1418 
contributed to the retention of the compositional robustness of the Ameridians 1419 
microbiome which is not only the richest in diversity and functions so far studied- 1420 
compared to both Westernised and other non-Westernised cohorts, but also one 1421 
demonstrating little inter-individual variability (Clemente et al., 2015).  1422 
As discussed in Chapter 1.1., habitual dietary patterns impact the individual’s 1423 
longitudinal microbiota compositional profile whereas dietary shifts lead to 1424 
reproducible microbiota responses (Flint et al., 2017). For example, O’Keefe et al. 1425 
(2015) showed that a 2-weeks switch of habitual diet between African Americans 1426 
that were in high CRC risk due to their high-fat/low fibre diet, and low cancer risk 1427 
rural Africans regularly consuming a low-fat/high-fibre diet, resulted in changes 1428 
associated with the switched diets in both the gut microbiota composition and 1429 
metabolome, and in colon mucosa CRC biomarkers. 1430 
The association of the gut microbiota and dysbiosis with a plethora of disease that 1431 
span all aspects of human physiology (reviewed in Chapter 1.1), and the 1432 
responsiveness of the microbiota to external stimuli such as diet, makes the gut 1433 
microbiota a promising therapeutic target (Levy et al., 2017). Importantly, recent 1434 
studies on animal models and humans have offered more evidence for the association 1435 
of dysbiotic microbiota with ageing (Jackson et al., 2016; Li et al., 2016; 1436 
Thevaranjan et al., 2017) Therefore, gut microbiota modulation is a promising 1437 
strategy towards ameliorating disease and also improving the life of the elderly in 1438 
whom gut microbiota compositional and metabolic changes correlate with age-1439 
related conditions and co-morbidity (Duncan and Flint, 2013). In the following 1440 
sections I will review the gut microbiota modulation approaches used to date. 1441 
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1.2.2 Prebiotics, Probiotics, and next-generation approaches 1442 
The term prebiotic was first coined two decades ago and its definition has been 1443 
repeatedly updated in order to encompass and reflect our increasing understanding of 1444 
how the interplay between diet and gut microbiota affects host health (Bindels et al. 1445 
2015). Prebiotics have moved from being a “non-digestible food ingredient that 1446 
beneficially affects the host by selectively stimulating the growth and/or activity of 1447 
one or a limited number of bacteria in the colon, and thus improves host health” 1448 
described by Gibson and Roberfroid (1995) to a “substrate that is selectively utilized 1449 
by host microorganisms conferring a health benefit” (Gibson et al., 2017). This latest 1450 
definition of the term prebiotic brought a consensus to the various definition updates 1451 
of the last 20 years. According to this definition, selectivity is important and not 1452 
restricted to bifidobacteria and lactobacilli that have been extensively used and 1453 
studied as the main prebiotic targets (Turroni et al., 2014). Importantly, a prebiotic 1454 
may act on body parts other than the GIT that are niches of microorganisms and 1455 
microbiota-mediated health effects must be demonstrated in the relevant host 1456 
(humans or other animals) (Gibson et al., 2017). If some evidence of causality is 1457 
provided between administration and health effect, other non-carbohydrate substrates 1458 
may qualify as prebiotics (Gibson et al., 2017). 1459 
Based on the existing scientific evidence, fructo-oligosaccharides (FOS) and galacto-1460 
oligosaccharides (GOS) are considered the substrates with most supportive data to fit 1461 
the description of prebiotics whereas other oligosaccharides (OS) including human 1462 
and bovine milk OS and other substrates such as dietary fibre, phenolic compounds, 1463 
conjugated linoleic acid (CLA) and polyunsaturated fatty acids (PUFA) are prebiotic 1464 
candidates but further research is required in order to confirm the prebiotic activity 1465 
(Gibson et al., 2017). The health benefits of prebiotic administration is likely to be 1466 
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mediated through microbial metabolite release and homeostatic signalling as a result 1467 
of the selective prebiotic fermentation by target microorganisms (Gibson et al., 1468 
2017). The selectivity is relevant to specialised bacterial hydrolases for complex 1469 
carbohydrates and mechanisms for substrate transfer into the cytoplasm which has 1470 
been extensively described for the prototypical prebiotic taxa lactobacillus and 1471 
bifidobacteria and the metabolism of OS (Goh and Klaenhammer, 2015).  1472 
Probiotics are organisms that when administered alive and at a certain dose confer a 1473 
health benefit to the recipient organism (Gareau et al., 210). As mentioned before, 1474 
bifidobacteria and lactobacilli are model probiotics and this can be attributed to 1475 
certain aspects of their metabolism related to host colonisation and adaptation, such 1476 
as dietary polysaccharide degradation, host-mucus utilization and bile salt hydrolysis 1477 
(Turroni et al., 2014). Certain physiological aspects such as the ability to survive 1478 
acidic conditions and bile salt exposure in the GIT after administration, and oxygen 1479 
tolerance, make the typical probiotics bifidobacteria and lactobacilli technologically 1480 
manageable, partly explaining why probiotic research and development has focused 1481 
on these taxa (Duncan and Flint, 2013). Importantly, the dominant notion that 1482 
probiotic activity is restricted to certain strains within a taxon is evolving: in spite 1483 
the fact that some strains may not have been thoroughly tested in human trials, 1484 
minimum probiotic potential is being recognised in these strains due to the fact that 1485 
they belong in well-established probiotic species and they demonstrate certain 1486 
species-wide characteristics related to probiotic activity (Sanders et al., 2018). Such 1487 
characteristics are cell-wall structure including mucin-binding proteins, pili and S-1488 
layer proteins, exopolysaccharides, complex polysaccharide metabolic pathways, 1489 
bile salt hydrolases and various primary and secondary metabolites such as SCFAs 1490 
and AA (reviewed in Lebeer et al., 2018; Sanders et al., 2018). 1491 
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Probiotics may contribute to health through various ways. The integrity of the gut 1492 
barrier is essential for host homeostasis (Köning et al., 2016) and administration of 1493 
probiotic Lactobacillus strains has been reported to improve tight junctions and 1494 
barrier function in vitro, in murine models and humans (Karczewski et al., 2010; 1495 
Miyauchi et al., 2012; Mujagic et al., 2017; Paveljšek et al., 2018). The SCFA 1496 
butyrate is essential for gut barrier function and immunity, as discussed in previous 1497 
sections, and probiotic administration can contribute to its production in the colon. 1498 
The metabolites lactate and acetate produced by prototypical probiotics such as 1499 
strains of bifidobacteria, can serve as substrates in cross-feeding interactions with 1500 
butyrate producing colonic bacteria (reviewed in Rivière et al., 2016). Probiotics can 1501 
regulate host homeostasis through microbial-associated molecular patterns (MAMPs) 1502 
recognised by host receptors (e.g. Toll-like receptors) and through secreted 1503 
molecules triggering immunity host responses like secretion of anti-inflammatory 1504 
cytokines (van Baarlen et al., 2013; Sanders et al., 2018). Importantly, these 1505 
responses vary and are defined by inter-individual genetic differences and the 1506 
probiotic strain (van Baarlen et al., 2013; Sanders et al., 2018). Probiotics may 1507 
contribute to regulation of metabolism (Simon et al., 2015) and may improve 1508 
cognition through eliciting neurotransmitter and anti-inflammatory cytokine release, 1509 
by being involved in γ-aminobutyric acid (GABA) and tryptophan regulation and in 1510 
the regulation of the hypothalamic-pituitary-adrenal (HPA) axis among other 1511 
mechanisms (reviewed in Sarkar et al., 2016).  1512 
Next-generation probiotics: Lactobacilli and bifidobacteria are the model probiotic 1513 
organisms that research, regulatory authorities and industry have focused on to date 1514 
(Duncan and Flint, 2013). Other bacteria such as E. coli, Bacillus spp., various 1515 
enterococci, Weissella spp. and the fungus Saccharomyces have been also used as 1516 
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probiotics (O’Toole et al., 2017). Importantly, next-generation sequencing and 1517 
metagenomics that have enabled a better understanding of the role of certain GIT 1518 
bacterial consortia in health and disease (Gilbert et al., 2016), and the latest 1519 
culturomics interest that has enlarged the list of isolated and routinely maintained in 1520 
the laboratory GIT strict anaerobes (Lagier et al., 2015), are contributing towards the 1521 
development of novel probiotics.  1522 
Candidate probiotics can be strictly anaerobic health-relevant taxa that are dominant 1523 
or subdominant members of the “healthy” gut microbiota, as opposed to the 1524 
traditionally used probiotics that do not reach dominant abundances in the healthy 1525 
gut, and have a record of reduced abundance in certain disease (Duncan and Flint, 1526 
2013). Next-generation probiotics must comply with the probiotic definition and the 1527 
traditional regulatory requirements for probiotics, that is, safety record and a well-1528 
established pre-clinical and clinical record for the health-benefit conferred to the host 1529 
by its administration (O’Toole et al., 2017). Bacteroides fragilis and B. xylanisolvens, 1530 
F. prausnitzii, A. muciniphila, and Clostridum butyricum are candidates for next-1531 
generation probiotics (NGPs) (reviewed in O’Toole et al., 2017). Importantly, given 1532 
the effort to develop NGPs based on gut microbiota members for which significantly 1533 
reduced abundances have a causal link to targeted disease, NGPs or live 1534 
bacteriotherapeutics, including isolated bacteria or bacterial consortia, may be likely 1535 
to be regulated and delivered as pharmaceutical products rather than food products as 1536 
the traditional probiotics (O’Toole et al., 2017).  1537 
1.2.3 Live bacteriotherapy alternatives to FMT 1538 
Faecal Microbiota Transplantations: Faecal microbiota transplantation (FMT) is 1539 
the gastrointestinal administration of faecal material in suspension from a donor to a 1540 
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recipient, aiming to confer a health benefit by altering the recipinet’s gut microbiota 1541 
composition and potentially eliminating pathogenic colorization (Gupta et al., 2016). 1542 
Faecal microbiota transplantation has been successfully used to treat Clostridium 1543 
difficile infection (CDI) and it is recommended for clinical practice that FMT be 1544 
used in relapsing CDI when antibiotic treatment fails and when the risk of morbidity 1545 
is prevalent (Gupta et al., 2016). Clostridium difficile exploits the inflammatory state 1546 
of the “dysbiotic” GIT often but not exclusively related to antibiotics exposure, in 1547 
order to colonize the colon either asymptomatically or causing diarrhoea of variant 1548 
severity due to toxin release that confers an advantage to the pathogen against 1549 
commensals (Hryckowian et al., 2017). Importantly, CDI correlates to reduced 1550 
phylogenetic diversity in the gut microbiota as observed in hospitalized CDI patients 1551 
(Vincent et al., 2013).  1552 
Faecal microbiota transplantation introduces GIT commensals that compete for 1553 
nutrients and niche with pathogens (Kelly et al., 2015). Increase in the post-FMT 1554 
phylogenetic diversity of the recipient’s gut microbiota plays a significant role in C. 1555 
difficile colonisation resistance and CDI resolution (Schubert et al., 2015; Khanna et 1556 
al., 2017). Increase in the conversion of primary bile salts to secondary and in the 1557 
abundance of relevant bacterial taxa involved in the bile salts metabolism such as 1558 
Clostridium scindens of the Lachnospiraceae in the recipient faecal microbiota 1559 
correlates with resolution of CDI (Buffie et al., 2015; Staley et al., 2016). 1560 
Introduction of gut microbiota commensals that are able to utilize mucosa-derived 1561 
sugars like sialic acids is reported as another mechanism of CDI resolution through 1562 
FMT (Ng et al., 2013). Antimicrobials released by members of the “healthy” donor 1563 
faecal microbiota and the increase in abundance of butyrate-producing bacteria are 1564 
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other routes through which FMT may ameliorate CDI (Rea et al., 2011; Antharam et 1565 
al., 2013).  1566 
Given that antibiotic exposure may lead to reduced resilience to 1567 
pathogens/pathobionts colonisation and expansion in the GIT of taxa such as C. 1568 
difficile, enterococci, Klebsiella and E. coli (Lewis et al., 2015), and the fact that 1569 
other than C. difficile bacteria such as Clostridium perfringens and Staphylococcus 1570 
aureus are associated with antibiotic-associated diarrhoea (AAD) (Larcombe et al., 1571 
2016), FMT could be efficient in treating AAD of various bacterial aetiology. 1572 
Importantly, it is postulated that the therapeutic potential of FMTs can reach beyond 1573 
the treatment of AAD and it can be extrapolated in other disease where dysbiosis is 1574 
strongly associated with the condition. For example, faecal microbiota 1575 
transplantation has been used to treat UC and CD (Moayyedi et al., 2015) and FMT 1576 
from lean to obese individuals resulted in amelioration of insulin resistance (Vrieze 1577 
et al., 2012; He et al., 2017). In spite of the promising results from recent case 1578 
studies of FMT treatment of conditions like IBD and metabolic disease, and contrary 1579 
to CDI FMT treatment for which some scientific consensus exists allowing for 1580 
recommendations and guidelines to clinicians, more research is necessary to 1581 
establish similar workflow for other conditions such as IBD, IBS and metabolic 1582 
disease (Cammarota et al., 2017).  1583 
Faecal microbiota transplantation is highly efficient in the treatment of recurrent CDI 1584 
and holds some promise for the treatment of other dysbiosis-related conditions. 1585 
Importantly, adverse outcomes have been reported for FMT including IBD flare and 1586 
aspiration, and the long-term effect of FMT on the metabolic status of the recipient is 1587 
yet unknown (Kelly et al., 2015). There is scientific interest in refining the FMT 1588 
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approach in order for its implementation to be more clinician- and patient- friendly, 1589 
safer and more standardized (Cammarota et al., 2017). Importantly, research on how 1590 
donor strains establish in the recipient gut microbiota environment is pointing 1591 
towards the development of defined gut microbiota consortia that will allow for a 1592 
highly personalised therapeutic strategy where recipient GIT ecology and immunity 1593 
are taken into consideration for the development of the therapeutic consortium (Li et 1594 
al., 2016). 1595 
Examples of live bacteriotherapy promoting health: Lawley et al. (2012) 1596 
demonstrated in a murine model of recurrent CDI that a cocktail of six faecal 1597 
bacteria (MixB) isolated from healthy mice was as efficient in resolving infection as 1598 
FMT from healthy to diseased mice. The MixB was composed of the taxa 1599 
Staphylococcus warneri, Enterococcus hirae, Lactobacillus reuteri and the newly 1600 
then isolated Anaerostipes sp., Bacteroides sp. and Enterorhabdus sp. that were 1601 
isolated from faecal samples used for the comparison FMT. The study underlined the 1602 
importance of the phylogenetic diversity of the bacterial combination in resolving 1603 
CDI and restoring the murine faecal microbiota to pre-infection composition and 1604 
further showed that a mix of Bacteroides/Lactobacillus representing a probiotic-1605 
based treatment was not able to restore dysbiosis and resolve infection. Using a 1606 
murine models Atarashi et al. (2013) isolated 17 strains from a human faecal 1607 
microbiota donor that were able to induce Treg cell proliferation and anti-1608 
inflammatory components when introduce in germ-free mice. These strains that 1609 
belonged to Clostridium clusters XIVa, IV and XVIII were efficient in attenuating 1610 
inflammation in a chemically induced colitis murine model (Atarashi et al., 2013). 1611 
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Petrof et al. (2013) introduced the “RePOOPulate” stool substitute that was used to 1612 
treat refractory CDI in two patients with a highly infectious C. difficile strain. The 1613 
bacterial mix consisted of 33 strains isolated from the faecal sample of a healthy 1614 
adult and belonged to various phylogenetic groups that are abundant in the gut 1615 
microbiota (Petrof et al., 2013). Six months after the administration of 1616 
“RePOOPulate” stool the patients were free of CDI symptoms and sequences (as 1617 
revealed by 16S rRNA gene sequencing) not abundant pre-treatment were still 1618 
present post-treatment suggesting a perseverance of the introduced bacteria in the 1619 
recipient microbiota (Petrof et al., 2013). This consortium referred to as microbial 1620 
ecosystem therapeutic-1 (MET-1) was subsequently used in a murine model of 1621 
Salmonella typhimurium infection (Martz et al., 2015). MET-1 could not resolve 1622 
infection but was found to be protective of tight-junctions activity which prevented 1623 
the pathogen from establishing systemic infection (Martz et al., 2015). The microbial 1624 
ecosystem therapeutic-2 (MET-2) was developed from 33 strains isolated from the 1625 
faeces of a healthy donor representing the minimal gut microbiota of the derivative 1626 
donor (Yen et al., 2015) and is currently being used in a clinical trial for the 1627 
resolution of refractory CDI 1628 
(https://clinicaltrials.gov/ct2/show/study/NCT02865616). In another recent clinical 1629 
trial, Khanna et al. (2016) successfully treated CDI patients with SER-109, a 1630 
therapeutic mix of encapsulated spores from 50 spore-forming Firmicutes species 1631 
isolated from healthy donors.   1632 
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1.2.4 In vitro and in vivo models for the development of gut microbiota 1633 
therapeutics 1634 
In vitro GIT models and in vivo animal models are facilitating research on the 1635 
therapeutic manipulation of the gut microbiota before applying these therapeutic 1636 
approaches in clinical trials.  1637 
In vitro models: Single- and multi-stage chemostats have been used for decades for 1638 
temperature and pH controlled anaerobic faecal fermentations of selected substrates 1639 
allowing for the simulation and study of basic aspects of faecal microbiota metabolic 1640 
activity (Allison et al., 1989; Macfarlane et al., 1989). Model design varies from a 1641 
single stage chemostat operating as batch or continuously, to multistage 1642 
interconnected chemostats that operate in a continuous flow, simulating one or 1643 
various parts from proximal to distal colon depending on the set pH of the different 1644 
vessels (Payne et al., 2012). More advanced continuous models such as SHIME and 1645 
TIM aim at incorporating the host digestion factor (Payne et al., 2012). TIM-2 was 1646 
developed based on the stomach and small intestine TNO TIM-1 in vitro GIT model, 1647 
and is a computer-controlled model for the large intestine that can simulate 1648 
peristaltic movements and dialysis (reviewed by Venema, K., 2015). The simulator 1649 
of the human intestinal microbial ecosystem SHIME is composed of five vessels 1650 
mimicking the GIT from the stomach to the colon parts (reviewed by Van de Wiele 1651 
et al., 2015). Other in vitro models that are being used are the 4-vessel simulator of 1652 
colon parts EnteroMix and the Lacroix model that allows for better growth of both 1653 
lumen-living and attached to surfaces microbiota (reviewed in Venema and Van den 1654 
Abbeele, 2013). 1655 
In vitro models present inherent limitations such as the lack of the host immune and 1656 
metabolic responses, the lack of epithelial cell barriers and mucin adhesion sites, and 1657 
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the lack of the high level of compartmentalisation that is achieved in the host GIT 1658 
(Macfarlane and Macfarlane, 2007). Researchers have developed various in vitro 1659 
model set-ups aiming at tackling these limitations; for example the multistage 1660 
systems that have been developed in order to simulate various GIT tract parts as 1661 
discussed previously. The introduction of mucin surfaces in two-stage systems 1662 
offered an attachment site for sessile faecal bacteria such as Bacteroides fragilis-1663 
related taxa, clostridia and enterobacteria (Macfarlane et al., 2005). Cinquin et al. 1664 
(2006) applied a faecal microbiota immobilization technique in order to prevent 1665 
wash-out of faecal microbiota in a three-stage continuous system. Modifications of 1666 
the SHIME system allowed for incorporating a mucin environment (M-SHIME) that 1667 
deterred wash-out of sessile members of the faecal microbiota such as Clostridium 1668 
cluster XIVa belonging taxa leading to more in-vivo relevant conditions (Van den 1669 
Abbeele et al., 2012; Van den Abbeele et al., 2013). In a more sophisticated set-up, 1670 
SHIME was combined with a platform of host cells and microbiota interaction (HMI) 1671 
(Marzorati et al., 2014).  1672 
In spite of the limitations, in vitro systems allow for a relatively low-cost, 1673 
straightforward and high-throughput approach to study the effect of various 1674 
substrates from candidate probiotics and prebiotics to novel drugs on the 1675 
compositional and metabolic profile of the faecal microbiota deriving from healthy 1676 
or diseased donors (Macfarlane and Macfarlane, 2007). The compositional effect on 1677 
the faecal microbiota is analysed with various molecular methods such as 16S rRNA 1678 
gene next-generation sequencing, qPCR and fluorescent in situ hybridisation (FISH) 1679 
and analytical techniques such as HPLC are being used for SCFA production.  1680 
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For example, Van den Abbeele et al. (2013) compared the effect of long-chain 1681 
arabinoxylan (LC-AX) and inulin on the human faecal microbiota in SHIME and 1682 
TIM and reported that in both systems LC-AX demonstrated similar to inulin 1683 
prebiotic effects on distinct bifidobacteria population and SCFA production. 1684 
Compared to the FOS faecal fermentation pattern that was utilized in the simulated 1685 
proximal colon area, arabinogalactan (AG) was available for fermentation in distal 1686 
parts of the simulated colon in the SHIME system revealing a potential role of AG in 1687 
reducing the distal colonic pH by increasing carbohydrate fermentation in the distal 1688 
colon and promoting the growth of butyrate-producers such as F. prausnitzii 1689 
(Terpend et al., 2013).  1690 
Chung et al. (2016) using a three-vessel in vitro system with variant fixed-pH 1691 
conditions showed that the prebiotic effect of non-digestible substrates like pectin 1692 
and inulin is determined by the faecal microbiota inter-individual compositional 1693 
variations, the fluctuations in pH that naturally occur in the colon as opposed to the 1694 
stable conditions of the simulated colonic fermentations, and that responses to 1695 
substrates cannot be easily extrapolated to the whole taxonomic structure based on 1696 
individual taxon-members responsiveness. Poeker et al. (2018) investigated the 1697 
prebiotic effect of the dietary fibres β-glucan, a-galacto-oligosaccharides (α-GOS) 1698 
and xylo-oligosaccharides (XOS) on the faecal microbiota of healthy individuals 1699 
using a three-vessel continuous system (PolyFermS). They reported that the in vitro 1700 
response of the faecal microbiota was largely dependent on the inter-individual 1701 
variations of the baseline microbiota and proposed that the metabolic responses of 1702 
the microbiota such as the SCFA production can be the most comparable measure of 1703 
the prebiotic potential of test substrates on microbiotas from different subjects 1704 
(Poeker et al., 2018). 1705 
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Other potentially prebiotic substrates tested in in vitro systems are wheat dextrin, α-1706 
gluco-oligosaccharides, fructo-, galacto- and iso- malto- oligosaccharides, lactulose 1707 
and lactosucrose (Hobden et al., 2013; Sarbini et al., 2013; Takagi et al., 2016), as 1708 
well as food ingredients such as whey, fruits and phenolic compounds (Sanchez-1709 
Patan et al., 2015; Koutsos et al. 2017; Sanchez-Moya et al., 2017). Probiotics have 1710 
been tested in in vitro systems alone or combined with prebiotic substrates and in 1711 
combination with pathobionts in pre-clinical tests investigating the potential of 1712 
probiotics to prevent pathogen establishment in the GIT tract (Martinez et al., 2013; 1713 
Cardarelli et al., 2016; van den Abbeele et al., 2016). 1714 
In vitro systems simulating colonic fermentation in studies of prebiotic and probiotic 1715 
modulation of the faecal microbiota of healthy older subjects have been used but to a 1716 
limited extent (Likotrafiti et al., 2014; Liu et al., 2016). Fehlbaum et al. (2015) 1717 
proposed the use of the adjusted PolyFermS multi-stage in vitro system as a 1718 
reproducible set-up for the study of various factors such as diet, on the faecal 1719 
microbiota of older donors. The PolyFermS employed immobilized faecal 1720 
microbiota to continuously seed connected fermentation vessels and medium turn-1721 
over period was regulated in order to represent colonic transit times observed in 1722 
healthy older people (Fehlbaum et al. 2015). Faecal microbiota from healthy elderly 1723 
has been used in in vitro studies and to my knowledge no study has explored the in 1724 
vitro modulatory effect of prebiotic candidates on the low-diversity faecal microbiota 1725 
from frail elderly.  1726 
Murine models in gut microbiota research: Mouse models such as germ-free (GF) 1727 
and gnotobiotic mice, human microbiota associated (HMA) and conventional mice, 1728 
offer an in vivo environment to study interactions between the gut microbiota and 1729 
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exogenous factors like diet and therefore, circumvent to some extent the 1730 
aforementioned limitations of the in vitro environment. In spite of caveats in 1731 
translating observations from mice to humans, murine models have largely 1732 
facilitated pre-clinical research on the host-microbiota interactions and causality with 1733 
regards to health and disease, diet and novel therapeutics (Nguyen et al., 2015). 1734 
Germ-free (GF) mice are reared aseptically in order to prevent the development of 1735 
their indigenous gut microbiota, they are kept under sterile conditions throughout 1736 
their life and they allow the researcher to define the gut microbiota of the 1737 
experimental animal by selected colonisation (Martin et al., 2016). 1738 
Conventionalisation can be performed by transplanting selected microbiota strains or 1739 
whole faecal microbiota from healthy or diseased donors, mice or humans 1740 
(“humanisation”). Due to shared host responses and colonisation mechanisms, 1741 
microbiotas from ecologically divergent hosts can survive and establish in other than 1742 
their indigenous GIT niche (Rawls et al., 2006; Seedorf et al., 2014).  1743 
The primary concern with gnotobiotic models is the successful establishment of the 1744 
donor microbiota and the potential metabolic impact on the recipient animal. 1745 
Bäckhed et al. (2004) using GF C57BL/6 adult mice reported that microbiota 1746 
transplantation from conventional to GF mice resulted in increased energy harvest 1747 
mediated by the transplanted microbiota showing not only the importance of the gut 1748 
microbiota in energy harvesting for the host but also that the transplantation could 1749 
alter the recipient metabolic profile. Turnbaugh et al. (2006) demonstrated that 1750 
metabolic profiles like obesity that are associated with certain gut microbiota 1751 
composition (Ley et al., 2005) can be transmitted from conventional obese mice to 1752 
GF. The potential of metabolic profile transfer through conventionalisation is an 1753 
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essential tool in metabolic disease and obesity pre-clinical research allowing for 1754 
causality and mechanistic observations on how the whole microbiota composition, 1755 
certain taxa and the metabolome respond to Western diet mediating adiposity 1756 
(Turnbaugh et al., 2009). 1757 
Due to rearing in the absence of the indigenous microbiota, the GF mouse has certain 1758 
GIT physiology alterations and immunity impairments compared to conventional 1759 
animals such as fewer and smaller Peyer patches and mesenteric lymph nodes, 1760 
alterations in the villus formations of the epithelial cells and lower expression levels 1761 
of Toll-like receptors (reviewed in Round and Mazmanian, 2009). These 1762 
physiological differences compared to conventional animals and constraints 1763 
regarding the laborious process of generation and maintenance of GF murine strains, 1764 
have led to the development of methods for the depletion of the indigenous gut 1765 
microbiota of conventional mice with antibiotic (Abx) treatment (Bereswill et al., 1766 
2011; Hintze et al., 2014). The metabolic profile transfer demonstrated in GF murine 1767 
models was partly demonstrated in ampicillin-treated C57BL/6 adult and weaning 1768 
mice that received microbiota transplants from obese and lean mice (Ellekilde et al., 1769 
2015). The donors microbiota compositional profile was maintained and some 1770 
obesity-related clinical outcomes were observed for a certain post-transplantation 1771 
period before the microbiota composition begun to revert back to the murine baseline 1772 
(Ellekilde et al., 2015). 1773 
Antibiotic treatment of conventional mice prior to microbiota transplantation 1774 
presents certain advantages and disadvantages compared to GF mice (summarised in 1775 
Lundberg et al., 2016). The relatively lower maintenance cost and the fact that the 1776 
Abx approach can be applied to the desired mouse strain by the researcher as 1777 
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opposed to the limited available GF mouse strains that are prepared in specialised 1778 
laboratories are some advantages of the Abx method. The fully mature immune 1779 
system of the Abx mice is another comparative advantage. Overgrowth of 1780 
pathobionts, antibiotic resistance expansion and re-emergence of the indigenous 1781 
baseline microbiota are some of the negative aspects of the Abx approach that may 1782 
lead to spurious reproducibility. Furthermore, it has been reported that 1783 
conventionalisation of GF C57BL/6 adult mice resulted in “conventionalisation” of 1784 
the innate and adaptive immune system 30 days post microbiota transplantation (El 1785 
Aidy et al., 2012; El Aidy et al., 2014). Importantly, Chung et al. (2013) 1786 
demonstrated that it is the mouse-related (or host-related) gut microbiota that can 1787 
“normalise” the immature GF mouse immunity. The potential of achieving 1788 
normalisation of the immune system of GF mice within a certain time should be 1789 
taken into account when designing experiments on host-immunity-microbiota 1790 
interactions. 1791 
Efficacy of human microbiota colonisation of the murine gut and use of 1792 
conventional mice in gut microbiota studies: Another point of consideration on 1793 
gnotobiotic mouse models is the efficacy of the establishment of the xenomicrobiota 1794 
in the recipient gut. It is well documented that the host selective pressure that shapes 1795 
the indigenous microbiota will be also applied to the transplanted microbiota 1796 
reshaping it in order to match the host physiology, immunity and diet (Messer et al., 1797 
2016). Therefore, certain donor species such as taxa that depend on host-specific 1798 
niches like the mucosa, may be proven unable to establish in the recipient gut 1799 
rendering the transplanted microbiota significantly dependant on the given diet 1800 
(Arrieta et al., 2016). Wos-Oxley et al. (2012) comparing the colonisation patterns of 1801 
GF rats, GF mice and ciprofloxacin-treated mice with human faecal microbiota 1802 
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under a low-fat high-polysaccharide diet, reported that mice favoured the 1803 
Bacteroidetes establishment whereas major Firmicutes taxa belonging to Clostridium 1804 
cluster IV, XIVa and the Clostridium leptum group did not reach a high level of 1805 
colonisation efficacy.  1806 
Arrieta et al. (2016) proposed that, at least in studies focusing on the overall 1807 
ecological effect on the gut microbiota of an exogenous factor such as diet, 1808 
conventional mice with their intact gut microbiota could be a more informative pre-1809 
clinical approach. Caveats in the extrapolation of conclusions from studies with 1810 
conventional mice to humans that to some extent can be generalised for the 1811 
aforementioned murine models, are the differences in physiology and anatomy of the 1812 
murine and human GIT tract including size, mucosal surfaces, the existence or not of 1813 
forestomach and the caecum size, that define specific niches for host-adapted taxa 1814 
(Nguyen et al., 2015). The taxa shared between murine and human gut microbiota 1815 
significantly differ in relative abundances and distinct bacterial groups dominate the 1816 
two microbiotas; for example, Faecalibacterium, Ruminococcus and Prevotella are 1817 
dominant in the human gut microbiota whereas Lactobacillus, Alistipes and 1818 
Turicibacter dominate the murine gut (Nguyen et al., 2015).  1819 
Importantly, the murine microbiota differs between the various available mouse 1820 
strains and even within strains, the provider company, the maintenance facilities, co-1821 
housing and coprophagy may significantly contribute to the baseline murine 1822 
microbiota, thus affecting reproducibility of experiments and comparisons between 1823 
studies (Hugenholtz and de Vos, 2018). Given the importance of mouse models in 1824 
host-gut microbiota research, the determinative role of the baseline murine 1825 
microbiota in the study outcomes and the lack of extensive studies focusing on the 1826 
86 
 
indigenous murine microbiota, Lagkouvardos et al. (2016) established a collection of 1827 
isolated murine bacterial strains, analogous to human culturomics.  1828 
So far, I have discussed major mouse models i.e. GF and Abx-treated mice 1829 
conventionalised with murine microbiota or “humanised” with human microbiota, 1830 
and points of consideration for each approach such as immune responses in GF mice 1831 
and efficacy of colonization with xenomicrobiota. Importantly, conventional mice 1832 
are a valuable tool in the study of host-microbiota interactions since every model is 1833 
accompanied by certain considerations when it comes to translating observations 1834 
from mouse to humans. With regards to reproducibility, gnotobiotic mice remain a 1835 
well-controlled, reproducible animal model used in many studies that have 1836 
significantly contributed to our increased understanding of the complicated 1837 
interactions between gut microbiota-host-dysbiosis-exogenous factors. The selected 1838 
in vivo studies shown in Table 3 demonstrate the breadth of the scientific questions 1839 
conserning gut microbiota diet, health and disease that have been investigated 1840 
through employing mouse models and it is not an exhaustive review of the existing 1841 
murine model studies. 1842 
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Table 3 Selected studies employing murine models in the study of gut microbiota, diet, health and disease. 1843 
Mouse model Donor microbiota Condition Test substrate  Outcomes Reference 





High-fat sugar rich 
“Western” diet 
 human faecal microbiota establishment in GF 
mice  
 microbiota transmission from gnotobiotic mice to 
offspring 
 rapid and reproducible responses in composition 
metabolome and gene expression of the 
microbiota due to switch to “Western” diet altered 
 transmission of host diet-induced adiposity to 
gnotobiotic mice 
 isolation of obesity associated Erysipelotrichia 
taxa 
 




- Diet-induced obesity  High-fat diet (HF)  
 
Arabinoxylan (AX) 
AX restored gut microbiota changes due to HF diet: 
 ↑ Bacteroides-Prevotella spp., Roseburia spp. 
 ↑ caecal bifidobacteria 
AX decreased adiposity, improved tight junctions function 
 




-  Diet-induced obesity High-fat diet (HF)  
 
Arabinoxylan OS (AXOS) 
AXOS restored obesity measurements: 
 ↓ insulin resistance 
 ↓ metabolic endotoxemia 
 ↓ macrophage infiltration 
 ↓ IL6 in plasma 
AXOS improved gut microbiota factors: 
 ↑ caecal bifidobacteria 
 Up-regulations of tight junction proteins  
















B. thetaiotaomicron  
and  
B. longum  
bi-colonisation 
 
“humanisation” and diet 







 distinct metabolomes in humanised and 
conventional mice 
 distinct clustering of the “humanised” microbiotas 
(UniFrac distances) and metabolomes based on 
PD and PDD diet  
 colonisation with simple defined microbiotas 
model to some extent the “humanisation” 
metabolic process  




8 bacterial strains from 
human gut microbiota  
diet-induced obesity +/-Clostridium ramosum 
(Erysipelotrichia) 
 
High-fat diet (HFD) 
 
Low-fat diet (LFD) 
 
 HFD promoted C. ramosum abundance and 
obesity 
 C. ramosum related transcription upregulation of 
glucose and fat transport proteins in jejunal and 
ileum mucosa 




- Frailty and ageing Standard chow frailty index correlated to ageing 
 
characteristics of the “aged” murine microbiota composition 
and function : 
 ↑Alistipes (Rikenellaceae)  
 ↓cobalamin, biotin biosynthesis 
 ↑creatine degradation related to muscle wasting 
 ↓di-,oligo- and poly-saccharide utilisation genes 
 




Human C. difficile infection Antibiotic treatment 
 
C. difficile spores  
 “humanised” microbiota transferred to offsprings 
 establishment of  CDI and recurrent CDI in 
gnotobiotic murine model 
 






Murine ageing and systemic 
inflammation 
Standard chow microbiota transfer from conventional old to GF young mice 
promoted inflammageing : 
 ↑TM7 and Protoebacteria taxa 
 ↓Akkermansia  
  ↑ T cell activation 
 ↑inflammation inducing bacterial components in 
circulation 




1.3 The effect of milk and glycomacropeptide on the gut microbiota 1844 
1.3.1 The effect of milk on human health and the gut microbiota  1845 
Dairy products and milk have been a component of human nutrition since the 1846 
seventh millennium BC (Evershed et al., 2008). According to the Food and 1847 
Agriculture Organisation of the United Nations (FAO) 1848 
(http://www.fao.org/home/en/) in Europe the annual consumption of milk rises to 1849 
more than 150 kg per capita providing to consumers 9% of the dietary energy 1850 
supply, 19% of the protein supply and the 11%-14% of the dietary fat. Milk 1851 
consumption is higher in developed countries but many developing countries are 1852 
steadily increasing their per capita milk consumption (FAO; Gateway to dairy 1853 
production and products).  1854 
Milk is a rich source of nutrients (Table 4) composed of lipids including saturated 1855 
and unsaturated fatty acids, milk fat globule membranes (MFGM), phospholipids 1856 
and glycosphingolipids, proteins such as casein and whey, vitamins such as vitamin 1857 
A, E and B12, and minerals including calcium, magnesium, phosphorus and zinc 1858 
(Haug et al., 2007). The carbohydrate profile of bovine milk is composed mainly of 1859 
the disaccharide lactose, traces of neutral and acidic sialic acid containing 1860 
oligosaccharides, and glycoconjugates (Gopal and Gill, 2000; Hsieh et al., 2015). 1861 
Glycoproteins like the extensively sialylated mucins, and glycolipids comprise the 1862 
glycoconjugate component of bovine milk (O’Riordan et al., 2014).  1863 
The beneficial effect of milk and dairy in human diet has been challenged mostly on 1864 
the basis of the high saturated fat content in milk but the evidence supporting this 1865 
notion is inconclusive. Meta-analysis of various observational and prospective cohort 1866 
studies has concluded that no consistent association between milk consumption and 1867 
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increased all-cause mortality can be established (Guo et al., 2017). Conversely, 1868 
various studies including epidemiological studies indicate the multitude of health 1869 
benefits of moderate milk consumption (Visioli and Strata, 2014). 1870 
Table 4 Bovine milk components. The data is taken from the Society of Dairy 1871 
Technology (https://www.sdt.org/pages/) and O’Riordan et al. (2014). The table is 1872 
not exhaustively presenting all milk components, but the main ones. 1873 
Component and 
proportion in bovine 
milk 
Detailed composition 
Fat 4% Small globules covered by the milk fat globule 
membrane (MFGM), rich in proteins and phospholipids 
Proteins 3.3%  Caseins (76%) in casein micelles structure: 
αs1, αs2, β, κ 
 Whey (18%): β-lactoglobulin, α-lactalbumin 
Carbohydrates 5%  Lactose (4.7%) 
 Free oligosaccharides, glycoconjugates 
Minerals 0.7% Calcium, phosphorus  
Organic acids 0.2% Citric and lactic acid 
Vitamins traces  Fat-soluble: A, D, E, K 
 Water-soluble: B1, B2, B6, B12 
Water  87%  
1.3.1.1 Cardio-metabolic disease and all-cause mortality 1874 
Certain co-occurring metabolic conditions including obesity, insulin resistance and 1875 
high lipidaemia, grouped under the term Metabolic Syndrome (MetS), may be risk 1876 
factors for cardiovascular disease (CVD), diabetes type 2 (T2D) and hepatic steatosis 1877 
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(reviewed in Lusis et al., 2008; Catrysse and van Loo, 2017). Cardio-metabolic 1878 
conditions are prevalent in Western countries; chronic low-grade inflammation is an 1879 
underlying factor of these conditions and apart from human genetics, high-fat dietary 1880 
choices and sedentary life style are strongly associated with MetS development 1881 
(Catrysse and van Loo, 2017).  1882 
Evidence from large Western cohorts and meta-analysis of prospective cohort studies 1883 
support milk and dairy inclusion in a balanced diet and the positive association of 1884 
increased dairy consumption with a reduction in risk of coronary health and MetS 1885 
risk (Panagiotakos et al., 2010; Benatar et al., 2014; Crichton and Alkewri, 2014; 1886 
Drehmer et al., 2016). In Asian countries like Korea and Japan, where in spite of 1887 
Western influence dietary patterns remain different from those in Western countries, 1888 
a higher milk and dairy consumption was associated with a lower risk of MetS 1889 
development (Jun et al., 2016). In another non-Western cohort of Iranian adults, 1890 
regular weekly whole milk consumption but not daily consumption was associated 1891 
with reduced CVD risk (Talaei et al., 2017).  1892 
Conversely, in two cohorts (n≈100,000 older adults) in Sweden, where consumption 1893 
of fluid milk is one of the highest worldwide, a high milk consumption was 1894 
associated with adverse health outcomes, i.e. all-cause mortality and hip fracture 1895 
(Michaelsson et al., 2014; Tognon et al., 2017). Michaelsson et al. (2014) observed 1896 
that ≥3 glasses of milk per day was associated with increased mortality and hip-1897 
fracture in two Swedish cohorts followed for 11 and 20 years. Tognon et al. (2017) 1898 
observed that high consumption of non-fermented milk (>2.5 intakes per day) 1899 
correlated with an increased risk of all-cause mortality in a dose-response manner in 1900 
a mean follow-up time of approximately 14 y. Importantly, Tognon et al. (2017) 1901 
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observed that non-fermented milk consumption was associated with consumers with 1902 
poorer educational level compared to cheese consumers who had comparatively 1903 
reduced all-cause mortality risk. This observation may indicate that residual 1904 
confounding factors associated with life-style may have masked a more relevant to 1905 
milk consumption effect on the participants’ health.  1906 
Milk-based diets were shown to attenuate oxidative stress in obese and overweight 1907 
subjects compared to non-dairy intervention control diets (Zemel et al., 2010; 1908 
Stancliffe et al., 2011). Milk and dairy consumption may improve blood pressure 1909 
and arterial plasticity potentially due to milk proteins and peptides released upon 1910 
digestion (Lovegrove and Hobbs, 2016). In spite of the heavy load in whole milk and 1911 
dairy products of saturated fatty acids (SFA) (Mansson, 2008) evidence suggests that 1912 
whole dairy (excluding butter) does not contribute to significant or detrimental 1913 
increase in blood low-density lipoprotein cholesterol (LDL-C) (reviewed in 1914 
Lovegrove and Hobbs, 2016). For the milk proteins whey and casein, data from 1915 
clinical studies are relatively consistent indicating towards a potential positive effect 1916 
on blood glucose regulation (Fekete et al., 2016). Importantly, frequent low-fat milk 1917 
and dairy consumption may be associated with a lower risk of T2D (Aune et al., 1918 
2013; Díaz-López et al., 2016). 1919 
Observational studies have often provoked controversy on the effect of milk 1920 
consumption and all-cause mortality (Larsson et al., 2015). Importantly, adjustment 1921 
for a wide array of confounding factors such as background dietary patterns, life-1922 
long exposure to dairy, life-style and exercise, smoking, age, sex, education, self-1923 
reported milk and dairy servings could leverage bias in observational study design. 1924 
Leverage of the confounding factors effect and clinical trials with well-defined dairy 1925 
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products (ex. non-fermented milk with variant fat content) could further elucidate 1926 
existing controversy. 1927 
1.3.1.2 Frailty 1928 
Frailty is a condition of functional disability observed in older age, that is 1929 
characterised by the gradual loss of homeostatic maintenance of the organism even 1930 
under minor challenges and it may lead to increased dependency, adverse outcomes 1931 
after hospitalization and even death (Clegg et al., 2013). The frailty phenotype is not 1932 
restricted to older age but it is also observed in people with advanced HIV and 1933 
cancer (Deeks, 2011; Ethun et al., 2017). Sarcopenia which is the state of de-1934 
regulated muscular homeostasis leading to the progressive loss of muscle mass and 1935 
functionality decline is widely recognised as a syndrome and it is one of the main 1936 
frailty manifestations; metabolic, inflammatory and dietary challenges may 1937 
contribute to the development and progression of the syndrome (Fielding et al., 1938 
2011). Importantly, frailty assessment models can successfully predict the risk of 1939 
osteoporosis-related bone fracture in older age (Li et al., 2017). New drug 1940 
development, physical activity and dietary interventions are being employed towards 1941 
reversing the frailty scores in sufferers (Keevil and Romero-Ortuno, 2015). 1942 
Muscle maintenance results from the balance between muscle protein synthesis 1943 
(MPS) triggered by dietary anabolic stimuli like proteins and amino acids and the 1944 
naturally occurring process of proteolysis (Mitchell et al., 2016). Glucose regulation 1945 
and muscle protein turn-over pass through the homeostatic metabolic junction of the 1946 
mechanistic target of rapamycin (mTOR) where the essential amino acids especially 1947 
leucine, and insulin are key signalling molecules (Barzilai et al., 2012; Saxton and 1948 
Sabatini, 2017). In older age anabolic resistance blunts the sensitivity of the 1949 
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organism to respond to these signals and consecutively to translate the signals to 1950 
muscle accretion eventually leading to wasting; nutritional interventions with 1951 
leucine-rich and easily ingested high in protein dietary supplements and physical 1952 
activity may reverse the adverse outcome of severe muscle loss (Moore, 2014). 1953 
Whey protein is considered “fast” in releasing amino acids in blood after digestion 1954 
and may stimulate postprandial MPS whereas casein that is considered “slow” 1955 
confers a moderate prolonged aminoacidaemia and supresses muscle protein 1956 
breakdown (MPB) (Boirie et al., 1997). Fast postprandial aminoacidaemia was 1957 
initially considered as an MPS driver but it seems that the amino acid composition of 1958 
the dietary proteins ingested (ex. leucine content) is key to the anabolic activity 1959 
(Mitchell et al., 2016). The milk proteins whey and casein that contain all essential 1960 
amino acids and are rich in leucine (Hall et al., 2003) have been studied in human 1961 
trials in the concept of “fast” and “slow” protein and MPS. 1962 
Consumption of fluid skim milk that combines the two types of “slow” and “fast” 1963 
proteins after exercise resulted in greater muscle accrual in young adults compared to 1964 
isonitrogenous and isoenergetic soy beverage consumption (Hartman et al., 2007; 1965 
Wilkinson et al., 2007). Whey supplementation alone was reported efficient to better 1966 
sustain protein synthesis and lean mass gain in adults after resistance exercise and 1967 
compared to casein or soy protein (Tang et al., 2009; Volek et al., 2013).  1968 
For older subjects in whom high quality dietary amino acids intake is essential for 1969 
muscle accretion, the rapidly digested rich-in-leucine whey protein may be a suitable 1970 
dietary protein source (Landi et al., 2016). Twenty g of whey protein were more 1971 
effective in postprandial muscle protein retention in healthy men over 74 yrs without 1972 
any exercise intervention compared to the ingestion of the same amount of casein or 1973 
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casein hydrolysate (Pennings et al., 2011). Mitchell et al., (2015) reported that 20 g 1974 
of either milk protein isolate or whey protein dietary supplementation resulted in the 1975 
same postprandial muscle protein fractional synthetic rates (FSR) in healthy mostly 1976 
sedentary men aged 45-60 yrs. This suggests that milk protein is a widely accessible 1977 
food component and is thus adequate source of dietary protein for older adults. 1978 
In observational studies of large population cohorts, older people that are regular 1979 
consumers of dairy i.e., milk, yoghurt and cheese, have improved measurements for 1980 
skeletal muscle and bone mass compared to less regular consumers. Observations 1981 
from the Quebec NuAge cohort of people over 67 yrs, showed that community-1982 
residing people consuming ≥2 serving of dairy (milk, yoghurt, cheese) per day had 1983 
better functionality and mobility measurements and increased lean mass compared to 1984 
people consuming less servings per day (Farsijani et al., 2017). In the Quebec 1985 
NuAge study the reduced risk of pre-frailty or frailty was more pronounced among 1986 
men with high dairy intake compared to low intake than in the respective group of 1987 
women. Among 564 community-dwelling women with mean age 85 yrs, high dairy 1988 
consumption (≥2.2 servings per day) assessed for the previous 12 months associated 1989 
with higher bone density and skeletal muscle mass (Radavelli-Bagatini et al., 2014). 1990 
Radavelli-Bagatini et al. (2013) had previously reported similar positive effects on 1991 
muscular and bone health for a larger cohort of women aged 70-85 yrs. In a cohort 1992 
(n=1,871) of non-hospitalized non-frail adults over 60 yrs, consumption of ≥7 1993 
serving per week of low-fat milk and yoghurt was associated with reduced frailty 1994 
risk in a 3.5 years follow-up (Lana et al., 2015).  1995 
Regarding bone density and risk of fracture in older age, Sahni et al. (2014) observed 1996 
that for adults over 77 yrs (Farmingham, USA) who regularly consumed milk or 1997 
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milk and yoghurt, the risk of hip fracture was significantly lower compared to that 1998 
low in frequency consumers of dairy products. The group also showed that high milk, 1999 
yoghurt and dairy consumption may benefit bone health among elderly under dietary 2000 
vitamin D supplementation (Sahni et al., 2017a). Recent studies suggest that diets 2001 
rich in dairy may be beneficial for bone mineral density and reduced risk of hip 2002 
fracture in elderly population (de Jonge et al., 2017; Durosier-Izart et al., 2017).  2003 
Other studies contradict the beneficial effect or report no effect of milk on skeletal 2004 
health. For example, a 2011 meta-analysis of cohort studies showed that there was 2005 
no association between milk consumption and bone fracture risk for older women 2006 
whereas for men there was a marginal inverse association (Bischoff-Ferrari et al., 2007 
2011). In two large Swedish cohorts (≥45.000 subjects each) of adults from 39 to 79 2008 
yrs old and for a long follow-up period of over a decade high milk intake was 2009 
positively correlated with higher mortality and hip fracture (Michaelsson et al., 2014) 2010 
as discussed above in this review. The study of Michaelsson et al. (2014) reported 2011 
that the female high-milk-consuming participants showed increased health risk in a 2012 
20 yrs follow-up period. This prolonged follow-up period potentially increased the 2013 
confounding factors; in older adults mortality will increase over the years and older 2014 
age co-morbidities may have masked the effect of dairy products on the participants’ 2015 
health (Sahni et al., 2017b). 2016 
1.3.1.3 Other potential health benefits of milk consumption 2017 
There are conflicting studies on the beneficial effect of milk consumption on 2018 
cognition. In older adult populations with Western life-style, total low fat dairy and 2019 
cheese consumption but not milk alone was reported beneficial for various cognition 2020 
measurements (Crichton et al, 2010; Park and Fulgoni, 2013). Camfield et al. (2011) 2021 
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after a thorough review of existing cross-section studies concluded that low-fat dairy 2022 
products including milk incorporated in balanced diet may positively affect cognitive 2023 
function of older adults. Similarly, Wu and Sun (2016) after reviewing available 2024 
studies on milk and dairy consumption, concluded that there may be a trend 2025 
suggesting that regular milk consumption improves cognition. This trend was more 2026 
pronounced in Asian cohorts and it was attributed to the fact that total dairy intake is 2027 
less common as a background diet in Asia compared to Western countries (Wu and 2028 
Sun, 2016) making the effect of milk more detectable. More prospective studies with 2029 
standardized measurements and adjustment for a wider range of cofounding factors 2030 
(Wu and Sun, 2016) as well as clinical trials are needed in order to draw robust 2031 
conclusions on the effect of milk on cognitive function.  2032 
Many studies have explored the impact of regular milk consumption on several 2033 
cancers but firm conclusion cannot be drawn yet (Visoli and Strata, 2014). An area 2034 
of particular interest has been colorectal cancer (CRC) and dairy calcium intake. 2035 
According to the WHO, CRC is the second most prevalent cause of cancer death 2036 
among Europeans and a major cause of mortality worldwide with life-style factors 2037 
such as diet being one of the risk factors (http://www.euro.who.int/en/health-2038 
topics/noncommunicable-diseases/cancer/news/news/2012/2/early-detection-of-2039 
common-cancers/colorectal-cancer). 2040 
Park et al. (2009) conducted a large prospective study on American older adults ≥50 2041 
yrs (293,907 men and 198,903 women) and assessed incidents of cancer and dairy 2042 
products (milk, yoghurt, cheese) consumption over 7 years. The group found no 2043 
adverse outcomes from dairy consumption and cancer incident; high dairy and 2044 
supplemental calcium intake was related to 16% and 23% lower risk of GIT cancers 2045 
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(especially CRC) in men and women respectively. Of note was the observation that 2046 
people with higher dairy consumption tended to have a healthier life-style and be 2047 
college educated. Aune et al. (2012) conducted a meta-analysis on 19 cohort studies 2048 
performed until May 2010 and concluded that high milk and total dairy intake (200 g 2049 
and 400 g per day respectively) was associated with reduced CRC incident.  2050 
More recently, Murphy et al. (2013) investigated the effect of dairy product habitual 2051 
consumption and colorectal cancer risk in a prospective study on European adults 2052 
(EPIC cohort: 10 countries, n=477,122, over 35 yrs old, 11 years follow-up). A 2053 
portion of whole-fat or skimmed milk and dairy per day but not supplemental 2054 
calcium was inversely associated with CRC occurrence. In a USA cohort of 77,712 2055 
older adults, a 7 year old follow-up study showed that milk consumption and dairy 2056 
(milk, yoghurt, cheese) may be protective for rectal and CRC; the group suggested 2057 
that dietary calcium may be protective against CRC (Tantamango-Bartley et al., 2058 
2017).  2059 
The existing data do not suggest a significant effect of milk intake on breast cancer 2060 
occurrence. A prospective study of 64,904 Norwegian women showed that dairy 2061 
consumption had no significant impact on pre- or post-menopausal breast cancer 2062 
incidence (Hjartaker et al., 2010). In a meta-analysis of 18 prospective cohort studies 2063 
intake level of total dairy products (milk, yoghurt, cheese, butter) but not milk alone 2064 
was associated with reduced risk of breast cancer (Dong et al., 2011). Similarly, lung 2065 
cancer did not seem to be significantly associated to milk or dairy products 2066 
consumption (Yang et al., 2016).  2067 
Milk consumption may play a detrimental role in the progression of prostate cancer. 2068 
Among 3,918 mostly Caucasian men in U.S.A. (Health Professionals Follow-Up 2069 
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Study) diagnosed with prostate cancer at baseline those that frequently consumed 2070 
whole milk had increased risk of disease progression compared to the less frequent 2071 
whole milk consumers or those frequently consuming low-fat dairy products who 2072 
demonstrated reduced risk for disease progression after 7.6 years of follow-up 2073 
(Pettersson et al., 2013). In another cohort of 926 men diagnosed with non-2074 
metastatic prostate cancer (Physician’s Health Study) 3 servings of dairy per day 2075 
associated with higher risk of total and prostate cancer-related mortality compared to 2076 
men consuming 1 serving per day (Yang et al., 2016). Downer et al. (2017) reported 2077 
that ≥3 servings per day of high-fat milk correlated with higher risk of prostate 2078 
cancer mortality compared to 1 serving per day. Both Yang et al. and Downer et al. 2079 
observed a borderline positive association for low-fat dairy and reduced cancer 2080 
mortality. Some studies have suggested a link between milk and dairy lactose to risk 2081 
for ovarian cancer (Larsson et al., 2006; Qin et al., 2016) whereas dietary calcium 2082 
was inversely associated to the disease (Qin et al., 2016; Song et al. 2017).  2083 
A small number of recent studies suggest a beneficial role of dairy products in renal 2084 
health. Regular low fat dairy products and dietary calcium was reported beneficial 2085 
for kidney function in a cohort of ≥50 yrs old Australians (Gopinath et al., 2016). 2086 
Rebholz et al. (2016) also observed a protective effect of a healthy diet rich in low-2087 
fat milk and yoghurt against kidney disease in a large cohort of middle-aged African-2088 
American and Caucasians. 2089 
1.3.1.4 Strengths and weaknesses of cohort observation studies assessing the 2090 
effect of milk on various-cause mortality  2091 
With regards to prospective cohort studies assessing the effect of milk and dairy 2092 
products consumption on various causes of mortality in adults, and despite some 2093 
conflicting observations, meta-analysis tends to agree that regular milk intake 2094 
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especially low-fat incorporated in a healthy diet may be beneficial in lowering the 2095 
risk of cardiometabolic disease, improving frailty indices in the general adult 2096 
population and potentially contributing to cognitive function in elderly (Camfield et 2097 
al., 2011; Visioli and Strata, 2014).  2098 
Authors have suggested, as explanation for conflicting results relating to the effect of 2099 
milk and dairy products on human health, the adjustments for various confounding 2100 
factors in prospective cohort studies and the consecutive adjustments in meta-2101 
analysis. Background diet, socioeconomic status, smoking and life-style, baseline 2102 
measurements of health status, differences in self-reported portion measurement and 2103 
lack of discrimination between whole or low-fat dairy product are some of the 2104 
possible confounding factors reported in the prospective studies and meta-analysis 2105 
studies considered in this review that may have led to conflicting results or masking 2106 
potential effects of dairy consumption. Interestingly, some studies report that milk 2107 
and dairy products consumers had higher education and socioeconomic status as well 2108 
as enjoying a healthier life-style compared to those with lower frequency dairy 2109 
product consumption (Wu et al., 2016), whereas in other studies milk consumption 2110 
was higher among people of lower socioeconomic status (Talaei et al., 2017).  2111 
Milk contains a wealth of nutrients that may synergistically and/or individually 2112 
mediate the reported potential effects of milk and dairy products ingestion in human 2113 
health. Various peptides such as lactoferrin, α-lactalbumin, β-lactoglobulin, fractions 2114 
of α-, β- and κ-casein and peptides released from dairy after digestion, gut 2115 
microbiota fermentation and food preparation, have been reported to play a 2116 
beneficial role as anti-thrombotic compounds, inhibiting angiotension and potentially 2117 
as insulintropics (reviewed in Horner et al., 2016). Calcium, vitamin D and 2118 
conjugated linoleic acid (CLA) may be mediators of the chemoprotective activity of 2119 
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milk (Song et al., 2015). Conversely, D-galactose, lactose, IGF-1, calcium, saturated 2120 
fat and hormones contained in milk have been proposed as factors with detrimental 2121 
effects in oxidative stress and cancer incidence (Yang et al., 2016(a); Yang et al., 2122 
2016(b); Berghlodt et al., 2017). Well-designed prospective studies adjusting for a 2123 
wide range of confounding factors and clinical trials on selected cohorts and in vitro 2124 
/vivo studies will further elucidate the role of whole dairy and individual milk 2125 
components in human health and reveal the mechanism that mediate the effects.  2126 
1.3.1.5 Lactose-intolerance  2127 
Dietary oligosaccharides and disaccharides are hydrolysed by intestinal 2128 
disaccharidases in order for the constituent monomers to be absorbed by the 2129 
enterocytes in the small intestine (Amiri et al., 2015). Oligosaccharides and 2130 
disaccharides that escape hydrolysis and absorption in the small intestine reach the 2131 
distal colon where they can cause osmotic flux of water and increased H2, CO2 and 2132 
fatty acids concentration due to fermentation by colonic bacteria (Amiri et al., 2015). 2133 
The disaccharide lactose (consisting of galactose and glucose) is the main 2134 
carbohydrate in human and farm animal milk (Silanikove et al., 2015). In humans, 2135 
hydrolysis of lactose is highly active during lactation and declines after weaning; 2136 
more than half of the human population has low lactase activity as a result of the 2137 
genetically programmed decline of lactase synthesis (lactose non-persistent subjects 2138 
- LNP) (Deng et al., 2015). Lactase deficiency may also occur after a GIT disease or 2139 
as a rare congenital condition in early life; in all cases malabsorbed lactose persists 2140 
in the distal GIT and in some cases it may lead to symptoms of lactose intolerance 2141 
(Deng et al., 2015). Not all adults lose lactase synthesis activity and the ability to 2142 
thoroughly digest lactose (lactose persistent subjects- LP). In modern populations 2143 
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deriving from ancient pastoral populations, lactase synthesis may remain active 2144 
throughout adulthood (Gerbault et al., 2011).  2145 
Lactose malabsorption in LNP individuals does not always lead to lactose 2146 
intolerance symptoms and to a clinically detectable condition (Misselwitz et al., 2147 
2013). Lactose maldigestion can be accompanied by bloating, abdominal pain, 2148 
borborygmi, diarrhoea and nausea, and subjects reporting such discomforts may 2149 
follow certain diagnostic steps towards the clinical evaluation of their condition 2150 
(summarized by Misselwitz et al., 2013). The diagnosis includes tests for 2151 
malabsorption such as the lactose H2-breath test alone or after the ingestion of milk. 2152 
Throughout the lactose intolerance diagnosis procedure, other conditions such as IBS 2153 
or small intestinal bacterial overgrowth (SIBO) should be considered as potential 2154 
contributors to the self-reported discomforts (Misselwitz et al., 2013).   2155 
People with self-reported symptoms of lactose malabsorbance or lactose intolerance 2156 
tend to avoid milk and dairy products therefore excluding from their daily diet a 2157 
valuable source of important nutrients and calcium (Heaney, 2013). Avoidance of 2158 
dairy foods is not recommended for the improvement of lactose intolerance (Szilagyi, 2159 
2015a) especially when, apart from lactose malabsorption or intolerance, there is 2160 
another condition that could be improved by dairy consumption (Szilagyi et al., 2161 
2016). Lactase non-persistent individuals can tolerate an average of 12 g of lactose 2162 
per day (approximately one glass of milk) without developing symptoms (Szilagyi, 2163 
2015b). Lactase non-persistent individuals can develop tolerance to lactose through 2164 
adaptation of the colonic microbiota to lactose fermentation, a phenomenon that 2165 
indicates that lactose may have a prebiotic effect on the gut microbiota of LNP 2166 
subjects (Szilagyi, 2015b).  2167 
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1.3.1.6 Milk and the gut microbiota 2168 
Little is known about the effect of non-human fluid non-fermented milk on the 2169 
human gut microbiota and the prebiotic potential of its carbohydrate load. The 2170 
carbohydrate fraction of milk consists mainly of lactose, oligosaccharides (OS) and 2171 
glycoconjugates (Table 4). Mature human milk has higher content of lactose (70 g/l) 2172 
and OS (5-15 g/l) compared to bovine milk (48 g/l and 0.05 g/l respectively) 2173 
(summarized in Bode, 2012). Glucose, galactose, fucose, N-acetylneyraminic acid 2174 
(NeuAc/sialic acid) and N-acetylglucosamine (GlcNAc) are the simple carbohydrates 2175 
that compose the milk OS; N-glycolylneuraminic acid (NeuGc) and lactose amine 2176 
are present only in bovine milk (Tao et al., 2008). The human milk oligosaccharides 2177 
(HMOs) are mostly fucosylated whereas a high proportion of the bovine milk 2178 
oligosaccharides (BMOs) is sialylated (Bode, 2012). 2179 
Fructo-oligosaccharides and GOS that are widely used as prebiotics (see Chapter 1.2) 2180 
do not reach the structural and compositional complexity of HMOs or the (similar in 2181 
structure) highly complex BMOs (Zivkovic and Barile, 2011). Human milk 2182 
oligosaccharides have been extensively studied because of their potent prebiotic 2183 
effect on the infant gut microbiota (Smilowitz et al., 2014). If BMO prebiotic 2184 
activity is proven, BMOs could then be used as an alternative to HMOs for food 2185 
supplementation and the dairy industry could scale-up the relevant BMO isolation 2186 
(Zivkovic and Barile, 2011). 2187 
Bovine milk OS exist only in trace amounts in mature bovine milk, and whey 2188 
concentrate that naturally contains large amounts of OS (approximately 200 mg/L) is 2189 
currently used for BMO isolation (Zivkovic and Barile, 2011). There are ongoing 2190 
efforts to develop scalable methods to isolate highly pure BMOs and sensitive 2191 
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analytical tools for the characterisation of the OS isolate profiles in order to further 2192 
elucidate the structural complexity and natural variation extend of BMOs 2193 
(Sundekilde et al., 2012; Mehra et al., 2014; de Moura Bell et al., 2018). Importantly, 2194 
only a few BMOs (approximately 40) have been identified compared to the more 2195 
than 100 known HMOs (Bode, 2012). 2196 
To my knowledge there are no extensive studies yet exploring the effect of non-2197 
human non-fermented fluid milk on the gut microbiota. Tannock et al. (2012) 2198 
reported that the faecal microbiota of bovine milk supplemented formula-fed infants 2199 
had relatively greater abundance of Lachnospiraceae compared to breast-fed. Yin et 2200 
al. (2014) reported that ingestion of acidified milk-supplemented standard chow 2201 
increased the abundance of Lachnospiraceae in the murine faecal microbiota 2202 
compared to milk supplemented with probiotic Lactobacillus or water. 2203 
A few recent studies exploring the effect of isolated BMOs on the gut microbiota 2204 
gave some insight on the beneficial potential of milk carbohydrates in GIT health. 2205 
Charbonneau et al. (2016) showed that in both germ-free mice and gnotobiotic 2206 
piglets, sialylated BMO (S-BMO) supplemented diet resulted in a faecal microbiota-2207 
mediated attenuation of the effects of malnutrition on lean body mass, muscle and 2208 
bone health and cognitive function. Karav et al. (2016) demonstrated in vitro that OS 2209 
derived from bovine milk glycoproteins supported Bifidobacterium longum subsp. 2210 
infantis growth. Bifidobacterium infantis is a member of the gut microbiota of 2211 
breast-fed infants and selectively grows on HMOs. Bovine milk glycans may 2212 
represent a selective substrate for gut microbiota taxa alternative to HMOs (Karav et 2213 
al., 2016).  2214 
105 
 
Boudry et al. (2017) reported that BMOs normalized diet-induced obesity effects on 2215 
the gut microbiota composition and gut barrier function in a murine model. Similarly, 2216 
Hamilton et al. (2017) showed that, in a mouse model, BMO supplemented diet was 2217 
more efficient in attenuating the effect of high fat diet on gut barrier function and gut 2218 
microbiota compared to prebiotic inulin supplementation. A recent study 2219 
investigating the effect of dietary supplementation with BMOs in humans showed 2220 
that equivalent to plant-origin prebiotic doses of BMOs were well tolerated by 2221 
healthy adults but with no drastic effect on stool consistency and gut microbiota 2222 
composition after 11 days of dietary intervention (Smilowitz et al., 2017).  2223 
Other components of milk may confer gut microbiota-mediated health benefits. 2224 
Norris et al. (2016) reported that a bovine milk sphingomyelin-supplemented diet 2225 
counteracted the negative effect of high-fat diet in a mouse model by lowering the 2226 
serum cholesterol and by reducing the circulating LPS with a concomitant increase 2227 
in the relative abundance of faecal Firmicutes and Actinobacteria, predominantly 2228 
Bifidobacterium. In a neonatal murine model, bovine MFGM-supplemented formula 2229 
effectively attenuated the GIT deformities observed under the influence of MFGM-2230 
deprived diet; the gut microbiota composition of the mice fed the MFGM 2231 
supplemented formula clustered with the faecal microbiota of mice fed maternal 2232 
milk that contains naturally occurring MFGM (Bhinder et al., 2017). Lee et al. (2018) 2233 
observed improvement of metabolism and changes in microbial metabolites in 2234 
malnourished children due to bovine MFGM supplementation. Conversely, in a 2235 
murine model, ingestion of a diet high in saturated milk fat resulted in the increased 2236 
abundance of the sulphur-reducing bacterium Bilophila wadsworthia in the faecal 2237 
microbiota, and increased the incidence of colitis in genetically susceptible mice but 2238 
not in wild type (Devkota et al., 2012).  2239 
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Exploring the effect of individual milk components on the gut microbiota and health 2240 
is useful on its own merit but it does not allow for a deep comprehension of the 2241 
synergistic effect of milk components. Despite some research on the effect of milk 2242 
components on the GIT and the gut microbiota, the synergistic effect of all the 2243 
constituent components of fluid milk and variations of the standard bovine milk such 2244 
as whole and lactose free, remains largely unexplored.  2245 
1.3.1.7 The prebiotic potential of the dairy product Glycomacropeptide (GMP)  2246 
Glycomacropeptide (GMP) is the glycosylated form of the caseinomacropeptide 2247 
(CMP) that is released in whey during cheese production when chymosin (rennin) 2248 
hydrolyses milk kappa casein (κ-CN) into para-κ-CN and caseinomacropeptide 2249 
(CMP) fractions (Neelima, 2013). The genetic variations of the amino acid (AA) 2250 
sequence of κ-CN and the variant phosphorylation and glycosylation sites contribute 2251 
to the heterogeneity of the GMP peptides (reviewed in Thoma-Worringer et al., 2252 
2006). Approximately 50% of the bovine CMP is glycosylated with 5 variations of 2253 
O-linked mono- to tetra-saccharide carbohydrate chains containing combinations of 2254 
NeuAc, Gal and GalNAc (Thoma-Worringer et al., 2006). Glycomacropeptide has a 2255 
high content of essential and branched chain AA (EAA and BCAA respectively) 2256 
compared to the average dietary protein and depending on the efficiency of GMP 2257 
isolation and purification, none to trace amounts of the aromatic AA phenylalanine 2258 
(Phe), tyrosine (Tyr) and tryptophan (Trp) (Etzel, 2004). In whey, GMP makes up 2259 
approximately 25% of the protein content, and ultrafiltration of whey is 2260 
recommended as the most efficient method for the commercial recovery of GMP 2261 
(Neelima, 2013). 2262 
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Glycomacropeptide has a number of health relevant properties. Based on a number 2263 
of in vitro studies it was suggested that GMP may inhibit binding by Cholera toxin, 2264 
Shigella flexneri, Salmonella enteritidis and pathogenic E. coli to the mammalian 2265 
cell mostly due to its sialic acid content (Kawasaki et al., 1992; Oh et al., 2000; 2266 
Nakajima et al., 2005; Bruck et al., 2006; Feeney et al., 2017). Glycomacropeptide 2267 
exerts some effect on the immune system as demonstrated in in vitro studies 2268 
(Requena et al., 2009; Gong et al., 2014). In murine models of induced colitis and 2269 
ileitis, GMP administration normalized the systemic and local inflammation and 2270 
attenuated the macroscopically observed GIT damage due to the inflammatory 2271 
treatment (Requena et al., 2008; Lopez-Posadas et al., 2010; Xu et al., 2013; Ortega-2272 
Gonzalez et al., 2014; Cui et al., 2017). Hvas et al. (2016) observed the anti-2273 
inflammatory potential of GMP administration on patients with UC. 2274 
Glycomacropeptide has been successfully used in clinical trials as a naturally 2275 
occurring, low in Phe, dietary alternative to synthetic AA protein for 2276 
phenylketonuria (PKU) dietary management (Ney et al., 2016; Ahring et al., 2017). 2277 
There is inconclusive evidence on the prebiotic potential of GMP. Supplementation 2278 
of growth medium with GMP could sustain the growth of probiotic strains of 2279 
Lactobacillus and Bifidobacterium in pure culture conditions (Robitaille, 2013). The 2280 
growth promoting effect of GMP on probiotic Lactobacillus and Bifidobacterium 2281 
taxa was not confirmed when complex faecal microbiota from either infants or adults 2282 
was used for in vitro fermentations of GMP supplemented media (Bruck et al., 2006; 2283 
Hernandez-Hernandez et al., 2011; Ntemiri et al., 2017; Chapter 2, this thesis).  2284 
In a piglet model GMP feeding resulted in the increase of Lactobacillus counts and 2285 
decrease of pathogenic E.coli (Hermes et al. 2013). Sawin et al. (2015) reported that 2286 
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wild type (WT) and PKU mice fed GMP-supplemented diet had significantly 2287 
reduced relative abundance of the sulphur-reducing taxon Desulfovibrio in the faecal 2288 
and caecal microbiota compared to mice fed casein and AA supplemented diet 2289 
respectively. In the caecum and faecal microbiota of PKU mice fed GMP-2290 
supplemented diet the relative abundance of Bacteroidetes was significantly higher 2291 
compared to an AA-based feeding regime; increase in Bacteroidetes was not 2292 
observed for WT mice fed GMP (Sawin et al., 2015). Sawin et al. (2015) provided 2293 
valuable insight on the effect of GMP on the murine faecal and caecal microbiota in 2294 
comparison to the AA and casein effect. However, the group did not provide 2295 
compositional information of the baseline microbiota of WT and PKU and did not 2296 
present microbiota data at a fine taxonomical level which would have put in context 2297 
the observed effect of the diets on the microbiota. Recently, Jimenez et al. (2017) 2298 
using an allergy rat model observed that GMP administration conferred significant 2299 
increase in the faecal Lactobacillus and Bifidobacterium population. Bacteroides 2300 
population also increased in rats with allergy after GMP administration (Jimenez et 2301 
al., 2017). These two recent papers report an effect of GMP on the Bacteroidetes 2302 
population; baseline microbiota composition information is necessary in order to 2303 
clarify what compositional “dysbiosis”, if any, was restored with GMP 2304 
administration.  2305 
109 
 
1.4  Aims and objectives  2306 
In this chapter have reviewed the general aspects of the gut microbiota composition, 2307 
how the microbiota is established in the human gut at birth and during the first years 2308 
of life, and how the gut microbiota composition and functionality is associated with 2309 
health and disease throughout life span, and with ageing. Importantly, changes in the 2310 
gut microbiota composition and functionality are associated with age-related frailty. 2311 
The gut microbiota is a modifiable factor for maintaining health and ameliorating 2312 
disease, and one of the means to modify the microbiota is the use of dietary 2313 
components with prebiotic potential. This research thesis focused on exploring the 2314 
potential of certain dietary substrates of animal- and plant-origin to modulate the gut 2315 
microbiota of older people aiming at identifying changes in the gut microbiota 2316 
composition that can be associated to a “healthy” gut microbiota profile. The dietary 2317 
substrates of interest were the milk-derived glycomacropeptide (GMP), whole milk 2318 
(with or without lactose) and blueberry fruit. Milk is a source of nutrients including 2319 
carbohydrates and oligosaccharides but the prebiotic potential of milk and its by-2320 
products remains largely unexplored. Blueberries are rich in polyphenols; these 2321 
compounds can modulate the gut microbiota but there are no clear associations 2322 
between microbiota members and the bioconversion of phenolic compounds. 2323 
Importantly, the potential of “dysbiotic” faecal microbiota to respond to dietary 2324 
supplementation was investigated. An in vitro colon model was established in order 2325 
to evaluate the prebiotic potential of the dietary substrates before proceeding to an in 2326 
vivo model.   2327 
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2.1 Abstract 3157 
The potential of milk-derived glycomacropeptide (GMP) and lactose for modulating 3158 
the human gut microbiota of older people, in whom loss of diversity correlates with 3159 
inferior health, was investigated. We used an in vitro batch fermentation (artificial 3160 
colon model) to simulate colonic fermentation processes of two GMP products, i.e. a 3161 
commercially available GMP concentrate and a semi-purified GMP concentrate, and 3162 
lactose. Faecal samples were collected from healthy and frail older people. Samples 3163 
were analysed by Illumina Miseq sequencing of rRNA gene amplicons. The 3164 
commercial GMP preparation had a positive effect on the growth of Coprococcus 3165 
and Clostridium cluster XIVb and sustained a higher faecal microbiota diversity 3166 
compared to control substrates or lactose. Lactose fermentation promoted the growth 3167 
of Proteobacteria including Escherichia/Shigella. This work provides an in-depth 3168 
insight on the potential of GMP and lactose for modulating the gut microbiota and 3169 
contributes more evidence confirming the prebiotic activity of GMP.  3170 
Keywords: Glycomacropeptide, lactose, artificial colon model, faecal microbiota, 3171 
healthy elderly, frail elderly  3172 
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2.2 Introduction 3173 
The human gastrointestinal tract (GIT) harbours a phylogenetically diverse bacterial 3174 
community that significantly contributes to host health (Donaldson et al., 2015).The 3175 
gut microbiota is determinatively shaped by habitual diet (Claesson et al., 2012; 3176 
Jeffery et al., 2016; Sonnenburg et al., 2016). Dysbiosis refers to alterations from 3177 
typical proportions of taxa in the gut microbiota composition and altered diversity, 3178 
changes often related to non-healthy conditions (Cho et al., 2012). Targeted 3179 
modulation of the gut microbiota is emerging as an approach for ameliorating a 3180 
series of conditions related to dysbiosis (Foxx-Orenstein et al., 2012).  3181 
There is evidence linking the process of ageing-related health loss to the gut 3182 
microbiome (Heintz et al., 2014). From adulthood to older age the gut microbiota 3183 
undergoes significant compositional and metabolic changes that define the gut 3184 
microbiota profile of the elderly (Claesson et al., 2011; O’Tole and Jeffery, 2015). 3185 
These shifts in the gut microbiome increase pathobiont infection susceptibility in the 3186 
older population
 
(Rea et al., 2012).  3187 
Recent studies suggest a link between dairy consumption and a number of health 3188 
benefits including muscle maintenance and bone density in older subjects (Sahni et 3189 
al., 2014; Lana et al., 2015). Little is known about the effect of milk components on 3190 
the gut microbiota. The content of lactose in commercial milk is ~4% (Albenzio et 3191 
al., 2016). Lactose is a candidate prebiotic (Roberfroid, 2007) especially among 3192 
lactase non-persistent people (LNP) related to its demonstrated growth promotion of 3193 
lactobacilli and bifidobacteria (Szilagyie et al., 2015), with a potential protective role 3194 
in colorectal health (Jatvinen et al., 2001). 3195 
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Caseinomacropeptide (CMP) is produced from milk during cheese making; during 3196 
this procedure, chymosin hydrolyses the kappa-casein (κ-CN) of milk resulting in 3197 
the para-κ-CN (residues 1-105) and CMP (residues 106-169) (Neelima et al., 2013). 3198 
Glycomacropeptide (GMP) is the glycosylated form of CMP; GMP has five mucin-3199 
type glycans namely N-acetylneuraminic acid (NeuAc) or sialic acid, galactose 3200 
(Gal), and N-acetylgalactosamine (Gal-Nac) that anchor to the CMP through O-3201 
glycosidic linkages (Kreuss et al., 2008). GMP is rich in branched chain amino acids 3202 
(BCAA) and essential amino acids (EAA) and purified GMP concentrate is depleted 3203 
of aromatic amino acids (Thoma-Worringer et al., 2006).  3204 
The major health-relevant effects of GMP are anti-inflammatory activity, protection 3205 
against GIT pathogens and contribution to phenylketonouria (PKU) nutritional 3206 
management (Thoma-Worringer et al., 20106; Van Calcar and Ney, 2012). There are 3207 
contradictory data on the effects of GMP on the growth promotion of 3208 
Bifidobacterium and Lactobacillus strains (Bruck et al., 2006; Hernandez-Hernandez 3209 
et al., 2011; Robitaille, 2013). Recently Sawin et al. (2015) reported that GMP 3210 
feeding resulted in a significant decrease in the abundance of Proteobacteria and the 3211 
genus Desulfovibrio in the caecal and faecal microbiota of wild type and 3212 
phenylketonouric mice. Although the data were based on murine microbiota and no 3213 
extended description of the microbiota was provided, the study offered a more 3214 
conclusive view of the effect of GMP on the gut microbiota compared to previous 3215 
studies. 3216 
The aim of this study was to explore the prebiotic potential of two GMP products, a 3217 
commercially available product and a semi-purified preparation, and of lactose, on 3218 
the faecal microbiota in an in vitro batch fermentation system over 24 hrs. The 3219 
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responsiveness to these growth substrates of low diversity and higher diversity 3220 
microbiota was investigated in faecal samples obtained from healthy and frail elderly 3221 
subjects, since the latter are characterised by reduced microbiota diversity. 3222 
2.3 Material and Methods 3223 
Faecal samples: Faecal samples were collected from healthy older donors 3224 
(community samples) (EM425 male 81 yrs, EM278 female 69 yrs, EM604 female 75 3225 
yrs) and older donors that reside in long term residential care units (longstay 3226 
samples) (EM703 male 93 yrs, EM297 female 82 yrs, EM704 male 89 yrs). All 3227 
practices were approved by the local Clinical Research Ethics Committee. Each stool 3228 
sample was placed in a container with a reducing agent (Anaerocult A; Merck 3229 
Millipore, Ireland) and transferred to an anaerobic cabinet less than an hour after 3230 
defecation. Each stool was thoroughly homogenised (10% w/v) in sterile reduced 3231 
phosphate buffer saline (PBS) and 20% glycerol. Faecal slurries from each stool 3232 
sample were prepared as inocula for the fermentation vessel and stored frozen in 3233 
aliquots at -80 °C before thawing and adding to the fermenter.  3234 
Commercial and semi-purified GMP: For the in vitro tests, Lacprodan CGMP-10 3235 
(CGMP-10) was obtained from Arla Foods Ingredients, Viby J, Denmark. The semi-3236 
purified GMP (tGMP) was produced as described below. Sweet whey protein isolate 3237 
powder (sWPI) was sourced from Kerry Group plc, Listowel Ireland. A GMP 3238 
enriched whey fraction was prepared using a modified method as developed by 3239 
Tanimoto et al (1991). Three hundred grams of sWPI was reconstituted in 1 L 3240 
distilled water, stirred at room temperature for 2 hrs and left to rehydrate at 4 °C 3241 
overnight. The sWPI was pH adjusted to 3.8 using 1 M HCl and stirred at room temp 3242 
for 30 min. The sWPI was then processed through a 30 kDa molecular weight cut off 3243 
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(MWCO) membrane (Vivaflow 200 tangential flow units; Sartorius, Göttingen, 3244 
Germany) at an operating TMP of ~2.25 bar, and 300 mL of permeate (Pr1) was 3245 
collected. Peristaltic pumps (230V Masterflex L/S Easy-Load peristaltic pumps; 3246 
Cole Parmer, Niles, IL, USA) and size 16 PVC pump tubing was used. Pr1 was then 3247 
pH adjusted to pH 7.0 using NaOH and processed using 10 kDa MWCO 3248 
polyethersulfone membrane following 30 min acclimatisation period in full 3249 
recirculation mode, and the GMP enriched retentate was collected. Diafiltration was 3250 
carried out with equivalent volume of distilled water and diluted retentate was 3251 
concentrated back to its original volume and frozen at -20°C. GMP enriched 3252 
solutions were freeze dried using Wizard 2.0 freeze drier (Virtis AdVantage, UK). 3253 
Quantification of the whey proteins α-lactalbumin, β-lactoglobulin and GMP (for 3254 
both GMP products) was carried out by RP-HPLC using automated Waters 2695 3255 
Separation module (Waters Associates, Milford, MA, USA) fitted with a quaternary 3256 
pump, mobile phase degasser, auto-sampler and a multi-wavelength detector. 3257 
Calibration curves were obtained for each of the standards i.e. α-lac, β-lg and GMP 3258 
and Waters Empower data analysis software was used to quantify the α-lac, β-lg and 3259 
GMP content.  3260 
In vitro fermentations: A single stage chemostat system and basal medium (no 3261 
carbohydrates supplementation) was used as described previously to simulate the 3262 
colonic microbiota fermentation of the selected substrates (Hernandez-Hernandez et 3263 
al., 2011). The pH (pH 7.0) and temperature (37°C) controlled batch fermentations 3264 
were conducted in 1 L working volume, under continuous flow of CO2 over a period 3265 
of 24 h. Twenty-four hr fermentation was chosen over a continuous fermentation as a 3266 
standard approach to study prebiotic effects on the faecal microbiota (Hernandez-3267 
Hernandez et al., 2011; Zhang et al., 2016). 
22, 26
 Cysteine-HCL was filter sterilised 3268 
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(0.2 μm filters) and added to the basal medium after sterilisation. Glucose and 3269 
lactose were filtered sterilised and added to the sterilised medium at a final 3270 
concentration of 1% w/v. GMP preparations were added to the sterilised medium 3271 
after dilution in sterile distilled water. Six substrate conditions were used for each of 3272 
the faecal samples: i. basal medium, ii. Glucose (Sigma-Aldrich), iii. lactose (Sigma-3273 
Aldrich), iv. CGMP-10, v. tGMP, vi. CGMP-10 combined with glucose. All 3274 
substrates were added to a final concentration of 1%; for substrate condition vi. 3275 
CGMP-10 and glucose were added to 0.5% respectively. The faecal samples were 3276 
thawed in an anaerobic cabinet and inoculation in the fermenter vessel was 3277 
performed anaerobically immediately after thawing at a final concentration of 1% 3278 
w/v. At time points zero hours and twenty-four hours 50 mL of fully stirred 3279 
fermentation culture was retrieved and immediately centrifuged. Faecal pellet and 3280 
supernatant were kept separately in -20 °C for genomic DNA (gDNA) extraction and 3281 
SCFA analysis respectively.  3282 
Genomic DNA extraction: Genomic DNA (gDNA) was extracted using the QIamp 3283 
Fast DNA Stool (Qiagen) kit. Faecal pellets were weighed and suspended in 1 ml 3284 
sterile PBS. 200 μL of the suspended slurry was retrieved for gDNA extractions in 3285 
order to provide the 200 mg of faeces required for the QIamp Fast DNA Stool 3286 
(Qiagen) extraction kit protocol. The faecal slurry was placed in sterile tubes 3287 
containing 0.1 mm, 0.5 mm and 1.0 mm zirconia / glass beads (Thistle Scientific, 3288 
UK). One ml of InhibitEX buffer was added to the samples and then homogenised 3289 
under two pulses of 1 min and a final of 30 sec using a Minibeadbeader (Biospec 3290 
Products). In the intervals of the homogenisation steps the samples were placed on 3291 
ice for 1 min. The samples were then placed in a 70 °C heat-block for 10 min. The 3292 
following steps of the DNA extraction were carried out as described in the Qiagen 3293 
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protocol using 15 μL of proteinase K with 200 μL of AL buffer, 200 μL of lysate and 3294 
200 μL of ethanol at the relevant steps.   3295 
16S rRNA amplicon Illumina library preparation: The Illumina MiSeq System 3296 
(San Diego, California, USA) was used for amplicon sequencing of the 16S rRNA 3297 
variable region V3 and V4. The universal 16S ribosomal RNA gene primers forward 3298 
primer for V3 region 5’ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCC 3299 
TACGGGNGGCWGCAG 3’ and reverse primer for V4 region 5’ GTCTC GTGG 3300 
GCTC GGAG ATGTGTATA AGA GACAGGACTAC HV GGG TATC TA ATCC 3301 
3’ were used (Klindworth et al., 2013). The library preparation and sequencing was 3302 
performed according to the Illumina MiSeq System protocol. The PCR products 3303 
were purified and dual-index barcodes attached to the amplicon (Nextera XT V.2 3304 
Index Kits sets A and D, Illumina). Amplicons were purified using Agencourt 3305 
AMPure XP-PCR Purification system (Beckman Coutler, Inc.) and quantified using 3306 
a Qubit dsDNA HS Assay Kit (Thermo Fischer Scientific, MA, USA). Samples were 3307 
pooled in order to achieve the same concentration of DNA per amplicon and 3308 
sequenced by Eurofins Genetics Services Ltd. (Wolverhampton UK) on a MiSeq 3309 
Illumina platform and 2x300 bp Chemistry. 3310 
16S amplicon sequence analysis: For all demultiplexed samples barcodes were 3311 
reattached with relevant custom scripts (Flemer et al., 2016), primers were removed 3312 
by the cutadapt tool, forward and reverse reads per sample were joined using the 3313 
FLASH computational tool (Magoc et al., 2011).  The reads were demultiplexed 3314 
using the split_libraries.py script in Qiime. De novo operation taxonomic unit (OTU) 3315 
table based on the data reads was generated via Usearch; reads were assigned to 3316 
OTUs as follows. Based on length size unique sequences were selected using the 3317 
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derep_fulllength command discarding singletons by –minuniquesize -2 command. 3318 
Clustering of the sequences was performed using cluster_otus command (Edgar et 3319 
al., 2013). Sequences were screened for chimeras using the ChimeraSlayer utility 3320 
(Haas et al., 2011). To map all reads to the representative sequences OTUs database 3321 
the Usearch_global command was used based on 97% identity threshold. The uc file 3322 
generated was converted to an OTU table via uc2otutab.py command. Taxonomy 3323 
was assigned to each OTU (classify.seqs) to genus level using Mothur and the RDP 3324 
16S rRNA database (Wang et al., 2007). 3325 
Microbiota composition statistics: The R software package was used for the 3326 
statistical analysis of the sequenced data (R Core Team, 2014). From the sequenced 3327 
samples only those with a number of reads >5000 were kept for further analysis. The 3328 
OTU counts per sample were rarefied to a common minimum of reads per sample. 3329 
Metrics of phylogenetic distance between the sequenced samples were calculated 3330 
using the weighted and unweighted UniFrac method (Lozupone and Knight, 2008). 3331 
The data was visualised using principal components analysis (PCoA) with functions 3332 
s.class and dudi.pco from the ade4 package. The row counts data table was 3333 
transformed to relative abundances (0:100) table for obtaining relative abundance of 3334 
the bacterial populations in the samples to genus level. Relative abundances results 3335 
were obtained for individual samples and aggregated community-type and longstay-3336 
type samples. The Shannon diversity index was used as a metric of within-sample 3337 
alpha diversity and species evenness (Lozupone and Knight, 2008). A pairwise 3338 
Wilcoxon rank test was performed to identify significant Shannon diversity changes 3339 
from 0 hrs to 24 hrs due to medium fermentation. The DESeq2 package (Love et al., 3340 
2014) was used for pairwise comparisons of 0hrs and 24hrs for the fold changes 3341 
(log2 fold change) in the bacterial populations at genus level based on row read 3342 
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counts per sample. Normalisation of read counts is embedded in the DESeq2 3343 
function. P value for DESeq2 results was adjusted for multiple comparisons using 3344 
the Benjamini-Hochberg method. Results were considered significant if the p 3345 
adjusted values were padj≤ 0.05 while padj <0.1 were regarded as a trend.  3346 
Short chain fatty acid analysis and statistics: High performance liquid 3347 
chromatography (HPLC) was used for the analysis of acetate, propionate and 3348 
butyrate production (Hernandez-Hernandez et al., 2011). Slurry retrieved from the 3349 
fermenter vessel was centrifuged for 30 min. The supernatant was filtered through 3350 
0.2 μm filter and 1 ml was used for SCFA analysis HPLC. An agilent 1200 HPLC 3351 
system with a refractive index detector was used. An Agilent Hi-Plex H 300x7.7mm 3352 
column was used with 0.01N H2SO4 elution fluid, at a flow rate of 0.6 mL/min and 3353 
column temperature at 65°C. Graph Pad Prism 5 Software was used for the analysis 3354 
and visualisation of the HPLC results. A Kruskal-Wallis non-parametric test with a 3355 
post hoc Dunn’s test was applied using GraphPad Prism 5 in order to compare the 3356 
SCFA production in the faecal microbiota after 24 hrs fermentation with the 3357 
supplements against glucose-supplemented medium fermentation. 3358 
2.4 Results 3359 
Chemical composition of GMP preparations 3360 
Two GMP preparations were investigated in this study, a commercial fraction 3361 
obtained from Arla Foods Ingredients called Lacprodan CGMP-10 (CGMP-10), and 3362 
a GMP preparation prepared in our laboratories in Teagasc Moorepark Food 3363 
Research Centre (tGMP). The chemical composition of these two GMP products is 3364 
shown in Table 5. CGMP-10 had a higher content of GMP (70.2%) and lower 3365 
content of lactose (<2%) compared to tGMP with 51.4% and 4.4% respectively. The 3366 
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protein content in CGMP-10 and tGMP was 80-84% and 65.6% respectively. The 3367 
two products varied in their content of the whey proteins beta-lactoglobulin (β-3368 
lactoglobulin) and alpha-lactalbumin (α-lac) with 10.6% and 8% respectively for 3369 
CGMP-10 and 1.5% and 19.3% respectively for tGMP. To investigate the feasibility 3370 
of using less purified GMP, both preparations were carried forward into the artificial 3371 
colon model. 3372 
Table 5 Chemical composition of the two glycomacropeptide products used in 3373 
this study, Lacprodan CGMP-10 and semi-purified tGMP. 3374 
Component CGMP-10 tGMP 
β-lg
a
 10.63% 1.48% 
α-lac
b
 8.02% 19.32% 
GMP 70.22(±4.7)% 51.39(±7.1)% 
Lactose <2% 4.4% 
Total protein 80-84% 65.61% 
a
β-Ιg, beta lactoglobulin. 
b
α-Lac, alpha lactalbumin.  
Compositional differences between the faecal microbiota from healthy and frail 3375 
older donors 3376 
We have previously reported that elderly subjects living in long-term residential care 3377 
units have a lower diversity microbiota of a characteristic composition compared to 3378 
that of community dwelling subjects (Claesson et al., 2012; Jeffery et al., 2016).The 3379 
compositional differences include significantly reduced Lachnospiraceae abundance 3380 
in the microbiota of longstay subjects compared to community including genera such 3381 
as Coprococcus and Roseburia, and significant enrichment in Proteobacteria 3382 
abundance including Enterobacteriaceae. We re-enrolled 3 community-dwelling and 3383 
3 long-term care unit residing ELDERMET (Claesson et al., 2012) 
 
subjects (i.e., a 3384 
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cohort of 500 elderly whose gut microbiota composition was characterised and link 3385 
between health and microbiota was investigated) and re-examined their microbiota 3386 
several years after initial analysis to ensure that thecomposition had the expected 3387 
profile as described in previous studies (Claesson et al., 2012; Jeffery et al., 2016). 3388 
Based on the principal coordinates analysis (PCoA) of the Weighted (Figure 3 A) 3389 
and Unweighted UniFrac (Figure 3 B) distances based on the sequenced 16S rRNA 3390 
gene sequences in the faecal samples at baseline (time point 0 hrs), two of the 3391 
samples obtained from frail elderly (EM297 and EM704) clustered closer together 3392 
and separated from the other four samples (EM703, EM425, EM604, EM278). Thus, 3393 
one of the longstay subjects had a community type microbiota. For the downstream 3394 
analysis of the samples collected after 24 hrs of in vitro fermentation, the samples 3395 
were aggregated as follows. Samples EM297 and EM704 were aggregated into 3396 
longstay type (LS), and sample EM703 obtained from a frail individual was 3397 
considered together with EM425, EM604, EM278 obtained from healthy older 3398 
individuals as community type (COM). Across all six medium / supplementation 3399 
combinations, all six time point 0 hrs microbiota clustered by donor, indicating an 3400 
accurate baseline microbiota / inoculum for each fermenter condition tested. 3401 
The composition of the community and longstay type faecal microbiota at phylum 3402 
and family level is shown in Figure 4 and 5 respectively. The two types of 3403 
microbiota had distinct differences. Longstay type samples were significantly 3404 
enriched for Euryarchaeota (average 27% relative abundance) and Proteobacteria 3405 
(average 14% relative abundance) compared to the community type microbiota. The 3406 
community type microbiota had higher relative abundance of Firmicutes 3407 
(approximately 68%) and Bacteroidetes (approximately 22.5%) compared to an 3408 
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average 22% and 11% respectively in the longstay type microbiota. At family level 3409 
Lachnospiraceae comprised up to around 37% of the community type microbiota 3410 
whereas in longstay type microbiota, Lachnospiraceae were present with an average 3411 
4% relative abundance. Other distinct differences between the two sample types 3412 
were the relative abundance of the Ruminococcaceae family, average 14% in 3413 
community type and 6% in longstay type, and the enrichment in the longstay type 3414 
faecal microbiota of the Verrucomicrobiaceae, Synergistetes and 3415 
Methanobacteriaceae compared to community type (Figure 5 B).  3416 
The observations here are broadly consistent with our previous description of 3417 
microbiota composition in frail elderly subjects, allowing us to conclude that the 3418 
available samples were suitable representatives to allow for the investigation of the 3419 




Figure 3 Principal coordinates analysis of UniFrac Unweighted (A) and 3422 
Weighted (B) distances. “■” time points 0 hrs and “□” time points 24 hrs, “▲” 3423 




Figure 4 Composition of the baseline (0 hrs) faecal microbiota at Phylum level. 3426 
The relative abundance of the various phyla is shown for aggregated community 3427 
(COM; EM425, EM278, EM604 and EM703) and aggregated longstay (LS; EM297, 3428 




Figure 5 Composition of the baseline (0hrs) faecal microbiota at Family level. 3431 
The relative abundance of the various families is shown for (A) aggregated 3432 
community (EM425, EM278, EM604 and EM703) and (B) aggregated longstay type 3433 
faecal microbiota (EM297, EM704).  3434 
GMP supplementation sustained a higher diversity faecal microbiota compared 3435 
to other media 3436 
We tested the development of the microbiota in the artificial colon in a basal medium 3437 
without carbohydrates supplementation, compared to five supplementation regimes 3438 
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with the two GMP preparations, glucose (a common carbohydrate of typical human 3439 
diet) and lactose. Regardless of any supplementation of the medium, there was an 3440 
overall decrease in the alpha diversity of the faecal microbiota after 24 hrs in vitro 3441 
fermentation, measured here by the Shannon diversity index. The decrease in the 3442 
microbiota diversity was expected due to the adaptation to the in vitro conditions and 3443 
it was in line with published in vitro studies that reported that the microbiota 3444 
diversity decreased over the first fermentation hours and began to increase after 72 3445 
hrs without attaining the diversity level of the initial stool sample (Rajilic-Stojanovic 3446 
et al., 2010). Here, we aimed to observe which of the supplementation regimes 3447 
sustained the highest microbiota diversity. The effect on faecal microbiota by 3448 
medium supplementation is shown in Figure 6 A aggregated across all six donors 3449 
for each growth medium; the diversity of the respective 0 hrs sample, and the 3450 
diversity of the initial stool are also shown in Figure 6 A. The mean Shannon 3451 
diversity index value at time-point 0 hrs was 3.4 (±0.6 SD). After 24 hrs 3452 
fermentation with basal medium (no carbohydrate supplementation), supplemented 3453 
with glucose or with lactose, the diversity decreased to a Shannon diversity value of 3454 
ca. 2.4. Fermentation with medium supplemented with GMP resulted in higher 3455 
diversity values. Supplementation with CGMP-10, CGMP-10 combined with 3456 
glucose, and supplementation with tGMP resulted in Shannon diversity scores of 3.0 3457 
(±0.4 SD), 2.7 (±0.6 SD) and 2.8 (±1 SD) respectively. Wilcoxon test of ranking of 3458 
the Shannon diversity index of paired individual samples by medium 3459 
supplementation and time (between 24 hrs and 0 hrs) showed that after lactose 3460 
fermentation, the faecal microbiota alpha diversity decreased significantly (p=0.03) 3461 
compared to 0 hrs. There was a stronger trend in the decrease of Shannon diversity 3462 
after fermentation with basal medium or medium supplemented with glucose, or with 3463 
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CGMP-10 combined with glucose (p=0.06) compared to the decrease in Shannon 3464 
diversity after fermentation with CGMP-10 supplemented medium (p=0.16). Similar 3465 
effect of the substrates on the faecal microbiota diversity was observed on 3466 
aggregated community samples, and aggregated longstay type samples, where the 3467 
CGMP-10 supplemented medium sustained higher microbiota diversity compared to 3468 




Figure 6 Effect of the fermentation substrates on the alpha diversity (Shannon 3471 
diversity index) of the faecal microbiota. Effect on diversity of aggregated 3472 
microbiota composition across all donors (A) and microbiota separated by donor 3473 
residential location, i.e. community (COM) and longstay (LS) (B). Stool sample 3474 
represents the faecal microbiota before the preparation of inoculum faecal slurry. 3475 
Wilcoxon test result: “*” p<0.05; “a” p<0.1.   3476 
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Detailed microbiota responses to GMP supplementation 3477 
Community type microbiota: Although retention of microbiota diversity upon 3478 
supplementation with GMP is desirable, it was necessary to examine fine-detail 3479 
microbiota effects. The microbiota profile at family and genus level for community 3480 
aggregated samples is shown in Figure 7 A and B. The baseline high proportion of 3481 
Lachnospiraceae was maintained after fermentation supplemented with all substrates 3482 
tested (except after basal medium fermentation) and predominantly with CGMP-10 3483 
combined with glucose (average 51% relative abundance). Supplementation of the 3484 
fermentation medium with CGMP-10 had a unique effect on the relative abundance 3485 
of the families Rickenellaceae and Acidaminococcaceae that increased from an 3486 
average 1.8% abundance to 3% and 4.5% respectively. Supplementation of the 3487 
fermentation medium with CGMP-10 supressed the growth of Erysipelotrichaceae 3488 
compared to supplementation with the other substrates as shown in Figure 7 A. The 3489 
lowest proportion of the family Bacteroidaceae was observed after lactose 3490 
fermentation (average 4% relative abundance) whereas after fermentation with the 3491 
other tested media the relative abundance of the family remained similar to baseline 3492 
(approximately 10%). High Enterobacteriaceae relative abundance increase was 3493 
observed after fermentation with basal medium from an average 0.8% relative 3494 
abundance at baseline to an average 30%. Substantial increase in the relative 3495 
abundance of Enterobacteriaceae was also observed after fermentation with lactose 3496 
or tGMP supplemented medium. In both supplementation regimes, i.e. lactose or 3497 
tGMP, the proportion of the Enterobacteriaceae increased to approximately 17% 3498 
relative abundance. The Enterobacteriaceae affected comprised mainly of the genera 3499 
Escherichia/Shigella (Figure 7 B). Clostridiaceae 1 (comprised of the Clostridium 3500 
sensu stricto cluster) relative abundance demonstrated an increasing trend regardless 3501 
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of fermentation substrate (Figure 7 A). After basal medium fermentation 3502 
Clostridiaceae 1 relative abundance had the highest increase compared to the other 3503 
substrate fermentations, increasing from approximately 1.6% relative abundance at 3504 
baseline to 13%. Fermentation with GMP-supplemented medium resulted in >6.5% 3505 
relative abundance of Clostridiaceae 1. 3506 
Longstay type microbiota: In fermenters seeded with the longstay type microbiota 3507 
the increase in relative abundance of the Clostridiaceae 1 and Enterobacteriaceae 3508 
families was the predominant observation irrespective of the fermentation medium 3509 
suggesting loss of major taxa in the faecal microbiota under 24 hrs in vitro 3510 
conditions (Figure 7 A). The dominant genera were Clostridium sensu stricto and 3511 
Escherichia/Shigella respectively (Figure 7 B). The proportion of the relative 3512 
abundance occupied by the families Clostridiaceae 1, Enterobacteriaceae and 3513 
Peptostreptococcaceae exceeded 60% across the samples. The predominant group in 3514 
Peptostreptococcaceae was Clostridium cluster XI (Figure 7 B). Interestingly, 3515 
although fermentation supplemented with CGMP-10 resulted in a high combined 3516 
relative abundance of the families Clostridiaceae 1, Enterobacteriaceae and 3517 
Peptostreptococcaceae (approximately 70%) there was also an increase in the 3518 
relative abundance of Lachnospiraceae from approximately 4% to 11%, and 3519 
maintenance of the low relative abundance of Streptococcaceae (<0.5%). 3520 
Fermentation supplemented with lactose also resulted in increased Lachnospiraceae 3521 
relative abundance (to approximately 7.5%) but lactose also promoted the growth of 3522 
Streptococcaceae from <0.5% relative abundance to approximately 20%.  3523 
CGMP-10 positively affected the growth of health-related taxa, predominantly 3524 
in community type microbiota 3525 
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To provide further resolution we used the DESeq2 algorithm to identify bacterial 3526 
taxa showing altered abundance after 24 hrs fermentation supplemented with the 3527 
selected substrates (Figure 8). For certain taxa, change in the abundance after 24 hrs 3528 
fermentation was similar irrespective of the fermentation supplement. The 3529 
abundance of Clostridium cluster IV, Ruminococcus and Lachnospira decreased in 3530 
both faecal microbiota types irrespective of fermentation supplement. With one 3531 
exception (fermentation of glucose-supplemented medium by longstay type 3532 
microbiota) Sutterella abundance increased in both microbiota types after 3533 
fermentation with all fermentation supplements. Clostridium cluster sensu stricto and 3534 
Escherichia/Shigella abundance also showed an increasing trend irrespective of 3535 
fermentation supplement.  3536 
Supplementation with CGMP-10 of the artificial colon medium seeded with either 3537 
microbiota type led to an increase of Clostridium cluster XIVb and Coprococcus 3538 
abundance. In the community type microbiota the increase was approximately 6-fold 3539 
(padj<0.0005) and 3-fold (padj=0.05) respectively. In the longstay type microbiota 3540 
the respective fold-changes were approximately 10 (padj<0.0005) and 1 (not 3541 
significant). An increasing trend in the abundance of Pseudoflavonifractor was 3542 
observed after supplementation with CGMP-10; approximately 2-fold (not 3543 
significant) and 16-fold (padj=0.08) increase in community and longstay microbiota 3544 
respectively. After fermentation with medium supplemented with CGMP-10 by the 3545 
community type microbiota an increasing trend in the abundance of the genus 3546 
Roseburia by approximately 6-fold (padj=0.08) was observed. The abundance of the 3547 
genera Dorea increased by 8-fold without reaching significance. Importantly, 3548 
analysis of the composition of the faecal microbiota per individual sample after 3549 
fermentation with medium supplemented with CGMP-10 showed a consistent 3550 
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increase of the relative abundnace of Dorea in all samples from healthy donors and 3551 
EM703 (data not shown). Fermentations with CGMP-10 combined with glucose 3552 
yielded similar changes (but not significant) in the abundance of the aforementioned 3553 
taxa in the community samples as with fermentation with CGMP-10 alone. The 3554 
tGMP also increased the abundance of Clostridium cluster XIVb; approximately 16-3555 
fold (not significant) in community type microbiota and 9 log2fold (padj<0.0005) in 3556 
longstay microbiota.  3557 
For both microbiota types fermentation of lactose supplemented-medium yielded 3558 
(mostly not significant) increase in the abundance of Blautia (longstay type; 3559 
approximately 16-fold, padj<0.007), Clostridium cluster XVIII (community type; 3560 
approximately 64-fold, padj<0.06), Enterococcus, Streptococcus, 3561 
Escherichia/Shigella. Increase in Bifidobacterium abundance was observed only 3562 
when baseline abundance was high as in the case of EM278 (data not shown).  3563 




Figure 7 Faecal microbiota profile after 24 hrs fermentation. Community type 3566 
(COM) and longstay type aggregated (LS) microbiotas are presented at family level 3567 




Figure 8 Heat-map of the changes in bacterial genus abundance in the faecal 3570 
microbiota after 24 hrs fermentation with selected substrates. Comparisons were 3571 
performed pairwise between 0hrs and 24 hrs for aggregated microbiota types by 3572 
residential location as defined in main text. The logarithmic (log2) fold change 3573 
results were generated using the DeSeq2 package. COM and LS correspond to 3574 
community type and longstay type aggregated faecal microbiotas respectively. 3575 
Significance is denoted by “*” for p values adjusted for multiple testing using 3576 
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GMP supplementation and SCFA production in the faecal microbiota of 3578 
healthy elderly subjects 3579 
Community type faecal microbiota fermentation with GMP supplementation 3580 
(substrate conditions iv, v, vi as shown in Materials and Methods) resulted in higher 3581 
SCFA (i.e. propionate, acetate, butyrate) production compared to the other media 3582 
tested; GMP-supplemented media: >148μmol of propionate, acetate and butyrate 3583 
combined per grams of faecal pellet, lactose supplemented medium: mean of 113.3 3584 
μmol combined SCFA per g of faecal pellet, glucose supplemented medium: mean 3585 
of 133.7 μmol combined SCFA per g of faecal pellet, basal medium: mean of 66 3586 
μmol combined SCFA per g of faecal pellet (Figure 9 A). No significant differences 3587 
were obtained when comparing the SCFA production after supplementation with 3588 
either GMP supplementation regime or lactose against the SCFA production after 3589 
fermentation with medium supplemented with glucose; only fermentation with basal 3590 
medium resulted in significantly lower production of propionate (p<0.05) and 3591 
butyrate (p<0.005). For the longstay type microbiota the profile of the SCFA 3592 
production was similar irrespective of the fermentation substrate (Figure 9 B) 3593 
mirroring the loss of major taxa, among them potentially butyrate producers, 3594 
observed for the profile of the microbiota composition (Figure 7). No statistical 3595 
analysis was performed for longstay microbiota SCFA production due to the small 3596 




Figure 9 Short chain fatty acid (SCFA) levels in the faecal microbiota after 24 3599 
hrs fermentation in media supplemented as indicated. Concentration (μmol/g of 3600 
faecal pellet) of acetae, propionate and butyrate in aggregated community (A) and 3601 
longstay (B) microbiotas. Kruskal-Wallis test with Dunn’s post hoc test was 3602 
performed to compare SCFA production at 24 hrs after supplementation with the 3603 
various substrates against glucose supplementation in the community type 3604 
microbiota; “*” p<0.05, “**” p<0.005.  3605 
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2.5 Discussion 3606 
Prebiotic effect of GMP on the faecal microbiota of healthy older donors 3607 
We investigated the in vitro effect of GMP supplementation on the gut microbiota 3608 
using two GMP preparations and two types of faecal microbiota, i.e. community type 3609 
and longstay type. CGMP-10 had a lower concentration of lactose compared to 3610 
tGMP. The two microbiota types had major composition differences summarised by 3611 
reduced overall diversity and abundance of Firmicutes, enrichment in Euryarchaeota, 3612 
Proteobacteria and proteolytic taxa like Synergistetes and Verrucomicrobia in the 3613 
longstay compared to the community type. The distinctive longstay microbiota 3614 
profile apparently explains the loss of major taxa and the dominance of Clostridium 3615 
sensu stricto cluster that was observed after fermentations with all tested substrates, 3616 
because ecosystem stability and adaptive responsiveness to environmental changes 3617 
are known to increase with phylogenetic diversity (Cadotte et al., 2012; Salonene et 3618 
al., 2014; Alberdi et al., 2016).  3619 
For both microbiota types, supplementation of the fermentation medium with 3620 
CGMP-10 sustained a higher diversity microbiota compared to the other media 3621 
followed in rank order by the other two GMP-containing media, ie. tGMP and 3622 
CGMP-10 combined with glucose. GMP containing medium resulted in higher total 3623 
SCFA production from community microbiota-seeded fermentations compared to 3624 
the other substrates tested. Increased SCFA concentration in the colon is known to 3625 
correlate with a wide portfolio of health benefits (Koh et al., 2016).  3626 
The Lachnospiraceae member Coprococcus spp. is one of the health-relevant taxa 3627 
that was positively affected by CGMP-10 supplementation as shown by the increase 3628 
in the relative abundance of this group from the starting levels in the faecal 3629 
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microbiota of mostly healthy donors after 24 hrs fermentation. In our previous 3630 
studies, low abundance of coprococci in the faecal microbiota of older donors 3631 
correlated with poor health status and a less diverse diet that was low in fibre 3632 
(Claesson et al., 2012; Jeffery et al., 2016). Based on studies of the faecal microbiota 3633 
from patients with colorectal cancer increased relative abundance of Coprococcus 3634 
was negatively correlated with the condition (Flemer et al., 2016). CGMP-10 had a 3635 
positive effect on the abundance of Dorea in the faecal microbiota of community 3636 
dwelling older subjects. The increase in abundance of these two taxa indicates 3637 
potentially important health benefits deriving from the consumption of GMP because 3638 
Coprococcus and Dorea-enriched gut microbiota was found to be significantly 3639 
resistant to pathobiont colonisation (Kampmann et al., 2016). CGMP-10 also 3640 
positively affected the abundance of Clostridium cluster XIVb in both sample types. 3641 
In a murine model of leukaemia and cachexia, cluster XIVb and Parasutterella 3642 
species were among the first taxa to reduce in abundance in the murine faecal 3643 
microbiota in these two diseases (Bindels et al., 2016). In this study the abundance 3644 
of Parasutterella in the community type microbiota significantly increased after 3645 
CGMP-10 supplementation. Importantly, Clostridium cluster XIVb is among the 3646 
bacterial groups that increase in abundance after restoration of dysbiotic Clostridium 3647 
difficile-associated diarrhoea gut microbiota by faecal microbiota transplantation 3648 
(Brown et al., 2016). CGMP-10 had a positive effect on the abundance of Roseburia 3649 
but only for the community type microbiota. For this taxon it is well-documented 3650 
that it contributes to butyrate production which is a major contributor for colonic 3651 
health (Koh et al., 2016). The differential response may be due to the low starting 3652 
abundance levels of the genus Roseburia in the longstay type microbiota.  3653 
176 
 
Lactose content of supplemented medium increased Proteobacteria abundance  3654 
Lactose-dependent modulation of the gut microbiota resulted in increased relative 3655 
abundance of taxa related to inferior health status. Both lactose and tGMP enhanced 3656 
the growth of Enterobacteria of the phylum Proteobacteria. This Phylum harbours 3657 
pathobionts like the facultatives Escherichia/Shigella that can lead to disease 3658 
(Kamada et al., 2013). Lactose fermentation promoted the increase in abundance of 3659 
the Erysipelotrichaceae Clostridium cluster XVIII. This taxon has been associated 3660 
with inferior health status in older subjects residing in long-term care units (Jeffery 3661 
et al., 2016).
 
In this study we could not conclude on the prebiotic potential of lactose. 3662 
Other studies have reported a positive effect of lactose on lactobacilli and 3663 
bifidobacteria (Szilagyi, 2015). In vivo trials will be conducted to further elucidate 3664 
the effect of lactose on the faecal microbiota and to allow for lactose-related dietary 3665 
recommendations. 3666 
Effect of the in vitro conditions on the faecal microbiota 3667 
In this study faecal samples were treated individually as opposed to samples being 3668 
pooled from several donors, an approach used in some other studies (Aguirre et al., 3669 
2014). 
 
We opted for this because pooling faecal sample produce inocula that would 3670 
be non-representative of average “real” microbiota (Payne et al., 2012). Partly in 3671 
agreement with previous studies
 
(Rajilic-Stojanovic et al., 2012), here we report 3672 
decrease of microbiota diversity and decrease in abundance of Clostridium cluster IV 3673 
as a result of all of the in vitro conditions rather than a result of any individual 3674 
fermentation substrate. A decrease in the abundance of Ruminococcus was also 3675 
observed irrespective of fermentation substrate or microbiota type and potentially 3676 
due to the luck of resistant starch in the fermentation media (Ze et al., 2012). 3677 
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Omitting resistant starch was done to avoid missing the effects conferred by the 3678 
carbohydrates attached to the GMP. Interestingly, increase in Blautia spp. was 3679 
observed in most longstay samples irrespective of fermentation medium suggesting a 3680 
potential underlying longstay-type related trend. Bacteria of the genus Blautia are a 3681 
prominent member of the healthy adult gut microbiota (Touyama et al., 2015) and 3682 
are reduced in abundance in older individuals (Claesson et al., 2012). In spite of the 3683 
predominant role of this taxon in the “healthy” adult microbiota, increased 3684 
abundance of Blautia spp. can correlate to colorectal cancer (Flemer et al., 2016).  3685 
For this reason the health benefit of promoting their growth by prebiotics is 3686 
debatable, at least until species detail is available. 3687 
In search for new potential prebiotics we demonstrate here the capacity of GMP, a 3688 
milk derivative with documented anti-inflammatory properties, to modulate in vitro 3689 
the gut microbiota of elderly subjects by promoting the growth of several health-3690 
relevant taxa. GMP also increased SCFA production and sustained the diversity of 3691 
the microbiota from healthy elderly inocula and to a lesser extend in inocula from 3692 
frail elderly under in vitro conditions. In vivo trials are necessary to confirm the 3693 
microbiota programming by GMP observed here since in vitro systems present 3694 
certain limitations in simulating the real-life effect of diet compounds on the gut 3695 
microbiota. 
49
 Importantly, since there are indications that inferior gut microbiota 3696 
diversity may be associated with frailty in older age (O’Toole and Jeffery, 2015) 
 3697 
GMP could contribute to amelioration of frailty scores by promoting gut microbiota 3698 
diversity.  3699 
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3.1 Abstract 3858 
Compositional and phylogenetic diversity shifts of the gut microbiota, i.e. dysbiosis, 3859 
may lead to disease. Dysbiotic changes in the microbiota are observed during ageing. 3860 
Manipulation of the gut microbiota using prebiotics is a therapeutic strategy towards 3861 
improving dysbiosis. Milk is a source of nutrients including complex 3862 
oligosaccharides (OS), the prebiotic potential of which remains unexplored. We used 3863 
a murine model to explore the effect of milk products on high and low diversity 3864 
faecal microbiota (from healthy and frail older subjects, respectively) in comparison 3865 
to soy protein supplementation, a product known to promote microbiota diversity 3866 
and health in mice. 3867 
The gut microbiota of conventional mice was eradicated using antibiotics; the mice 3868 
were gavaged with microbiota from either a frail or a healthy donor. The mice 3869 
received purified diets supplemented with either lactose free or whole milk, 3870 
glycomacropeptide GMP, (a potentially prebiotic rich in sialic acid dairy product) or 3871 
soy-protein. The gut microbiota was studied after a month of diet.  3872 
Lactose-free milk diet was as efficient as the control diet in retaining microbiota 3873 
diversity and it retained significantly higher diversity than the other diets in mice 3874 
transplanted with microbiota deriving from either human donor type. Whole milk 3875 
was not as efficient as lactose-free milk in retaining microbiota diversity but the 3876 
relative abundance of health relevant taxa like Ruminococcus bromii were increased. 3877 
Glycomacropeptide supplementation alone led to significantly decreased diversity 3878 
compared to lactose-free milk and previously reported prebiotic activity was not 3879 
confirmed in vivo. Bacteroidetes and Enterobacteriaceae were highly responsive to 3880 
GMP supplemented diet; the sialic acid content of GMP may partly explain this 3881 
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microbiota response. When lacking lactose, the remaining carbohydrate component 3882 
of milk sustained the growth of a wider range of microbiota members and promoted 3883 
phylogenetic diversity in this murine model. Our results indicate the prebiotic 3884 
potential of lactose-free milk.  3885 
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3.2 Introduction 3886 
During the last decade, the bacterial component of the human gut microbiota has 3887 
been extensively studied allowing for a more comprehensive understanding of the 3888 
compositional and functional profile of the gut microbiota in health and disease 3889 
(Marchesi et al., 2015). Predominantly the habitual diet and to a lesser extent host 3890 
genetics are two shaping factors of the gut microbiota (Sonnenburg and Bäckhed, 3891 
2016; Kurilshikov et al., 2017; Rothschild et al., 2018). The term dysbiosis refers to 3892 
shifts in the composition, function and phylogenetic diversity of the gut microbiota 3893 
of non-healthy individuals in comparison to healthy controls (Manor et al., 2017). 3894 
Metabolic disease, functional GIT disorders and cognitive disorders have been 3895 
linked to dysbiosis (reviewed in Levy et al., 2017).  3896 
The low-grade chronic inflammation that characterises older age reflects the decline 3897 
of immune system fitness to respond to stressors, a phenomenon called 3898 
inflammageing (Franceschi and Campisi, 2014). Aberrant intestinal permeability and 3899 
dysbiotic gut microbiota are potential inflammageing drivers (Franceschi and 3900 
Campisi, 2014; Li et al., 2016; Thevaranjan et al., 2017). Gut microbiota dysbiosis 3901 
can be further fuelled by the inflamed GIT environment (Zeng et al, 2016). For 3902 
prevention and treatment of dysbiosis and associated conditions, therapeutic 3903 
interventions based on probiotics, prebiotics or faecal microbiota transplants (FMT) 3904 
are being developed (Scott et al., 2014).  3905 
Milk combines many nutrients including calcium, vitamin K, conjugated linoleic 3906 
acid, fatty acids, complex sialylated oligosaccharides and glycoproteins (Rozenberg 3907 
et al., 2016; O’Riordan et al., 2014). There is accumulating data pointing towards 3908 
certain health benefits of milk and dairy consumption (Song et al., 2016; Larsson et 3909 
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al., 2015; Rozenberg et al., 2016). Importantly, milk consumption may contribute to 3910 
muscle and bone density maintenance in older consumers (Sahni et al., 2014; Lana et 3911 
al., 2015). Despite the potential health benefits, studies have shown that elderly 3912 
people often fail to meet current recommendations for daily dairy consumption 3913 
partly due to misconceptions on lactose mal-absorption and dairy fat content (Power 3914 
et al., 2014; Laird et al., 2016). 3915 
The effect of milk on the gut microbiota has not been extensively studied. A few 3916 
recent studies have focused on the potential prebiotic effect of milk oligosaccharides 3917 
on the gut microbiota. Charbonneau et al. (2016) using animal models “humanised” 3918 
with infant gut microbiota showed that sialylated bovine milk oligosaccharides 3919 
(BMO) promoted weight gain associated with Bacteroides fragilis and Escherichia 3920 
coli responsiveness to BMOs under malnutrition conditions. Karav et al. (2016) 3921 
showed that BMO released from glycoproteins could mimic human milk 3922 
oligosaccharide (HMO) selectivity on Bifidobacterium strains in the infant gut 3923 
microbiota. Boudry et al. (2017) observed that BMO-supplemented diet enhanced 3924 
gut barrier function, increased caecal and colonic microbiota diversity and 3925 
Lactobacillus relative abundance in a murine model of diet-induced obesity.  3926 
Glycomacropeptide (GMP) is a by-product of cheese making and it is released in 3927 
whey protein from the kappa-casein fraction of milk by the activity of chymosin 3928 
(Neelima et al., 2013). Glycomacropeptide has five mucin-type glycans, high content 3929 
of sialic acid, high content of branched chain amino acids (BCAA) and essential 3930 
amino acids (EAA) and it is depleted of aromatic amino acids (Neelima et al., 2013). 3931 
Glycomacropeptide is associated with a number of health benefits including anti-3932 
inflammatory and anti-GIT pathogen activity, and it is currently being used as an 3933 
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alternative source of protein for phenylketonuria (PKU) nutritional management (van 3934 
Calcar and Ney, 2012; Hvas et al., 2016).  3935 
There is inconclusive data on the prebiotic potential of GMP. Bifidobacterium and 3936 
Lactobacillus selective growth promotion by GMP has been reported based on tests 3937 
in pure cultures but the selectivity failed to be confirmed when complex faecal 3938 
microbiota communities were tested in vitro (Bruck et al., 2006; Hernandez-3939 
Hernandez et al., 2011; Robitaille, 2013; Ntemiri et al., 2017). Some in vivo studies 3940 
showed that GMP administration increased the colonic abundance of Lactobacillus 3941 
and Bifidobacterium (Hermes et al., 2013; Jimenez et al., 2017). Sawin et al. (2015) 3942 
reported that a GMP-supplemented diet significantly decreased the caecal and 3943 
colonic relative abundance of Desulfovibrio and Proteobacteria in wild type and 3944 
PKU mice. Interestingly, GMP selectivity on promoting growth of Bacteroidetes 3945 
taxa has also been reported (Sawin et al., 2015; Jimenez et al., 2017).  3946 
In this study, conventional mice were treated with a cocktail of antibiotics before 3947 
receiving FMT from either a healthy or a frail older donor. The effect of a diet 3948 
enriched in either whole milk, lactose-free milk or GMP on the faecal microbiota of 3949 
older humans was then investigated in these “humanised” mice.  3950 
3.3 Materials and Methods 3951 
Animals and experimental design: The Health Products Regulatory Authority 3952 
(HPRA) under the European Union Regulations authorised this project with 3953 
authorisation number AE19130/P033. Nighty-six 6 week-old female and male 3954 
C57BL/6 mice were purchased form Envigo RMS Ltd, Oxon, UK and caged in 3955 
groups of six of the same sex. The mice were weighed during the first week and 3956 
every subsequent week of the trial. 3957 
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The timeline of the mouse trial is outlined in Figure 10 A. The mice acclimatised to 3958 
the animal facility for one week before the commencement of the six weeks 3959 
antibiotics (Abx) treatment for the depletion of the indigenous murine gut 3960 
microbiota. Ampicillin (1g/L; Sigma Aldrich), Metronidazole (1g/L; Molekula), 3961 
Vancomycin (500 mg/L; Molekula), Imipenem (250 mg/L; Molekula) and 3962 
Ciprofloxacin-HCl (200 mg/L; Santa Cruz) were diluted in tap water and filtered 3963 
sterilised before given to animals as described before (Bereswill et al., 2011). 3964 
Animals had ad libidum access to Abx-water. Limited administration of HydroGel 3965 
(ClearH2O.com) during the Abx treatment was used for the prevention of weight 3966 
loss. One day wash-out with filtered tap-water followed the Abx treatment. 3967 
Subsequently, the animals were “humanised” with FMT from either a healthy older 3968 
donor or a frail older donor.  3969 
The mice were introduced to the experimental diets on the wash-out day. The 3970 
duration of the dietary intervention was one month. Six male and six female mice 3971 
were allocated to each diet Supplementary S Table 1. The animals were fed 3972 
maintenance diet (ssniff, Spezialdiäten GmbH, German) during the acclimatisation 3973 
period and during the Abx treatment. The experimental diets were isoenergetic and 3974 
isonitrogenous refined maintenance diets (ssniff, Spezialdiäten GmbH, Germany) 3975 
supplemented with one of the following powders: i. lac-free diet: 20% lactose-free 3976 
whole milk powder (Valio Ltd., Helsinki, Finland), ii. wmilk diet: 20% whole milk 3977 
powder (Valio Ltd., Helsinki, Finland), iii. GMP diet: 20% CGMP-10 (Arla Food 3978 
Ingredients, Denmark), iv. control diet: 20% soy protein isolate. In order to achieve 3979 
the isoenergetic and isonitrogenous profile of the diets, all diets were additionally 3980 
supplemented with soy protein isolate that was the basic protein ingredient for the 3981 
maintenance diet as shown in Table 6. The complete compositional content of the 3982 
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experimental diets is attached in Supplementary Material. All diets were sterilized 3983 
by irradiation.  3984 
 3985 
Figure 10 Timeline of the 11 weeks mouse trial. Time-points of samples 3986 
collection: T0 during the acclimatisation, T1 and T2 during the Abx treatment, T3, 3987 
T4 and T5 during the dietary intervention. The FMT source was used for the 3988 
“humanisation” of the Abx- treated animals. The isocaloric and isonitrogenous diets 3989 
were refined diets with 20% supplementation with the shown ingredients.   3990 
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Soy protein isolate  20.0 14.5 12.8 1.8 
Whole milk powder  - 20.0 - - 
Lactose-free milk 
powder 
- - 20.0 - 
Glycomacropeptide 
CGMP-10 
- - - 20.0 
Maltodextrin 33.1 33.2 32.9 32.0 
Sucrose 10.5 2.5 4.3 10.3 
Cellulose powder 6.0 4.9 5.0 5.2 
Soybean oil 7.5 2.3 2.3 7.5 
Proximate contents %     
Crude protein 18.1 18.1 18.1 18.1 
Crude fat 7.6 7.6 7.6 7.6 
Crude ash 4.6 5.4 5.6 5.5 
Starch 31.8 31.9 31.6 30.8 
Sugar (total) 12.3 12.3 12.3 12.3 
Lactose - 8.0 - - 
Energy (MJ/kg) 16.0 16.0 16.0 16.0 
kcal % Protein 19 19 19 19 
kcal % Fat 18 18 18 18 
kcal % 
Carbohydrates 
63 63 63 63 
Faecal slurry preparation and mouse “humanisation”: One faecal sample 3993 
from a healthy 81 yr old subject (EM425; community type microbiota, COM) and 3994 
one faecal sample from a frail 82 yrs old subject (EM297; longstay type microbiota, 3995 
LS) were collected under the approval of the local Clinical Research Ethics 3996 
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Committee. The samples were processed under anaerobic conditions for the 3997 
preparation of 10 % w/v faecal slurries in PBS and 20 % glycerol. The faecal slurries 3998 
were kept in aliquots at -80°C and thawed in the anaerobic cabinet before gavage to 3999 
mice. The animals received by oral gavage a total of 300 μl of faecal slurry in three 4000 
days. 4001 
Faecal and caecal sample collection: Faecal samples were collected during 4002 
the trial at various time points (T0 to T5) as indicated in Figure 10. One to two 4003 
faecal pellets were collected at each time point. Caecum content was collected at the 4004 
end of the trial by dissecting the caecum and emptying the caecum content in sterile 4005 
Eppendorf tubes. All samples were immediately frozen in liquid nitrogen before 4006 
being transferred to -80°C.  4007 
Genomic DNA extraction: Genomic DNA was extracted from murine faecal 4008 
pellets and caecum content using the QIamp Fast DNA Stool (Qiagen) kit. Murine 4009 
faecal and caecal pellets were weighed before performing the extraction using the 4010 
QIamp Fast DNA Stool (Qiagen) extraction kit protocol. The samples were placed in 4011 
sterile tubes containing 0.1 mm, 0.5 mm and 1.0 mm zirconia / glass beads (Thistle 4012 
Scientific, UK). Eight hundred ml of InhibitEX buffer was added to the samples and 4013 
then homogenised under one pulse of 1 min and a final of 30 sec using a 4014 
Minibeadbeader (Biospec Products). In the intervals of the homogenisation steps the 4015 
samples were placed on ice for 1 min. The samples were then placed in a 95°C heat-4016 
block for 5 min. The subsequent steps of the DNA extraction were carried out as 4017 
described in the Qiagen protocol using 15 μl of proteinase K with 200 μl of AL 4018 
buffer, 200 μl of lysate and 200 μl of ethanol at the relevant steps. The final elution 4019 
was performed at 70 μl of elution buffer. 4020 
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Library preparation for 16S rRNA gene amplicon sequencing:  The V3 / 4021 
V4 variable region of the 16S rRNA gene was targeted for Illumina MiSeq System 4022 
sequencing (San Diego, California, USA). The region was targeted and amplified 4023 
using the universal 16S ribosomal RNA gene primers; forward primer for V3 region 4024 
5’ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWG 4025 
CAG 3’ and reverse primer for V4 region 5’ GTCTCGTGGGCTCGGAGATGTG 4026 
TATAAGAGACAGGACTACHVGGGTATCTAATCC 3’ (Klindworth et al. 2012). 4027 
The PCR products were purified and the subsequent library preparation steps were 4028 
performed according to the Illumina MiSeq system protocol. Dual-index barcodes 4029 
were attached to the amplicon (Nextera XT V.2 Index Kits sets A and D, Illumina) 4030 
and then purified using the Agencourt AMPure XP-PCR Purification system 4031 
(Beckman Coutler, Inc.). The indexed amplicons were quantified using the Qubit 4032 
dsDNA HS Assay Kit (Thermo Fischer Scientific, MA, U.S.A.). The pooled library 4033 
containing the same concentration of each amplicon was sequenced on a MiSeq 4034 
Illumina platform using a 2 x 250 bp chemistry in the Teagasc Next Generation 4035 
Sequencing Facility (Fermoy, Ireland).  4036 
Microbiota composition analysis and statistics : FLASH (Magoč et al., 4037 
2011) was used to join the paired reads that were subsequently demultiplexed in 4038 
Qiime with the split_libraries.py script and forward and reverse primers were 4039 
removed from the reads. Usearch was used for the de novo generation of an 4040 
operational taxonomic unit (OTU) table. The reads were filtered by read length and 4041 
the number of identical sequences, before chimera filtering was applied. 4042 
Subsequently, all reads were mapped against the representative reads generated by 4043 
the filtering based on 97% identity. The reads per sample were rarefied at a number 4044 
of reads in order to include the majority of the samples collected throughout the 4045 
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study. The sequences were aligned using the PyNast tool (Caporaso et al., 2010) in 4046 
Qiime in order to generate alpha diversity indices i.e., Shannon, Simpson, PD whole 4047 
tree, Chao1 and observed species, and beta diversity indices i.e. Weighted UniFrac 4048 
and Unweighted UniFrac. The de novo OTU table generated based on the filtered 4049 
reads was taxonomically classified (classify.seqs) down to genus level by using 4050 
Mothur and the RDP v11.4/trainset 14 database (Wang et al., 2007). The Spingo 4051 
database was used in order to classify the reads at species level (Allard et al., 2015). 4052 
The software R (R Core Team) was used in order to convert the reads per sample 4053 
into relative abundances, to analyse and visualise the UniFrac distances, and to 4054 
visualise the alpha diversity of the microbiota. A Kruskal-Wallis with Dunn’s post 4055 
hoc test with p adjusted value with the Benjamini-Hochberg method were applied in 4056 
R in order to detect significant differences in the faecal microbiota diversity due to 4057 
diet at various time points. A Kruskal-Wallis with Dunn’s post hoc test with p 4058 
adjusted value with the Benjamini-Hochberg method was applied in order to detect 4059 
the differentially abundant taxa in the aggregated microbiota of female and male 4060 
mice at the end of the trial as a result of the different diets. Values were considered 4061 
significant when Kruskal-Wallis p value was ≤ 0.5, padj value ≤ 0.05 and Dunn’s post 4062 
hoc test padj values was ≤ 0.05.  4063 
3.4 Results 4064 
Milk supplemented diets resulted in the highest increase in body 4065 
weight from baseline 4066 
Due to severe weight loss during the first 2 weeks of Abx treatment, 6 animals were 4067 
euthanized (S Table 1). Some animals were given HydroGel for up to 9 days (S 4068 
Table 1) in order to prevent further weight loss due to a version of the mice to the 4069 
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Abx-containing water and subsequent abstaining from food. All animals began to 4070 
recover their body weight after the 2
nd
 week of Abx treatment (Figure 11) and at the 4071 
end of the trial the diets had a differential effect on weight gain compared to the 4072 
baseline body weight (Figure 11). Lactose-free milk supplemented diet resulted in 4073 
the highest increase in body weight in mice humanised with COM type microbiota 4074 
(Figure 11 A), while whole milk diet resulted in the highest increase in weight in 4075 
mice humanised with the LS type microbiota (Figure 11 B). Upon dissection all 4076 
animals had normal spleen weight (data not shown).  4077 
Differences between the human donors and the murine baseline faecal 4078 
microbiota composition 4079 
Compositional and phylogenetic diversity differences in the faecal microbiota of frail 4080 
long-term care unit-residing elderly subjects and healthy community-living were 4081 
described in the ElderMet study (Claesson et al., 2012). The ElderMet donors 4082 
EM297 (LS) and EM425 (COM) were re-enrolled and their faecal microbiota was 4083 
re-analysed in order to confirm suitability for the mouse trial. The compositional 4084 
differences between the faecal microbiotas from subjects EM297 (LS) and EM425 4085 
(COM) have been partly described in Chapter 2 (Ntemiri et al., 2017). Compared to 4086 
the COM type microbiota, the LS had lower Firmicutes relative abundance, it was 4087 
enriched in Proteobacteria, Synergistetes and Bacteroidetes, whereas the alpha 4088 
diversity was lower (Figure 12, S Tables 2 and 3). Thus, the inocula were 4089 
considered suitable for proceeding with mouse humanisation.  4090 
The composition of the murine faecal microbiotas is shown in Figure 12 (S Table 4091 
2). In the murine faecal microbiota, the phylum Bacteroidetes was the prevalent 4092 
phylum (56 % average relative abundance) followed by the Firmicutes. Compared to 4093 
199 
 
the human microbiota, the murine microbiota was enriched in certain Bacteroidia 4094 
including Barnesiella intestinihominis, Alistipes massiliensis, unclassified 4095 
Prevotellaceae and Porphyromonadaceae (S Table 2). Among the Firmicutes, taxa 4096 
that belonged to Lactobacillus and unclassified Lachnospiraceae were dominant in 4097 
the murine faecal microbiota. The alpha diversity of the baseline murine microbiota 4098 





Figure 11 Animal body weight during the 11 weeks of the trial. The body weight 4102 
from the first week of Abx treatment (W0) till the completion of the trial (W11), is 4103 
shown. Body weight change between baseline and end of trial is shown at the 4104 
bottom. A and B: COM: community type humanisation and LS: longstay type 4105 




Figure 12 Composition of the human and murine baseline faecal microbiota at 4108 
phylum level. Phyla that were present at ≥1 % relative abundance are presented. LS: 4109 
longstay type faecal microbiota; COM: community type faecal microbiota; murine: 4110 
aggregated faecal microbiota across all mice at baseline.  4111 
Efficiency of colonisation of the murine gut by the human faecal 4112 
microbiota  4113 
One week after humanisation (T3), the murine faecal microbiota had diverged from 4114 
baseline and did not revert back to the murine phylogenetic profile by the completion 4115 
of the trial as demonstrated by β diversity UniFrac analysis throughout the trial (S 4116 
Figure 1, 2). Importantly, the COM or LS phylogenetic profile was retained 4117 
throughout the trial as shown by principal coordinates analysis (PCoA) of the 4118 
Unweighted UniFrac distances at the end of the trial (T5) in spite of the strong effect 4119 
of diet (S Figure 1 B and 2 B).   4120 
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Lactose-free milk supplemented diet sustained significantly higher 4121 
alpha diversity faecal microbiota compared to the other diets in both 4122 
community and longstay type humanised mice.  4123 
Community type microbiota: There was no difference in the effect of lactose-free 4124 
diet and control diet on the microbiota diversity. In contrast the GMP diet resulted in 4125 
the lowest retention of alpha diversity across all indices (Figure 13). Lactose-free 4126 
milk, control and whole milk diets resulted in significantly higher Shannon, Simpson 4127 
and PD indices compared to GMP diet. For the indices Observed species and Chao1, 4128 
lac-free and control diet retained significantly higher faecal microbiota diversity 4129 
compared to both wmilk and GMP diet. A detailed summary of the statistical 4130 
analysis results is shown S Table 4. 4131 
Longstay type microbiota: The lactose-free milk diet intake resulted in significantly 4132 
higher Shannon and Simpson diversity indices compared to all diets including 4133 
control (Figure 14). The lactose-free diet intake resulted in significantly higher PD 4134 
whole tree index compared to the whole milk and GMP diet intake whereas alpha 4135 
diversity scores after control diet were significantly higher only compared to GMP 4136 
diet. The lactose-free and control diet resulted in significantly higher Observed 4137 
Species index compared to the whole milk and GMP diets. A detailed summary of 4138 




Figure 13 Alpha diversity indices at the end of the trial (T5) for mice humanised 4141 
with community (COM) type faecal microbiota. LAC_FREE: lactose-free milk 4142 
supplemented diet, WMILK: whole milk supplemented diet, GMP: 4143 
glycomacropeptide supplemented diet, CONTROL: soy-protein based control diet. 4144 
Only tests that passed the padj≤0.05 threshold for the Kruskal Wallis test are 4145 
presented. Asterisks refer to the Dunn’s post hoc test: * padj≤0.05, ** padj≤0.005, *** 4146 




Figure 14 Alpha diversity indices at the end of the trial (T5) for the faecal 4149 
microbiota of mice humanised with longstay (LS) type faecal microbiota. 4150 
LAC_FREE: lactose-free milk supplemented diet, WMILK: whole milk 4151 
supplemented diet, GMP: glycomacropeptide supplemented diet, CONTROL: soy-4152 
protein based control diet. Only tests that passed the padj≤0.05 threshold for the 4153 
Kruskal Wallis test are presented. Asterisks refer to the Dunn’s post hoc test: * 4154 
padj≤0.05, ** padj≤0.005, *** padj≤0.0005. Details on the values are given in S Table 4155 
5.  4156 
Lactose-free milk diet sustained higher abundances of health relevant 4157 
taxa including Ruminococcaceae compared to the other diets in mice  4158 
humanised with community type microbiota.  4159 
At the end of the dietary intervention (T5) the faecal microbiota clustered based on 4160 
diet; microbiota from mice fed all three dairy-supplemented diets clustered closer 4161 
compared to microbiota from mice fed control diet as shown in Figure 15 (Weighted 4162 
PCoA of the UniFrac distances of the sequenced 16S rRNA gene sequences in the 4163 
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relevant faecal microbiota samples). In the faecal microbiota of mice fed lac-free diet 4164 
the Porphyromonadaceae was the most abundant family (41% average relative 4165 
abundance) (Figure 16). The families Ruminococcaceae and Lachnospiraceae (17% 4166 
and 15% average relative abundance respectively) were the next most abundant 4167 
families in the microbiota composition of lactose-free diet fed mice; both families 4168 
reached significantly high abundance upon lac-free diet compared to the other diets 4169 
(S Figure 3 A). Other dominant families were the Bacteroidaceae, 4170 
Desulfovibrionaceae and Rikenellaceae. (Figure 16). Parabacteroides goldsteinii 4171 
was the most abundant taxon (28% average relative abundance) of the 4172 
Porphyromonadaceae followed by B. intestinihominis and Parabacteroides merdae 4173 
(Figure 17). Anaerotruncus colihominis and Oscillibacter taxa were the most 4174 
abundant among the Ruminococcaceae (6% and 5% average relative abundance 4175 
respectively) followed by Flavonifractor plautii (Figure 17). The Lachnospiraceae 4176 




Figure 15 Principal coordinates analysis (PCoA) of the murine faecal 4179 
microbiota at the end of the trial (T5). The mice were humanised with community 4180 
(COM) type faecal microbiota. A: Weighted UniFrac distances; B: Unweighted 4181 
UniFrac distances. LAC_FREE: lactose-free milk supplemented diet, WMILK: 4182 
whole milk supplemented diet, GMP: glycomacropeptide supplemented diet, 4183 
CONTROL: soy-protein based control diet.”●” denotes female mouse microbiota; 4184 
“▲” denotes male mouse microbiota.   4185 
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Gender dependent gut microbiota response to whole milk in mice 4186 
humanised with community type microbiota.  4187 
Based on the UniFrac analysis of the faecal microbiota of mice fed a whole milk 4188 
supplemented diet, two sub-clusters were formed separating female and male 4189 
microbiota responses (Figure 15 A, B). The Bacteroidaceae were more responsive to 4190 
the wmilk diet in the female mouse faecal microbiota (23.6% and 6.5% average 4191 
relative abundance in female and male mice respectively) whereas the 4192 
Erysipelotrichaceae were more abundant in the male mouse microbiota (23% and 2% 4193 
average relative abundance in male and female mice respectively) (S Table 6). 4194 
Bacteroides thetaiotaomicron and B. uniformis were the predominant representatives 4195 
of the Bacteroidaceae, and A. stercorianis and Turicibacter sanguinis were the major 4196 
representative taxa of the Erysipelotrichaceae in male and female mouse microbiota 4197 
respectively (Table 7). Gender based differences were also observed for the families 4198 
Ruminococcaceae (more abundant in male) and Peptostreptococcaceae (more 4199 
abundant in female) (S Table 6). Ruminococcus bromii (Ruminococcaceae) was 4200 
sustained only by the whole milk diet in the microbiota of male mice (6% average 4201 
relative abundance).  4202 
The compositional profile of the faecal microbiota aggregated across both genders is 4203 
shown in Figures 16 and 17. Bacteroidaceae and Erysipelotrichaceae relative 4204 
abundance was significantly increased upon whole milk diet compared to the other 4205 
tested diets (S Figure 3 A). Compared to the lactose-free diet Porphyromonadaceae 4206 
and Ruminococcaceae were less responsive to the whole milk diet whereas 4207 
Rikenellaceae and Acidaminococcaceae were more responsive (Figures 16; S 4208 
Figure 3 A). The Lachnospiraceae reached a relatively high abundance (11.7% 4209 
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average relative abundance) similar to that after lac-free diet and compared to the 4210 
other diets (S Figure 3 A).  4211 
Enrichment of the faecal microbiota in Porphyromonadaceae, 4212 
Desulfovibrionaceae and potential pathobionts due to 4213 
glycomacropeptide supplementation in community type humanised 4214 
mice. 4215 
We have previously presented evidence of GMP prebiotic activity in an artificial 4216 
colon model of elderly gut microbiota (Chapter 2; Ntemiri et al., 2017) but did not 4217 
confirm these findings in our mouse model. The microbiota of both female and male 4218 
mice responded similarly to the GMP diet as observed by the clustering on the PCoA 4219 
analysis (Figure 15 A and B). Compared to the other diets, the GMP diet resulted in 4220 
significant enrichment of the faecal microbiota in Porphyromonadaceae and the 4221 
Desulfovibrionaceae (50% and 12% average relative abundance respectively) 4222 
compared to most of the diets (Figure 16; S Figure 3 A). The main representative 4223 
taxa of the two aforementioned families were P. goldsteinii and B. wadsworthia 4224 
(46% and 12% average relative abundance respectively) (Figure 17). The GMP diet 4225 
had, similar to the wmilk diet, an effect on the Acidaminococcaceae (5% average 4226 
relative abundance) represented by P. faecium (Figure 17). Compared to the other 4227 
diets, feeding with the GMP diet resulted in significant microbiota enrichment in 4228 
Enterobacteriaceae and Enterococcaceae (4% and 2.5% average relative abundance 4229 
respectively) (Figure 16; S Figure 3 A); Enterococcus and Escherichia/Shigella 4230 
taxa were the dominant representatives (Figure 17).  4231 
Gender dependent gut microbiota response to control diet in 4232 
community type humanised mice.  4233 
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The faecal microbiota of mice fed the control diet clustered separately from the 4234 
microbiota of mice fed dairy-supplemented diets and gender based sub-clustering 4235 
was also observed (Figure 15). Differences in the composition between female and 4236 
male mice fed the control diet included differences in the abundance of taxa 4237 
belonging to the Porphyromonadaceae, Rikenellaceae, Ruminococcaceae and 4238 
Acidaminococcaceae (Table 7). Porphyromonadaceae was the next most abundant 4239 
family (21% average relative abundance) in the microbiota of control fed mice 4240 
following the Verrucomicrobiaceae (40% average relative abundance) represented 4241 
by A. muciniphila (Figures 16, 17). The compositional profile of the faecal 4242 
microbiota of mice fed the wmilk diet aggregated across both gender is shown in 4243 




Figure 16 Composition of the murine faecal microbiota at family level at the 4246 
end of the trial (T5) in mice humanised with community (COM) type human 4247 
faecal microbiota. LAC_FREE: lactose-free milk supplemented diet, WMILK: 4248 
whole milk supplemented diet, GMP: glycomacropeptide supplemented diet, 4249 




Figure 17 Composition of the murine faecal microbiota at species level at the 4252 
end of the trial (T5) in mice humanised with community (COM) type human 4253 
faecal microbiota. LAC_FREE: lactose-free milk supplemented diet, WMILK: 4254 
whole milk supplemented diet, GMP: glycomacropeptide supplemented diet, 4255 
CONTROL: soy protein based control diet. Only species present at ≥1 % are shown.   4256 
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Table 7 Differences in the female and male murine microbiota composition 4257 
associated with separation in the PCoA grouping by whole milk (WMILK) and 4258 
control diet at the end of the trial (T5). Only species present at ≥1 % relative 4259 
abundance are presented. The humanisation of the mice was performed with 4260 





















































OTU classification % average relative abundance 
Bacteroidaceae/Bacteroides/Bacteroides cellulosilyticus 0.0 0.6 2.6 0.0 
Bacteroidaceae/Bacteroides/Bacteroides thetaiotaomicron 14.1 1.3 2.3 2.3 
Bacteroidaceae/Bacteroides/Bacteroides uniformis 7.7 2.7 1.7 4.0 
Bacteroidaceae/Bacteroides/unclassified 1.3 0.4 0.2 1.0 
Porphyromonadaceae/Barnesiella/Barnesiella intestinihominis 3.1 2.7 2.4 4.1 
Porphyromonadaceae/Barnesiella/unclassified 0.1 0.04 4.7 0.2 
Porphyromonadaceae/Butyricimonas/Butyricimonas virosa 0.5 1.3 1.0 0.4 
Porphyromonadaceae/Parabacteroides/Parabacteroides distasonis 1.8 1.4 1.1 0.3 
Porphyromonadaceae/Parabacteroides/Parabacteroides goldsteinii 24.5 22.0 6.0 12.7 
Porphyromonadaceae/unclassified/unclassified 0.1 0.1 9.3 0.1 
Rikenellaceae/Alistipes/Alistipes putredinis 0.01 5.4 0.01 12.6 
Rikenellaceae/Alistipes/unclassified 6.5 4.2 0.4 4.7 
Bacteroidales/unclassified/unclassified/unclassified 1.3 1.0 0.8 1.7 
Lachnospiraceae/Clostridium XlVa/unclassified 6.4 0.2 0.002 0.6 
Lachnospiraceae/unclassified/unclassified 4.1 12.3 5.2 4.5 
Peptostreptococcaceae/Clostridium XI/ 
Clostridium ruminantium 
2.7 0.0 0.0 0.0 
Ruminococcaceae/Flavonifractor/Flavonifractor plautii 0.8 0.4 2.1 0.7 
Ruminococcaceae/Oscillibacter/Oscillibacter valericigenes 0.0 0.02 1.6 0.2 
Ruminococcaceae/Ruminococcus/Ruminococcus bromii 0.0 6.0 0.0 0.0 
Ruminococcaceae/unclassified/unclassified 0.7 0.7 4.9 2.6 
Clostridiales/unclassified/unclassified/unclassified 0.6 0.4 0.5 1.1 
Erysipelotrichaceae/Allobaculum/Allobaculum stercoricanis 0.001 22.0 0.0 0.0 
Erysipelotrichaceae/Turicibacter/Turicibacter sanguinis 1.6 0.0 0.0 0.001 
Acidaminococcaceae/Phascolarctobacterium/ 
Phascolarctobacterium faecium 
5.7 5.5 3.0 0.6 
Desulfovibrionaceae/Bilophila/Bilophila wadsworthia 7.5 1.8 3.7 4.9 
unclassified 5.3 1.5 0.9 0.2 
Verrucomicrobiaceae/Akkermansia/ 
Akkermansia muciniphila 
0.0 0.0 40.6 37.2 
  4262 
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Faecal microbiota compositional profile of mice fed lactose -free milk 4263 
supplemented diet and humanised with longstay type microbiota  4264 
At the end of the trial (T5) the faecal microbiota from mice humanised with LS 4265 
microbiota and fed milk-supplemented diets clustered closer compared to the 4266 
microbiota from mice fed GMP or control diet as shown in the PCoA in Figures 18 4267 
A and B. Compared to the other diets, the lactose-free diet resulted in the highest 4268 
Porphyromonadaceae abundance increase (29% average relative abundance) 4269 
represented predominantly by Parabacteroides merdae and to a lesser extent by 4270 
Parabacteroides distasonis (Figures 19, 20; S Figure 3 B). Lachnospiraceae (16% 4271 
average relative abundance), Rikenellaceae and Bacteroidaceae (14% average 4272 
relative abundance each) were the next most abundant families (Figure 19). The 4273 
families Desulfovibrionaceae (Desulfovibrio piger), Peptostreptococcaceae (C. 4274 
ruminantium), Ruminococcaceae (F. plautii) and Enterobacteriaceae (Shigella taxa) 4275 
reached the highest abundance after the lac-free diet feeding compared to the other 4276 
diets (Figures 19, 20). Limited differences in the composition of the faecal 4277 
microbiota between female and male mice, based on abundances of certain families 4278 
such as the Bacteroidaceae (more abundant in male) and Porphyromonadaceae (more 4279 
abundant in female) (Table 8, S Table 7) may explain the sub-clustering within the 4280 




Figure 18 Principal coordinates analysis (PCoA) of the murine faecal 4283 
microbiota at the end of the trial (T5). The mice were humanised with long stay 4284 
(LS) type faecal microbiota. A: Weighted UniFrac distances; B: Unweighted 4285 
UniFrac distances. LAC_FREE: lactose-free milk supplemented diet, WMILK: 4286 
whole milk supplemented diet, GMP: glycomacropeptide supplemented diet, 4287 
CONTROL: soy protein based control diet. .”●” denotes female mouse microbiota; 4288 
“▲” denotes male mouse microbiota.   4289 
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Gender dependent enrichment of Lachnospiraceae and 4290 
Erysipelotrichaceae due to whole milk supplemented diet in mice 4291 
humanised with longstay type microbiota.  4292 
The Weighted UniFrac analysis of the faecal microbiota of mice fed the whole milk 4293 
diet, resulted in two sub-clusters based on gender-dependent responses, (Figures 18 4294 
A). Different Lachnospiraceae taxa were responsive in the microbiota of female and 4295 
male mice whereas the Erysipelotrichaceae represented by A. stercorianis increased 4296 
only in the female mice microbiota (Table 8). The Bacteroidaceae that were among 4297 
the most abundant families in both female and male mouse microbiota (19% average 4298 
relative abundance in both) had gender associated differences in the responsive taxa 4299 
(S Table 7, Table 8). Other dominant taxa with gender associated variations in the 4300 
relative abundance belonged to the Porphyromonadaceae and Rikenellaceae (Table 4301 
8). The aggregated across gender mouse microbiota composition is shown in 4302 
Figures 19 and 20. Compared to the other feeding regimes, Lachnospiraceae and 4303 
Erysipelotrichaceae were significantly enriched upon the whole milk diet and 4304 
compared to the other feeding regimes (29% and 19% average relative abundance 4305 
respectively) (S Figure 3 B).  4306 
Effect of GMP and control diet on the longstay type microbiota  4307 
The Bacteroidaceae was the second most abundant family (25% average relative 4308 
abundance) in the microbiota of mice fed GMP diet following the 4309 
Verrucomicrobiaceae, with B. dorei and B. thetaiotaomicron as the main 4310 
representatives of the Bacteroidaceae family (Figures 19, 20). Compared to the other 4311 
feeding regimes, GMP diet sustained the highest Bacteroidaceae and 4312 
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Acidaminococcaceae (represented by P. faecium) relative abundances in the faecal 4313 
microbiota of mice humanised with LS microbiota (Figures 19, 20; S Figure 3 B).  4314 
Similar to aforementioned feeding regimes, the Verrucomicrobia were 4315 
overrepresented in the faecal microbiota of mice fed the control diet and humanised 4316 
with LS microbiota (Figure 19). Compared to the other diets, the control diet 4317 
resulted in enrichment of the microbiota in the Rikenellaceae family (22% average 4318 
relative abundance) (S Figure 3 B) and Alistipes putredinis was the prevalent 4319 
representative taxon (Figure 20). The Ruminococcaceae (represented by F. plautii 4320 
and other unclassified taxa) had a relatively high abundance comparable to that 4321 
observed under the lactose-free feeding regime whereas the families 4322 
Lachnospiraceae, Bacteroidaceae and Porphyromonadaceae had the lowest 4323 




Figure 19 Composition of the murine faecal microbiota at family level at the 4326 
end of the trial (T5) in mice humanised with longstay (LS) type human faecal 4327 
microbiota. LAC_FREE: lactose-free milk, WMILK: whole milk, GMP: 4328 
glycomacropeptide, CONTROL: soy-protein based control diet. Only families 4329 




Figure 20 Composition of the murine faecal microbiota at family level at the end 4332 
of the trial in mice humanised with longstay (LS) type human faecal microbiota. 4333 
LAC_FREE: lactose-free milk, WMILK: whole milk, GMP: glycomacropeptide, 4334 
CONTROL: soy-protein based control diet. Only families present at ≥1 % relative 4335 
abundance are shown.  4336 
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Table 8 Differences in the female and male murine microbiota composition 4337 
associated with separation in the PCoA grouping by lactose-free milk and whole 4338 
milk diets. Only species that were present at ≥1 % relative abundance are presented. 4339 




















































OTU classification % average relative abundance 
Bacteroidaceae/Bacteroides/Bacteroides dorei 0.0 0.0 9.9 18.7 
Bacteroidaceae/Bacteroides/Bacteroides thetaiotaomicron 8.6 25.0 7.8 0.002 
Bacteroidaceae/Bacteroides/unclassified 0.90 3.5 1.4 0.003 
Porphyromonadaceae/Parabacteroides/Parabacteroides distasonis 4.3 3.8 0.5 1.5 
Porphyromonadaceae/Parabacteroides/Parabacteroides merdae 28.2 14.9 3.1 26.0 
Rikenellaceae/Alistipes/Alistipes putredinis 13.5 15.3 5.1 11.8 
Enterococcaceae/Enterococcus/unclassified 1.0 1.4 0.002 2.2 
Lachnospiraceae/Blautia/unclassified 0.6 0.2 4.6 0.9 
Lachnospiraceae/Clostridium XlVa/unclassified 5.8 2.4 29.7 5.6 
Lachnospiraceae/unclassified/unclassified 11.6 7.9 0.2 15.4 
Peptostreptococcaceae/Clostridium_XI/Clostridium ruminantium 6.5 4.6 0.001 0.0 
Ruminococcaceae/Flavonifractor/Flavonifractor plautii 1.7 2.9 0.1 0.10 
Ruminococcaceae/unclassified/unclassified 2.1 2.0 0.1 3.0 
Clostridiales/unclassified/unclassified/unclassified 1.2 0.8 0.2 0.4 
Erysipelotrichaceae/Allobaculum/Allobaculum stercoricanis 0.001 0.001 32.3 0.01 
Acidaminococcaceae/Phascolarctobacterium/ 
Phascolarctobacterium faecium 
2.2 1.8 1.1 0.002 
Desulfovibrionaceae/Desulfovibrio/Desulfovibrio piger 8.0 8.0 1.4 0.0 
Desulfovibrionaceae/unclassified/unclassified 0.1 0.01 0.0 1.2 
Enterobacteriales/Enterobacteriaceae/Escherichia/ 
Shigella/unclassified 
1.1 2.7 0.5 0.001 
Enrichment of the microbiota in Verrucomicrobiaceae in some 4341 
dietary groups   4342 
In the faecal microbiota of some groups humanised with either microbiota type, an 4343 
enrichment (≥ 40% average relative abundance) in the Verrucomicrobiaceae family 4344 
represented by A. muciniphila was observed at the end of the trial (T5) (Figures 17, 4345 
20). Alpha diversity scores may have been biased due to the Akkermansia bloom 4346 
observed at (T5) and for this reason the microbiota composition and alpha diversity 4347 
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indices were analysed at an earlier time point, i.e. in the middle of the dietary 4348 
intervention (T4) (S Figure 4, S Tables 8, 9). The Verrucomicrobiaceae bloom was 4349 
detected at time point T4 for the mice humanised with COM microbiota but not for 4350 
the mice humanised with LS type microbiota (S Figure 4). At T4, the lactose-free 4351 
diet sustained significantly higher alpha diversity in the murine microbiota of COM 4352 
type humanised mice compared to the other feeding regimes; however, the 4353 
Verrucomicrobiaceae bloom may have contributed to the alpha diversity observed 4354 
for control feeding (S Table 8). For the LS type humanised mice at T4, both milk 4355 
supplemented diets sustained significantly higher alpha diversity indices compared 4356 
to both GMP and control diet (S Table 8). 4357 
3.5 Discussion 4358 
Prebiotic effect of the lactose-free milk supplemented diet on the gut 4359 
microbiota of mice humanised with faecal microbiota from older 4360 
donors 4361 
In mice colonised with either human microbiota type the lactose-free diet sustained 4362 
significantly higher faecal microbiota diversity compared to the whole milk or GMP 4363 
diets, performing as efficiently as soy protein supplemented diet. Some animal and 4364 
human studies indicate to the prebiotic potential of soy and its products (reviewed in 4365 
Huang et al., 2016). Decreased gut microbiota phylogenetic diversity is indication 4366 
biomarker of ageing and frailty, and dietary supplements contributing in sustaining 4367 
diversity may improve the ageing process (Claesson et al., 2012; Jackson et al., 4368 
2016). The efficiency of the lactose-free milk diet in retaining microbiota diversity 4369 
can be attributed partly to the BMOs available for microbiota fermentation. Bovine 4370 
milk oligosaccharides have attracted scientific interest as potential prebiotics due to 4371 
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their structural complexity and similarity to HMOs (Zivkovic and Barile, 2011; 4372 
Smilowitz et al., 2014).  4373 
The Ruminococcaceae enrichment of the microbiota associated with the lactose-free 4374 
diet associated observed mostly in COM type humanised animals could indicate that 4375 
such a dietary supplementation might contribute to colonic health and healthy ageing 4376 
as reported before (Kong et al., 2016; Mottawea et al., 2016). In the current study the 4377 
dominant Ruminococcaceae taxon was Anaerotruncus. Others have reported 4378 
probiotic-associated Anaerotruncus enrichment of dysbiotic murine microbiota after 4379 
Abx treatment (Grazul et al., 2016). Other dominant Ruminococcaceae taxa reported 4380 
here i.e., Oscillibacter and Flavonifractor, have been associated with resistant starch 4381 
degradation and identified in the gut microbiota of lean individuals (Walker et al., 4382 
2011; Kasai et al., 2015). However, caution is needed before extrapolating these 4383 
findings to human dietary interventions because some studies report enrichment of 4384 
Oscillibacter in cancer associated microbiota and Anaerotruncus enrichment in the 4385 
microbiota of frail elderly (Jeffery et al., 2016; Flemer et al., 2017). In the LS 4386 
humanised mice the Ruminococcaceae reached the highest relative abundance after 4387 
lactose-free (and control) diet but not as high as in COM type humanised mice, 4388 
potentially due to low starting abundance of this family in the LS microbiota. 4389 
Importantly, in LS humanised mice, lac-free diet resulted in increased D. piger 4390 
relative abundance; a taxon negatively correlated to health in elderly people (Jeffery 4391 
et al., 2016). The balance of these effects needs to be measured and considered in 4392 
human studies.  4393 
Prebiotic potential of whole milk  4394 
223 
 
The whole milk supplemented diet was less efficient than the lactose-free diet in 4395 
sustaining microbiota diversity. However, the comparative increase in the relative 4396 
abundance of certain taxa after wmilk diet warrants further investigation. 4397 
Ruminococcus bromii (Ruminococcaceae) was detected at high abundance 4398 
exclusively in (male) mice humanised with COM type microbiota fed whole milk 4399 
diet. Ruminococcus bromii is a dominant gut microbiota taxon highly responsive to 4400 
resistant starch, essential in nutrient degradation and as such it can be a prebiotic 4401 
target leading to substrate release in the colon and increase in cross-feeding mediated 4402 
by SCFA production (Ze et al., 2012; Scott et al., 2015). The (gender dependent) 4403 
Erysipelotrichaceae/A. stercorianis enrichment of the faecal microbiota of whole 4404 
milk fed mice may be a positive effect on the microbiota. In murine trials, high-fat 4405 
diet-associated dysbiosis and impaired gut barrier function were restored after BMOs 4406 
supplementation correlating to Allobaculum (and Ruminococcaceae) enrichment of 4407 
the microbiota (Boudry et al., 2017; Hamilton et al., 2017). Inulin supplementation 4408 
had similar effect on Allobaculum taxa associated with improved vascular function 4409 
(Catry et al. 2018). However, careful extrapolation to human diet is needed due to 4410 
Allobaculum association with thrombosis risk through TMAO metabolism and to 4411 
other erysipelotrichi associations with the obesity phenotype in murine models 4412 
(Woting et al., 2014; Zhu et al., 2016). Importantly the whole milk diet, similarly to 4413 
the lactose-free diet, sustained the highest Lachnospiraceae abundance in the murine 4414 
microbiota compared to the control and GMP diets, and especially in LS humanised 4415 
mice the whole milk diet resulted in a favourable ratio of Lachnospiraceae and 4416 
Bacteroidaceae. In aged humans with frailty indications, Bacteroidaceae were found 4417 
to dominate in abundance over Lachnospiraceae (Jeffery et al., 2016). Interestingly, 4418 
the increased relative ratio of Lachnospiraceae to Bacteroidaceae may explain the 4419 
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fact that milk-supplemented diets resulted in the highest weight gain from baseline 4420 
(Figure 11) (Turnbaugh et al., 2006; Jumpertz et al., 2011). 4421 
GMP was not associated with prebiotic activity  4422 
The Bacteroidetes (Bacteroidaceae, Bacteroidales unclassified and 4423 
Porphyromonadaceae), Enterobacteriaceae and Desulfovibrionaceae were responsive 4424 
to GMP and the milk diets depending on humanisation type (S Figure 3). In this 4425 
study we did not observe in vivo beneficial effects of the GMP supplementation on 4426 
the gut microbiota in contrast to previous studies in a conventional mouse model 4427 
(Sawin et al., 2015). In our study increased Desulfovibrionaceae/B. wadsworthia 4428 
abundance due to GMP supplementation in COM humanised mice was observed, 4429 
contrary to previous studies reporting decreased Desulfovibrionaceae/D. piger 4430 
relative abundance associated with 20% GMP-enriched diet (Sawin et al., 2015). 4431 
Intake of high-fat diet (milk-derived fat) resulted in B. wadsworthia associated 4432 
dysbiosis and inflammation in a conventional mouse model (Devkota et al., 2012). 4433 
Colonic health is promoted by reduced Bilophila relative abundances in human gut 4434 
microbiota (Vandeputte et al., 2017). The sialic acid content of the GMP may have 4435 
contributed to the comparative increase in Enterobacteriaceae/Escherichia/Shigella 4436 
taxa relative abundance in COM type humanised mice microbiota (Huang et al., 4437 
2015). A similar response was not observed in LS humanised mice; the 4438 
Enterobacteriaceae were more responsive to the lactose-free milk diet. In the 4439 
microbiota of LS colonised mice the Bacteroidaceae were highly responsive to 4440 
GMP-supplemented diet (and the other two dairy diets). Increase in Bacteroides 4441 
population due to GMP-supplementation has been reported in mouse models (Sawin 4442 
et al., 2015; Jimenez et al., 2017). Interestingly, different Bacteroidaceae taxa have 4443 
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been associated with sialidase activity with or without sialic acid utilisation ability 4444 
(Huang et al., 2015; reviewed in Juge et al., 2016). Charbonneau et al. (2016) 4445 
reported growth improvement in a gnotobiotic mouse and piglet model through 4446 
cross-feeding between Bacteroides taxa that could degrade sialic acid-containing 4447 
carbohydrates from sialylated BMO and secondary utilisers of sialic acid-containing 4448 
compounds like E. coli.  4449 
In Chapter 2, I reported the increased relative abundance of Lachnospiraceae taxa 4450 
like Coprococcus and Roseburia due to GMP in vitro supplementation; in this in 4451 
vivo model we did not observe similar microbiota responsiveness. As discussed in 4452 
the following section (and in details in Chapter 1.2.4 of this thesis), the mouse gut 4453 
may favour the colonisation of xenomicrobiota Bacteroidetes taxa and may be 4454 
refractory to Lachnospiraceae and other Firmicutes taxa colonisation. This could 4455 
partly explain why, in this in vivo model, Lachnospiraceae taxa were not observed to 4456 
be major responders to GMP supplementation.Establishment of the human 4457 
faecal microbiota in the murine GIT tract  4458 
Although the faecal microbiota across groups at the end of the trial strongly 4459 
separated from that at baseline grouping by humanisation type and diet (S Figures 2, 4460 
3), it is considered that the murine host played a role in re-shaping the 4461 
xenomicrobiota. For example, at the end of the trial, the Bacteroidetes and especially 4462 
Porphyromonadaceae enrichment across all dietary groups and the compositional 4463 
profile of the Lachnospiraceae can be viewed as the result of selective pressure 4464 
applied by the murine host to reshape the relative abundances of shared humans 4465 
xenomicrobiota taxa to best fit murine host physiology and immunity (Nguyen et al., 4466 
2015; Messer et al., 2016). In this study, similarly to previous observations, we 4467 
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observed gender dependent differential responses to diet partly attributed to 4468 
hormonal effects (Org et al., 2016; Wang et al., 2016). The Akkermansia bloom 4469 
could be attributed to the HydroGel treatment that interrupted the Abx treatment in 4470 
some dietary groups, to coprophagy and to cross-contamination between cages. 4471 
Interestingly, Dubourg et al. (2012) reported increased A. muciniphila colonisation 4472 
in gut microbiota after broad-spectrum Abx treatment.  4473 
3.6 Conclusions 4474 
Milk is a widely accessible dietary product, it combines an array of valuable 4475 
nutrients and many recent human cohort studies have demonstrated the health 4476 
benefits of milk consumption (Haug et al., 2007; Visioli and Strata, 2014; Guo et al., 4477 
2017). Importantly, BMOs may be an efficient prebiotic substrate similarly to HMOs 4478 
(Zivkovic and Barile, 2011; Smilowitz et al., 2014). We have discussed the gut 4479 
microbiota modulatory potential of (lactose free and whole) milk in a murine model. 4480 
Lactose free milk was found a better prebiotic candidate compared to whole milk as 4481 
it retained higher microbiota diversity. However, whole milk diet affected the 4482 
abundance of significant health-relevant microbiota taxa. When translating the 4483 
findings of the current study to humans, the fact that mice may not fully tolerate 4484 
lactose (van de Heijning et al., 2015), and that the lactose fermentation in wmilk diet 4485 
fed mice may have prevented BMOs utilisation by the gut microbiota, must be taken 4486 
into consideration. If the two milk types, i.e., whole milk and lactose-free milk, have 4487 
a differential effect on the gut microbiota of lactase persistent subjects remains to be 4488 
clarified in a clinical trial.  4489 
3.7 Funding Sources 4490 
227 
 
This work was financially supported by the Government of Ireland National 4491 
Development Plan by way of a Department of Agriculture, Food and the Marine 4492 
(DAFM) under a Food Institutional Research Measure (FIRM) award (11/F/053) for 4493 
the ELDERFOOD project.  4494 
3.8 Acknowledgements 4495 
We thank Arla Foods Ingredients, Denmark and Valio Ltd Finland for providing 4496 
Lacprodan CGMP-10 and milk powders, respectively. We thank Dr Celine Ribiere 4497 
for her help in the amplicon sequence analysis.   4498 
228 
 
3.9 References 4499 
Allard, G., Ryan, F. J., Jeffery, I. B., Claesson, M. J. (2015). SPINGO: A rapid 4500 
species-classifier for microbial amplicon sequences. BMC Bioinformatics, 16(1), 4501 
1–8.  4502 
Bereswill, S., Fischer, A., Plickert, R., Haag, L. M., Otto, B., Kühl, A. A., Dasti, 4503 
J. I., Zautner, A. E., Munoz, M., Loddenkemper, C., Gross, U., et al. (2011). 4504 
Novel murine infection models provide deep insights into the “Ménage à Trois” 4505 
of Campylobacter jejuni, microbiota and host innate immunity. PLoS One, 6(6), 4506 
e20953.  4507 
Boudry, G., Hamilton, M. K., Chichlowski, M., Wickramasinghe, S., Barile, D., 4508 
Kalanetra, K. M., Mils, D. A., Raybould, H. E. (2017). Bovine milk 4509 
oligosaccharides decrease gut permeability and improve inflammation and 4510 
microbial dysbiosis in diet-induced obese mice. J Dairy Sci, 100(4), 2471–2481.  4511 
Brück, W. M., Redgrave, M., Tuohy, K. M., Lönnerdal, B., Graverholt, G., 4512 
Hernell, O., Gibson, G. R. (2006). Effects of bovine alpha-lactalbumin and 4513 
casein glycomacropeptide-enriched infant formulae on faecal microbiota in 4514 
healthy term infants. J Pediatr Gastroenterol Nutr, 43(5), 673–9.  4515 
Caporaso, J. G., Bittinger, K., Bushman, F. D., Desantis, T. Z., Andersen, G. L., 4516 
Knight, R. (2010). PyNAST: A flexible tool for aligning sequences to a template 4517 
alignment. Bioinformatics, 26(2), 266–267.  4518 
Catry, E., Bindels, L. B., Tailleux, A., Lestavel, S., Neyrinck, A. M., Goossens, 4519 
J.-F., Lobysheval, I., Plovier, H., et al. (2018). Targeting the gut microbiota with 4520 
229 
 
inulin-type fructans: preclinical demonstration of a novel approach in the 4521 
management of endothelial dysfunction. Gut, 67(2), 271–283.  4522 
Charbonneau, M. R., O’Donnell, D., Blanton, L. V., Totten, S. M., Davis, J. C. 4523 
C., Barratt, M. J., Cheng, J., Guruge, J., et al. (2016). Sialylated milk 4524 
oligosaccharides promote microbiota-dependent growth in models of infant 4525 
undernutrition. Cell, 164(5), 859–871.  4526 
Claesson, M. J., Jeffery, I. B., Conde, S., Power, S. E., O’Connor, E. M., Cusack, 4527 
S., Harris, H. M., Coakley, M., et al. (2012). Gut microbiota composition 4528 
correlates with diet and health in the elderly. Nature, 488(7410), 178–184.  4529 
Devkota, S., Wang, Y., Musch, M. W., Leone, V., Fehlner-Peach, H., Nadimpalli, 4530 
A., Antonopoulos, D. A., Jabri, B., Chang, E. B. (2012). Dietary-fat-induced 4531 
taurocholic acid promotes pathobiont expansion and colitis in Il10 −/− mice. 4532 
Nature, 487(7405), 104–108.  4533 
Dubourg, G., Lagier, J. C., Armougom, F., Robert, C., Audoly, G., Papazian, L., 4534 
Raoult, D. (2013). High-level colonisation of the human gut by Verrucomicrobia 4535 
following broad-spectrum antibiotic treatment. Int J Antimicrob Agents, 41(2), 4536 
149–155.  4537 
Flemer, B., Lynch, D. B., Brown, J. M. R., Jeffery, I. B., Ryan, F. J., Claesson, 4538 
M. J., O’Riordan M., Shanahan, F., O’Toole, P. W. (2017). Tumour-associated 4539 
and non-tumour-associated microbiota in colorectal cancer. Gut, 66(4), 633–643.  4540 
Franceschi, C., and Campisi, J. (2014). Chronic inflammation (inflammaging) 4541 
and its potential contribution to age-associated diseases. J Gerontol A Biol Sci 4542 
Med Sci, 69(Suppl 1), S4–S9.  4543 
230 
 
Grazul, H., Kanda, L. L., Gondek, D. (2016). Impact of probiotic supplements on 4544 
microbiome diversity following antibiotic treatment of mice. Gut Microbes, 7(2), 4545 
101–114.  4546 
Guo, J., Astrup, A., Lovegrove, J. A., Gijsbers, L., Givens, D. I., Soedamah-4547 
Muthu, S. S. (2017). Milk and dairy consumption and risk of cardiovascular 4548 
diseases and all-cause mortality: dose–response meta-analysis of prospective 4549 
cohort studies. Eur J Epidemiol, 32(4), 269–287.  4550 
Gustavo Hermes, R., Molist, F., Francisco Pérez, J., Gómez de Segura, A., 4551 
Ywazaki, M., Davin, R., et al. (2013). Casein glycomacropeptide in the diet may 4552 
reduce Escherichia coli attachment to the intestinal mucosa and increase the 4553 
intestinal lactobacilli of early weaned piglets after an enterotoxigenic E. coli K88 4554 
challenge. Br J Nutr, 109(6), 1001–12.  4555 
Hamilton, M. K., Ronveaux, C. C., Rust, B. M., Newman, J. W., Hawley, M., 4556 
Barile, D., Mills, D. A., Raybould, H. E. (2017). Prebiotic milk oligosaccharides 4557 
prevent development of obese phenotype, impairment of gut permeability, and 4558 
microbial dysbiosis in high fat-fed mice. Am J Physiol Gastrointest Liver 4559 
Physiol, 312(5), G474–G487. 4560 
Haug, A., Høstmark, A. T., Harstad, O. M. (2007). Bovine milk in human 4561 
nutrition – a review. Lipids Health Dis, 6(1), 25.  4562 
Hernandez-Hernandez, O., Sanz, M. L., Kolida, S., Rastall, R. A, Moreno, F. J. 4563 
(2011). In vitro fermentation by human gut bacteria of proteolytically digested 4564 
caseinomacropeptide nonenzymatically glycosylated with prebiotic 4565 
carbohydrates. J Agric Food Chem, 59(22), 11949–55.  4566 
231 
 
Huang, Y.-L., Chassard, C., Hausmann, M., von Itzstein, M., Hennet, T. (2015). 4567 
Sialic acid catabolism drives intestinal inflammation and microbial dysbiosis in 4568 
mice. Nature Commun, 6(1), 8141. 4569 
Huang, H., Krishnan, H. B., Pham, Q., Yu, L. L., Wang, T. T. Y. (2016). Soy and 4570 
gut microbiota: Interaction and implication for human health. J Agric Food 4571 
Chem, 64(46), 8695–8709.  4572 
Hvas, C. L., Dige, A., Bendix, M., Wernlund, P. G., Christensen, L. A, Dahlerup, 4573 
J. F., Agnholt, J. (2016). Casein glycomacropeptide for active distal ulcerative 4574 
colitis: a randomised pilot study. Eur J Clin Invest, 46(6), 555–563.  4575 
Jackson, M., Jeffery, I. B., Beaumont, M., Bell, J. T., Clark, A. G., Ley, R. E., 4576 
O’Toole, P. W., Spector, T. D., Steves, C. J. (2016). Signatures of early frailty in 4577 
the gut microbiota. Genome Med, 8(1), 8. 4578 
Jeffery, I. B., Lynch, D. B., O’Toole, P. W. (2016). Composition and temporal 4579 
stability of the gut microbiota in older persons. ISME J, 10(1), 170–182.  4580 
Jimenez, M., Cervantes-Garcia, D., Munoz, Y. H., Garcia, A., Haro, L. M., 4581 
Salinas, E. (2017). Novel mechanisms underlying the therapeutic effect of 4582 
glycomacropeptide on allergy: Change in gut Microbiota, upregulation of TGF-β, 4583 
and inhibition of mast cells. Int Arch Allergy Immunol, 171(3–4), 217–226.  4584 
Juge, N., Tailford, L., Owen, C. D. (2016). Sialidases from gut bacteria: a mini-4585 
review. Biochem Soc Trans, 44(1), 166–175.  4586 
Jumpertz, R., Le, D. S., Turnbaugh, P. J., Trinidad, C., Bogardus, C., Gordon, J. 4587 
I., Krakoff, J. (2011). Energy-balance studies reveal associations between gut 4588 
232 
 
microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr, 94(1), 4589 
58–65.  4590 
Kasai, C., Sugimoto, K., Moritani, I., Tanaka, J., Oya, Y., Inoue, H., Tameda, 4591 
M., Shiraki, K., Ito, M., Takei, Y., Takase, K. (2015). Comparison of the gut 4592 
microbiota composition between obese and non-obese individuals in a Japanese 4593 
population, as analyzed by terminal restriction fragment length polymorphism 4594 
and next-generation sequencing. BMC Gastroenterol, 15, 100.  4595 
Klindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., 4596 
Glöckner, F. O. (2012). Evaluation of general 16S ribosomal RNA gene PCR 4597 
primers for classical and next-generation sequencing-based diversity studies. 4598 
Nucleic Acids Res, 41(1), e1.  4599 
Kurilshikov, A., Wijmenga, C., Fu, J., Zhernakova, A. (2017). Host genetics and 4600 
gut microbiome: Challenges and perspectives. Trends Immunol, 38(9), 633–647.  4601 
Laird, E., Casey, M. C., Ward, M., Hoey, L., Hughes, C. F., McCarroll, K., 4602 
Cunningham, C., Strain, J. J., McNulty, Molloy, A. M. (2016). Dairy intakes in 4603 
older Irish adults and effects on vitamin micronutrient status: Data from the 4604 
TUDA study. J Nutr Health Aging, 21 (9), 954-961.  4605 
Lana, A., Rodriguez-Artalejo, F., Lopez-Garcia, E. (2015). Dairy consumption 4606 
and risk of frailty in older adults: A prospective cohort study. J Am Geriatr Soc, 4607 
63(9), 1852–1860.  4608 
Larsson, S. C., Crippa, A., Orsini, N., Wolk, A., Michaëlsson, K. (2015). Milk 4609 
consumption and mortality from all causes, cardiovascular disease, and cancer: A 4610 
systematic review and meta-analysis. Nutrients, 7(9), 7749–7763.  4611 
233 
 
Levy, M., Kolodziejczyk, A. A., Thaiss, C. A., Elinav, E. (2017). Dysbiosis and 4612 
the immune system. Nat Rev Immunol, 17(4), 219–232.  4613 
Li, H., Qi, Y., Jasper, H. (2016). Preventing age-related decline of gut 4614 
compartmentalization limits microbiota dysbiosis and extends lifespan. Cell Host 4615 
Microbe, 19(2), 240–253.  4616 
Lundberg, R., Toft, M. F., August, B., Hansen, A. K., Hansen, C. H. F. (2016). 4617 
Antibiotic-treated versus germ-free rodents for microbiota transplantation 4618 
studies. Gut Microbes, 7(1), 68–74. 4619 
Magoc, T., and Salzberg, S. L. (2011). FLASH: Fast length adjustment of short 4620 
reads to improve genome assemblies. Bioinformatics, 27(21), 2957–2963.  4621 
Manor, O., and Borenstein, E. (2017). Systematic characterization and analysis 4622 
of the taxonomic drivers of functional shifts in the human Microbiome. Cell Host 4623 
Microbe, 21(2), 254–267.  4624 
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A, Hirschfield, G. M., 4625 
Hold, G., Quraishi, M. N., Kinross J., et al. (2016). The gut microbiota and host 4626 
health: a new clinical frontier. Gut, 65, 330–390.  4627 
Messer, J. S., Liechty, E. R., Vogel, O. A., Chang, E. B. (2017). Evolutionary 4628 
and ecological forces that shape the bacterial communities of the human gut. 4629 
Mucosal Immunol, 10(3), 567–579.  4630 
Mottawea, W., Chiang, C.-K., Mühlbauer, M., Starr, A. E., Butcher, J., 4631 
Abujamel, T., Deeke, S. A., Brandel, A., et al. (2016). Altered intestinal 4632 
234 
 
microbiota–host mitochondria crosstalk in new onset Crohn’s disease. Nat 4633 
Commun, 7, 13419.  4634 
Neelima, Sharma, R., Rajput, Y.S., Mann, B. (2013). Chemical and functional 4635 
properties of glycomacropeptide (GMP) and its role in the detection of cheese 4636 
whey adulteration in milk: a review. Dairy Sci Technol, 93(1), 21–43.  4637 
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., Raes, J. (2015). How informative 4638 
is the mouse for human gut microbiota research? Dis Model Mech, 8(1), 1–16.  4639 
Ntemiri, A., Ni Chonchuir, F., O’Callaghan, T. F., Stanton, C., Ross, R. P., 4640 
O’Toole, P. W. (2017). Glycomacropeptide sustains microbiota diversity and 4641 
promotes specific taxa in an artificial colon model of elderly gut microbiota. J 4642 
Agric Food Chem, 65(8), 1836–1846.  4643 
Org, E., Mehrabian, M., Parks, B. W., Shipkova, P., Liu, X., Drake, T. A., Lusis, 4644 
A. J. (2016). Sex differences and hormonal effects on gut microbiota 4645 
composition in mice. Gut Microbes, 7(4), 313–322.  4646 
O’Riordan, N., Kane, M., Joshi, L., Hickey, R. M. (2014). Structural and 4647 
functional characteristics of bovine milk protein glycosylation. Glycobiology, 4648 
24(3), 220–236.  4649 
Power, S. E., Jeffery, I. B., Ross, R. P., Stanton, C., O’Toole, P. W., O’Connor, 4650 
E. M., Fitzgerald, G. F. (2014). Food and nutrient intake of Irish community-4651 
dwelling elderly subjects: who is at nutritional risk? J Nutr Health Aging, 18(6), 4652 
561–572.  4653 
235 
 
Robitaille, G. (2013). Growth-promoting effects of caseinomacropeptide from 4654 
cow and goat milk on probiotics. J Dairy Res, 80(1), 58–63.  4655 
Rothschild, D., Weissbrod, O., Barkan, E., Korem, T., Zeevi, D., Costea, P. I., 4656 
Godneva, A., Kalka, I. N., Bar, N., Shilo, S., Lador, D., Vila, A. V., et al. (2018). 4657 
Environmental factors dominate over host genetics in shaping human gut 4658 
microbiota composition. Nature, 555(25973), 210–215.  4659 
Rozenberg, S., Body, J. J., Bruyère, O., Bergmann, P., Brandi, M. L., Cooper, C., 4660 
Devogelaer, J. P., Gielen, E., et al. (2016). Effects of dairy products consumption 4661 
on health: Benefits and beliefs—A commentary from the Belgian Bone Club and 4662 
the European Society for Clinical and Economic Aspects of Osteoporosis, 4663 
Osteoarthritis and Musculoskeletal Diseases. Calcif Tissue Int, 98(1), 1–17.  4664 
Sahni, S., Mangano, K. M., Tucker, K. L., Douglas, P. K., Casey, V. A., Hannan, 4665 
M. T. (2015). Protective association of milk intake on the risk of hip fracture: 4666 
Results from the Framingham Original Cohort. J Bone Miner Res, 29(8), 37–54.  4667 
Sawin, E. a, De Wolfe, T. J., Aktas, B., Stroup, B. M., Murali, S. G., Steele, J. L., 4668 
Ney, D. M. (2015). Glycomacropeptide is a prebiotic that reduces Desulfovibrio 4669 
bacteria, increases cecal short chain fatty acids and is anti-inflammatory in mice. 4670 
Am J Physiol Gastrointest Liver Physiol, 309(7), G590-601.  4671 
Scott, K. P., Antoine, J.-M., Midtvedt, T., van Hemert, S. (2015). Manipulating 4672 
the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis, 4673 
26, 25877.  4674 
236 
 
Smilowitz, J. T., Lebrilla, C. B., Mills, D. A., German, J. B., Freeman, S. L. 4675 
(2014). Breast milk oligosaccharides: Structure-function relationships in the 4676 
neonate. Annu Rev Nutr, 34(1), 143–169.  4677 
Song, M., Garrett, W. S., and Chan, A. T. (2015). Nutrients, foods, and 4678 
colorectal cancer prevention. Gastroenterology, 148(6), 1244–1260.  4679 
Sonnenburg, J. L., and Bäckhed, F. (2016). Diet–microbiota interactions as 4680 
moderators of human metabolism. Nature, 535(7610), 56–64.  4681 
Thevaranjan, N., Puchta, A., Schulz, C., Naidoo, A., Szamosi, J. C., Verschoor, 4682 
C. P., Loukov, D., Schenck, L. P., et al. (2017). Age-associated microbial 4683 
dysbiosis promotes intestinal permeability, systemic inflammation, and 4684 
macrophage dysfunction. Cell Host Microbe, 21(4), 455–466.e4.  4685 
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A, Magrini, V., Mardis, E. R., 4686 
Gordon, J. I. (2006). An obesity-associated gut microbiome with increased 4687 
capacity for energy harvest. Nature, 444(7122), 1027–31.  4688 
van Calcar, S. C., and Ney, D. M. (2012). Food products made with 4689 
glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative 4690 
to amino Acid-based medical foods for nutrition management of 4691 
phenylketonuria. J Acad Nutr Diet, 112(8), 1201–10.  4692 
Van de Heijning, B., Kegler, D., Schipper, L., Voogd, E., Oosting, A., Beek, E. 4693 
(2015). Acute and chronic effects of dietary lactose in adult rats are not explained 4694 
by residual intestinal lactase activity. Nutrients, 7(7), 5542–5555.  4695 
237 
 
Vandeputte, D., Falony, G., Vieira-Silva, S., Wang, J., Sailer, M., Theis, S., 4696 
Verbeke, K., Raes, J. (2017). Prebiotic inulin-type fructans induce specific 4697 
changes in the human gut microbiota. Gut, 66(11), 1968–1974.  4698 
Visioli, F., and Strata, A. (2014). Milk, dairy products, and their functional 4699 
effects in humans: a narrative review of recent evidence. Adv Nutr, 5(2), 131–4700 
143.  4701 
Walker, A. W., Ince, J., Duncan, S. H., Webster, L. M., Holtrop, G., Ze, X., 4702 
Brown, D., Stares, M. D., Scott, P., et al. (2011). Dominant and diet-responsive 4703 
groups of bacteria within the human colonic microbiota. ISME J, 5(2), 220–30.  4704 
Wang, J., Wang, J., Pang, X., Zhao, L., Tian, L., Wang, X. (2016). Sex 4705 
differences in colonization of gut microbiota from a man with short-term 4706 
vegetarian and inulin-supplemented diet in germ-free mice. Sci Rep, 6(1), 36137.  4707 
Woting, A., Pfeiffer, N., Loh, G., Klaus, S., Blaut, M. (2014). Clostridium 4708 
ramosum promotes high-fat diet-induced obesity in gnotobiotic mouse models. 4709 
MBio, 5(5), e01530-14-e01530-14.  4710 
Ze, X., Duncan, S. H., Louis, P., Flint, H. J. (2012). Ruminococcus bromii is a 4711 
keystone species for the degradation of resistant starch in the human colon. ISME 4712 
J, 6(8), 1535–1543.  4713 
Zivkovic, A. M., and Barile, D. (2011). Bovine milk as a source of functional 4714 
oligosaccharides for improving human health. Adv Nutr (Bethesda, Md.), 2(3), 4715 
284–9.  4716 
238 
 
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Wu, 4717 
Y., Mehrabian, M., et al. (2016). Gut microbial metabolite TMAO enhances 4718 
platelet hyperreactivity and thrombosis risk. Cell, 165(1), 111–124.  4719 
Zeng, M. Y., Inohara, N., Nuñez, G. (2016). Mechanisms of inflammation-driven 4720 
bacterial dysbiosis in the gut. Mucosal Immunol, 10(1), 18–26.   4721 
239 
 
3.10 Supplementary Chapter 3 4722 
S Table 1 Mouse treatment groups tested by diet, gender and the human 4723 
microbiota type. The number of mice at the end of the trial per group is indicated. 4724 
The experimental arms of groups A, B, C and D were performed simultaneously 4725 
followed by the experimental arms of groups E, F, G and H. The animals that 4726 
received HydroGel treatment during Abx period, is indicated. 4727 
  Community type human microbiota (COM) Longstay type human microbiota (LS) 
  female male female male 
Lactose free milk A (n=5) A (n=5) B (n=6) B (n=6) 
Whole milk C (n=6) C (n=6) D (n=4) D (n=5) 
GMP E (n=6)# E (n=6)# G (n=6) G (n=6) 
Control H (n=6)### H (n=6) F (n=6)## F (n=5)### 
 “#”,“##”,“###” three, six and nine days, respectively, of HydroGel intake during Abx treatment 
  4728 
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S Table 2 Composition of the baseline murine and the human faecal microbiota. 4729 
EM297; longstay type faecal microbiota (LS); EM425 community type faecal 4730 
microbiota (COM). Only species present at ≥1 % relative abundance in at least one 4731 
group are presented.  4732 
 MURINE EM297 LS EM425 COM 
OTU classification % average relative abundance 
Bifidobacteriaceae/Bifidobacterium/unclassified 0.0 1.1 0.0 
Bacteroidaceae/Bacteroides/Bacteroides acidifaciens 1.5 0.01 0.7 
Bacteroidaceae/Bacteroides/Bacteroides dorei 0.2 9.5 0.0 
Bacteroidaceae/Bacteroides/Bacteroides fragilis 0.0001 15.4 1.4 
Bacteroidaceae/Bacteroides/unclassified 0.1 8.0 0.6 
Porphyromonadaceae/Barnesiella/Barnesiella intestinihominis 7.9 0.7 2.6 
Porphyromonadaceae/Barnesiella/unclassified 1.1 0.02 0.2 
Porphyromonadaceae/Odoribacter/Odoribacter splanchnicus 0.4 1.7 0.3 
Porphyromonadaceae/Parabacteroides/Parabacteroides merdae 0.2 3.0 1.3 
Porphyromonadaceae/unclassified/unclassified 34.6 0.02 0.03 
Prevotellaceae/unclassified/unclassified 4.1 0.0 0.0 
Rikenellaceae/Alistipes/Alistipes massiliensis 3.2 0.0 0.0 
Rikenellaceae/Alistipes/Alistipes putredinis 0.04 0.7 1.3 
Rikenellaceae/Alistipes/unclassified 0.8 2.5 0.8 
Deferribacteraceae/Mucispirillum/Mucispirillum schaedleri 1.1 0.0 0.0 
Methanobacteriaceae/Methanobrevibacter/ 
Methanobrevibacter smithii 
0.0 1.6 0.3 
Lactobacillaceae/Lactobacillus/Lactobacillus reuteri 0.8 0.04 0.0 
Lactobacillaceae/Lactobacillus/unclassified 1.9 0.3 0.0 
Clostridiaceae_1/Clostridium sensu stricto/Clostridium disporicum 0.0 0.0 1.5 
Lachnospiraceae/Clostridium XlVa/unclassified 1.7 2.6 0.04 
Lachnospiraceae/Ruminococcus2/Ruminococcus torques 0.003 2.2 0.1 
Lachnospiraceae/unclassified/unclassified 24.6 0.8 18.3 
Peptostreptococcaceae/Clostridium_XI/Clostridium ruminantium 0.0001 0.0 1.5 
Ruminococcaceae/Clostridium IV/Clostridium leptum 0.02 3.9 0.004 
Ruminococcaceae/unclassified/unclassified 1.9 4.2 3.8 
Clostridiales/unclassified/unclassified/unclassified 5.2 0.8 10.2 




0.6 0.01 4.7 
Pseudomonadaceae/Pseudomonas/Pseudomonas aeruginosa 0.0001 4.2 0.003 
Synergistaceae/Cloacibacillus/Cloacibacillus evryensis 0.0001 21.3 0.0 
Anaeroplasmataceae/Anaeroplasma/unclassified 0.004 0.0 1.7 
unclassified/unclassified/unclassified/unclassified/ 
unclassified/unclassified 
1.1 0.5 2.5 
Verrucomicrobiaceae/Akkermansia/Akkermansia muciniphila 0.8 0.0 0.0 
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S Table 3 Alpha diversity indices of the faecal microbiotas of the human donors 4733 
and the murine baseline faecal microbiota. EM297: longstay type faecal 4734 
microbiota (LS); EM425: community type faecal microbiota (COM); murine: 4735 
aggregated faecal microbiota across all mice at baseline.  4736 




Shannon 6.0 4.0 6.0 
Simpson 1.0 1.0 1.0 
PD Whole tree 15.0 9.0 17.0 
Observed species 207.0 73.0 169.0 
Chao 1 346.0 104.0 264.0 
 4737 
S Figure 1 Principal coordinates analysis (PCoA) of the UniFrac distances one 4738 
week after “humanisation” (T3). A. Weighted UniFrac distances; B. Unweighted 4739 
UniFrac distances; “▲” community (COM) type faecal microbiota; “●” longstay 4740 
(LS) type faecal microbiota; red: baseline murine faecal microbiota; blue: T3 time 4741 









S Figure 2 Principal coordinates analysis (PCoA) of the UniFrac distances at 4744 
end of the trial (T5). A. Weighted UniFrac distances; B. Unweighted UniFrac 4745 
distances; “▲” community (COM) type faecal microbiota; “●” longstay (LS) type 4746 
faecal microbiota; red: baseline murine faecal microbiota; blue: T5 time point. The 4747 
inocula of human faecal microbiota are denoted as COM and LS. 4748 
S Table 4 Alpha diversity statistical analysis for community (COM) type 4749 
microbiota at the end of the trial (T5) LAC_FREE: lactose free diet; WMILK: 4750 
whole milk diet; GMP: GMP diet; CONTROL: control diet.  4751 























FREE VS  
WMILK 
Shannon 3.30E-05 0.0004 0.1 1.17E-05 0.2 0.01 0.03 
Simpson 0.0002 0.0004 0.4 0.001 0.4 0.0003 0.4 
PD  0.0001 0.0002 0.4 0.0003 0.02 0.06 0.02 
Observed 
species 
1.41E-06 1.20E-05 0.3 1.40E-05 0.004 0.06 0.003 
Chao1 0.001 0.002 0.4 0.004 0.02 0.23 0.02 
  4752 
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S Table 5 Alpha diversity statistical analysis for longstay (LS) type microbiota 4753 
at the end of the trial (T5) LAC_FREE: lactose free diet; WMILK: whole milk 4754 
diet; GMP: GMP diet; CONTROL: control diet.  4755 

























Shannon 3.83E-06 0.01 0.007 1.20E-06 0.1 0.2 0.0003 
Simpson 0.0002 0.30 0.001 7.73E-05 0.4 0.3 0.003 
PD  1.85E-05 0.004 0.1 5.01E-06 0.1 0.1 0.004 
Observed 
species 
8.68E-06 0.001 0.3 0.0004 0.0004 0.2 0.0002 
Chao1 0.05 0.09 0.4 0.09 0.05 0.3 0.066 
  4756 
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S Table 6 Differences in the female and male murine microbiota composition 4757 
associated with separation in the PCoA grouping by whole milk and control 4758 
diet. Only families that were present at ≥1 % relative abundance in at least one group 4759 
are presented. WMILK: whole milk diet; CONROL: control diet; community (COM) 4760 
type microbiota. 4761 






OTU assignment  % average relative abundance 
Bacteroidaceae 23.6 6.6 7.3 7.7 
Porphyromonadaceae 30.3 28.0 25.0 17.9 
Rikenellaceae 6.7 9.9 0.8 18.1 
Bacteroidales/unclassified 1.3 1.0 0.8 1.7 
Lachnospiraceae 10.9 12.8 5.4 5.4 
Peptostreptococcaceae 2.7 0.001 0.0 0.0 
Ruminococcaceae 1.7 7.7 9.2 4.6 
Clostridiales/unclassified 0.6 0.4 0.5 1.1 
Erysipelotrichaceae 2.3 23.1 0.6 0.004 
Acidaminococcaceae 5.7 5.5 3.0 0.6 
Desulfovibrionaceae 7.7 3.0 4.5 5.0 
unclassified 5.3 1.5 0.9 0.2 







S Figure 3 Differentially abundant taxa at family level at the end of the trial 4764 
(T5) for aggregated female and male mouse faecal microbiota. A: community 4765 
(COM) type colonisation; B: longstay (LS) type colonisation. Asterisks next to taxa 4766 
denote the result of Kruskal-Wallis comparison; markings above boxplots denote the 4767 
Dunn’s post hoc result. Significant values: “●” padj<0.1; “*” padj<0.05; “**” 4768 
padj<0.01; “***” padj<0.001; “****” padj<0.0001. COM type humanisation:  4769 
 4770 
S Table 7 Differences in the female and male murine microbiota composition 4771 
associated with separation in the PCoA grouping by the lac-free and whole milk 4772 
diet. Only families that were present at ≥1 % relative abundance in at least one group 4773 
are presented. LAC_FREE: lactose free diet; WMILK: whole milk diet; longstay 4774 
(LS) type microbiota. 4775 
 LAC-FREE FEMALE LAC-FREE MALE WMILK FEMALE WMILK MALE 
 % average relative abundance 
Bacteroidaceae 9.5 28.5 19.1 18.7 
Porphyromonadaceae 32.6 19.0 3.6 27.4 
Rikenellaceae 13.5 15.4 5.4 21.6 
Enterococcaceae 1.0 1.4 0.002 2.2 
Lachnospiraceae 18.5 10.8 34.6 22.8 
Peptostreptococcaceae 6.5 4.6 0.001 0.0 
Ruminococcaceae 4.2 5.2 0.1 3.7 
Clostridiales/unclassified 1.2 0.8 0.2 0.4 
Erysipelotrichaceae 0.8 0.6 33.1 0.6 
Acidaminococcaceae 2.2 1.8 1.1 0.002 
Desulfovibrionaceae 8.1 8.0 1.4 1.2 
Enterobacteriaceae 1.1 2.8 0.6 0.7 




S Figure 4 Composition of the murine faecal microbiota at phylum level at the 4778 
mid part of the dietary intervention (T4). COM: community type microbiota, LS: 4779 
longstay type microbiota. LAC_FREE: lactose free milk, WMILK: whole milk, 4780 
GMP: glycomacropeptide, CONTROL: soy protein based control diet. Only phyla 4781 
present at ≥1 % relative abundance are presented.  4782 
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S Table 8 Alpha diversity analysis for community (COM) type microbiota at the 4783 
mid part of the trial (T4) LAC_FREE: lactose free diet; WMILK: whole milk diet; 4784 
GMP: GMP diet; CONTROL: control diet.  4785 

























Shannon 1E-05 0.3 8E-05 7E-06 0.1 0.02 0.01 
Simpson 1E-04 0.3 6E-05 0.0003 0.2 0.4 0.001 
Observed 
species 
0.0002 0.01 0.04 4E-05 0.4 0.01 0.05 
PD whole 
tree 
0.0002 0.003 0.21 0.0003 0.3 0.001 0.3 
Chao1 0.001 0.02 0.05 0.0002 0.3 0.01 0.1 
 Alpha diversity average values 
 
Index 
  CONTROL GMP LAC-FREE WMILK  
Shannon   3 3 4 3  
Simpson   1 1 1 1  
Observed 
species 
  46 28 57 46  
PD whole 
tree 
  5 3 6 6  
Chao1   66 33 71 57  
  4786 
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S Table 9 Alpha diversity analysis for longstay (LS) type microbiota at the mid 4787 
part of the trial (T4) LAC-FREE: lactose free diet; WMILK: whole milk diet; 4788 
GMP: GMP diet; CONTROL: control diet.  4789 









L VS  
GMP 
CONTRO














Shannon 1E-06 0.4 0.0001 0.00004 0.0008 0.0002 0.4 
Simpson 2E-06 0.5 0.0001 0.0001 0.0003 0.0002 0.5 
PD whole 
tree 
1E-06 0.2 0.0007 1E-05 0.002 6E-05 0.4 
Observed 
species 
1E-06 0.4 0.0001 4E-05 0.001 0.0002 0.4 
Chao1 1E-06 0.4 0.0004 9E-05 0.0003 5E-05 0.4 





GMP LAC-FREE WMILK  
Shannon   2 2 4 4  
Simpson   1 1 1 1  
PD whole 
tree 
  2 1 3 3  
Observed 
species 
  14 12 31 31  
Chao1   16 14 39 42  
  4790 
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4 Chapter 4 - Effect of blueberry on the composition and 
metabolism activity of gut microbiota and artificial 
microbiota community from the elderly. 
Chapter 4 4791 
Effect of blueberry on the composition and 4792 
metabolism activity of gut microbiota and 4793 
artificial microbiota community from the 4794 
elderly  4795 
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4.1 Abstract 4796 
We tested the modulatory effect of freeze-dried blueberry powder on the human gut 4797 
microbiota of older subjects using an in vitro batch fermentation system. The 4798 
blueberry powder was rich in polyphenols and fibre. In older people, lower gut 4799 
microbiota diversity is associated with poor health and mortality. Therefore, two 4800 
types of faecal microbiota were used, i.e. low diversity longstay type (LS) 4801 
microbiota from older subjects residing in long-term care units, and higher diversity 4802 
community type (COM) microbiota from community-dwelling subjects. An artificial 4803 
gut microbiota community (MCC100) of 100 strains designed to emulate the 4804 
compositional profile of the gut microbiota of a healthy adult, was also used. The 4805 
fermentation medium was supplemented with either blueberry powder or prebiotic 4806 
mix alone, or a combination of the two supplementation regimes. The microbiota 4807 
was analysed at baseline and at time points 16 h and 24 h of fermentation by 4808 
Illumina MiSeq amplicon sequencing of the 16S rRNA gene. The differential 4809 
microbiota responsiveness to the blueberry supplementation was associated with the 4810 
baseline microbiota composition. Blueberry supplementation resulted in increased 4811 
Lactobacillales/Streptococcus relative abundance most likely due to the high sugar 4812 
content of the supplement. The blueberry supplementation increased the relative 4813 
abundance of Bifidobacteriales/Bifidobacterium when the taxon was abundant at 4814 
baseline. The increase in the relative abundance of the Proteobacteria across all 4815 
microbiotas tested could be the result of simple sugar fermentation. In the lower 4816 
complexity MCC100 artificial microbiota the combined supplementation resulted in 4817 
comparatively increased alpha diversity; a similar result was not observed in the 4818 
tested faecal microbiotas. The combined supplementation resulted in increased short 4819 
chain fatty acid production in MCC100 and the faecal microbiota. The high sugar 4820 
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content of the whole blueberry powder had a stong effect on the observed microbiota 4821 
responses to blueberry supplementation. Follow-up in vitro trials with isolated 4822 
phenolic compounds such as anthocyanins will elucidate the role of the gut 4823 
microbiota in the bioconversion of blueberry polyphenol extracts.   4824 
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4.2 Introduction 4825 
The gut microbiota is a recognised component of human health and it is shaped by 4826 
host genetics, environment, life-style and diet (Sonneburg and Backhed, 2016; 4827 
Messer et al., 2017). Based mostly on cohorts representing western populations and 4828 
life-style, and despite significant inter-individual variations in gut microbiota 4829 
composition, the existing data has enabled a general description of the healthy adult 4830 
gut microbiota (Marchesi et al., 2015). Various events throughout the lifespan such 4831 
as excessive antibiotic use, changes in dietary habits, and infections may ultimately 4832 
cause dysbiosis, that is, perturbations in the composition and reduction in the 4833 
phylogenetic diversity of the gut microbiota that is associated with disease (Petersen 4834 
and Round, 2014).  4835 
Immuno-senescence, hospitalization and changes in dietary habits may collectively 4836 
contribute to age-related microbiota alterations observed in the gut microbiota of 4837 
older individuals and to the increase of the inflammatory status in the elderly, a 4838 
known risk factor for mortality in humans and animal models (Jeffery et al., 2015; 4839 
Theveranjan et al., 2017). In conditions where dysbiosis is a disease feature, 4840 
manipulation of the gut microbiota can be a tool for prevention, improvement or 4841 
even therapy (Salazar et al., 2014). Probiotics, faecal microbiota transplants (FMT), 4842 
live bacteriotherapy, prebiotics and supplementation such as with polyphenols are 4843 
potential mechanisms for gut microbiota modulation (Petrof et al., 2013; Marchesi et 4844 
al., 2015).  4845 
Flavonoids are polyphenolic compounds that naturally occur in fruits, vegetables and 4846 
other plant-derived dietary components and can be sub-divided in to seven sub-4847 
classes including flavones, and anthocyanins (reviewed in Panche et al., 2016). 4848 
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Anthocyanins are present in plants as glycosylated anthocyanidins conjugated with 4849 
sugars including glucose, galactose, arabinose, rhamnose and xylose (reviewed in 4850 
Pojer et al., 2013). Dietary intake of these compounds has been associated with 4851 
health benefits based on in vitro and in vivo experimental models and human studies 4852 
(reviewed in Li et al., 2017). Ivey et al. (2017) reported that flavonoid-rich diet was 4853 
associated with improved health and reduced mortality in a follow-up cohort study of 4854 
young and middle-aged adults.  4855 
The reported flavonoid consumption in adult populations varies due to differences in 4856 
the analytical methods used to assess the flavonoid content in food products, and 4857 
because of widely varying dietary habits (reviewed in Chun et al., 2007; Chun et al., 4858 
2012; Pojer et al., 2013). Adults in the US, Europe and the UK have a daily 4859 
consumption of flavonoids that ranges from 177 mg/d up to 428 mg/d and 4860 
consumption of anthocyanidins that ranges from 4.2 mg/d up to 19 mg/d (Chun et al. 4861 
2007; Beking and Vieira 2011;Vogiatzoglou et al. 2015).  4862 
Unabsorbed phenolic compounds reach the colon where they may serve as substrates 4863 
for faecal microbiota fermentation (reviewed in Selma et al. 2009). Several in vitro 4864 
studies (Sánchez-Patán et al., 2012; Hidalgo et al., 2012; Cueva et al., 2013; Sánchez-Patán 4865 
et al., 2015; Zhang et al., 2016) and in vivo studies (Del Bo et al., 2010; Lacombe et 4866 
al., 2013; Fotschki et al., 2016; Collins et al., 2016) indicate towards the potential of 4867 
polyphenols to modulate the gut microbiota. There is also scientific interest in the 4868 
combined effect of dietary polyphenols and fibre on the gut microbiota and health 4869 
(Edwards et al., 2017). 4870 
In this study, we applied 16S rRNA gene amplicon sequencing in order to describe 4871 
the compositional changes that occurred in the faecal microbiota of older (>65 yrs) 4872 
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individuals after 24 h of pH and temperature controlled in vitro fermentations 4873 
supplemented with whole blueberry powder. Faecal samples collected from frail and 4874 
healthy older people were used to differentiate the responsiveness of low and higher 4875 
phylogenetic diversity faecal microbiota respectively to the selected substrates. To 4876 
move beyond whole community analysis, identifying the functional properties of 4877 
isolated gut bacteria will further enable preclinical studies towards targeted 4878 
restoration of dysbiosis based on artificial bacterial consortia (Clavel et al., 2017). 4879 
We therefore also tested an artificial bacterial consortium consisting of isolated 4880 
faecal bacteria from healthy donors and representing the faecal microbiota of a 4881 
healthy adult in the 24 h in vitro batch fermentation system for its fermentative 4882 
potential on the blueberry powder. 4883 
4.3 Materials and Methods 4884 
Faecal Samples: Faecal samples were collected from two community-dwelling 4885 
(COM) healthy older people (EM425 male 81 yrs, EM278 female 69 yrs) and two 4886 
frail long-term care unit-residing (LS) older people (EM297 female 82 yrs, EM704 4887 
male 89 yrs). The local Clinical Research Ethics Committee approved all practices. 4888 
The faecal samples were transferred to an anaerobic cabinet within an hour after 4889 
passing. Several 10% w/v slurries were prepared from each homogenised faecal 4890 
sample using sterile reduced phosphate buffer saline (PBS) with 20% v/v glycerol. 4891 
All faecal slurries were aliquoted and stored frozen at -80°C.  4892 
Artificial gut microbiota MCC100: This artificial bacterial consortium consisted of 4893 
100 strains of strict anaerobic and facultative anaerobic bacteria isolated from faeces 4894 
of healthy individuals and it was assembled based on the composition of the gut 4895 
microbiota profile of healthy western adult (Perez et al., in preparation). The 4896 
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bacterial consortium was premixed from individual purified cultures, concentrated 4897 
and stored in -80°C.  4898 
Single stage chemostat: Batch fermentations were used in order to simulate colonic 4899 
bacterial fermentation of the selected substrates (Hidalgo et al., 2012). The 4900 
fermentation conditions were as described before with some variations (Ntemiri et 4901 
al., 2017). The temperature and pH were kept stable at 37°C and 7.0 respectively. 4902 
The duration of the fermentation was 24 h. The fermentation vessel was purged 4903 
continuously with NO2 and the working volume used was 400 ml. The basal medium 4904 
was supplemented with 3 g/l of casein and antifoam A emulsion (1 ml/l) (Sigma 4905 
Aldrich). The vessels were inoculated in triplicate at 1% w/v faecal sample; faecal 4906 
samples were treated individually. Ten ml of thoroughly stirred fermentation liquid 4907 
was retrieved from the fermenter vessel for analysis at time points 0 h and 16 h. This 4908 
volume (10 ml) was selected in order not to reduce significantly the total volume of 4909 
the fermentation. At time point 24 h, 50 ml faecal slurry was retrieved. The 4910 
fermentation samples were immediately centrifuged and both supernatant and pellet 4911 
were kept at -20°C for future analysis.  4912 
Fermentation Substrates: The basal medium was supplemented in three different 4913 
ways: A: 1% w/v a mix of complex carbohydrates (MIX) consisting of xylan from 4914 
corncob (0.6 g/l), pectin from apple (0.6 g/l), amylopectin (0.6 g/l), arabinogalactan 4915 
(0.6 g/l), soluble starch (4.0 g/l), β-glucan (0.1 g/l), mucin type II (1.0 gr/l), glucose 4916 
(2.0 g/l); B: 1% w/v MIX supplemented with 1.5 % w/v blueberry powder 4917 
(BB.MIX); C:. 1.5 % blueberry powder (BB) alone. The blueberry powder was 4918 
freeze-dried whole fruit powder, 50:50 tifblue:rubel blend; courtesy of the U.S. 4919 
Highbush Blueberry Council, California) containing 21.4 g/100g of dietary fibre 4920 
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(16.8 g insoluble fibre, 4.6 g soluble fibre). The BB dose was calculated to approach 4921 
that of a high total flavonoid and anthocyanins daily dietary intake; approximately 4922 
200 mg per day and 70 mg per day respectively (Beking and Vieira, 2011) in an 4923 
approximately 400 ml of simulated wet colon content (Sender et al., 2016). The BB 4924 
powder contained 33 mg/g phenolics and 10.2 mg/g anthocyanins.  4925 
Bacterial DNA Extraction: Faecal pellets were weighted and resuspended in sterile 4926 
PBS in order to provide approximately 200 mg of pellet required for the QIamp Fast 4927 
DNA Stool (Qiagen) extraction kit protocol. The samples were homogenised 4928 
mechanically in sterile tubes containing InhibitEX solution and zirconia glass beads 4929 
of three sizes 0.1, 0.5 and 1.0 mm (Thistle Scientific, UK) using a Minibeadbeader 4930 
(Biospec Products). Subsequent steps of gDNA extraction were performed as 4931 
described before (Ntemiri et al., 2017).  4932 
Preparation of Illumina Library for 16S rRNA Amplicon Sequencing: The 4933 
variable region V3/V4 of the 16S rRNA gene was targeted for amplicon sequencing 4934 
using the Illumina MiSeq System (San Diego, California, USA). The universal 16S 4935 
rRNA gene primers were forward primer for V3 region 5’ TCGTCGGC 4936 
AGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 3’ and 4937 
reverse primer for V4 region 5’ GTCTCGTGGGCTCGGAGATGTGTATAAG 4938 
AGACAGGACTACHVGGGTATCTAATCC 3’ (Klindworth et al. 2012). The 4939 
amplicons were purified using the Agencourt AMPure XP-PCR Purification system 4940 
(Beckman Coulter, Inc.). Dual index barcoding was performed to the purified 4941 
products following the Illumina MiSeq System Protocol (Nextera XT V.2 Index Kits 4942 
sets A and D, Illumina). The barcoded amplicons were purified (Agencourt AMPure 4943 
XP-PCR Purification system; Beckman Coulter, Inc.) and quantified using the Qubit 4944 
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dsDNA HS Assay Kit (Thermo Fischer Scientific, MA, U.S.A.). Each sample was 4945 
pooled at the same concentration and sequenced in the Teagasc Next Generation 4946 
Sequencing Facility (Fermoy, Ireland) on a MiSeq Illumina platform using 2x250 bp 4947 
chemistry. 4948 
Analysis of 16S rRNA Amplicon Sequencing: Paired reads were joined using 4949 
FLASH (Magoč et al., 2011) and demultiplexed in Qiime using the split_libraries.py 4950 
script. The forward and reverse primers are removed and operational taxonomic unit 4951 
(OTU) table was generated de novo with Usearch. Filtering of the reads based on the 4952 
read length and the number of identical sequences was performed. Subsequently, 4953 
chimera filtering was performed and mapping of all the reads against the 4954 
representative reads generated by the filtering, based on 97% identity. The reads per 4955 
sample were rarefied and the sequences were aligned using the Qiime PyNast tool 4956 
(Caporaso et al., 2010). Alpha diversity indices i.e., Shannon, Simpson, PD whole 4957 
tree, Chao1 and observed species, and beta diversity indices i.e. Weighted UniFrac, 4958 
Unweighted UniFrac and Bray-Curtis, were generated in Qiime. The OTU table was 4959 
taxonomically classified (classify.seqs) to genus level by using Mothur and the RDP 4960 
v11.4/trainset 14 database (Wang et al., 2007). In order to further classify the OTUs 4961 
to species level Spingo database was used (Allard et al., 2015).  4962 
Statistical Analysis of microbiota composition: The R package (R Core Team) 4963 
was used for the generating taxa relative abundance from the rarified reads, for the 4964 
further analysis and visualisation of the UniFrac distances, for the visualisation of 4965 
the alpha diversity and for statistical analysis. A Kruskal-Wallis with Dunn’s post 4966 
hoc test and p adjusted value with the Benjamini-Hochberg method was applied in R 4967 
in order to detect significant differences in the microbiota composition due to 4968 
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substrate fermentation after 16 h and 24 h at Order, Family, Genus and Species level 4969 
and for the alpha diversity indices. The Kruskal-Wallis test was applied in order to 4970 
detect significant differences due to the effect of the substrate per donor, across all 4971 
donors and MCC100 per time point and per substrate. Values were considered 4972 
significant when Kruskal-Wallis p value was ≤ 0.05, padj value ≤ 0.05 and Dunn’s 4973 
post hoc test padj value (for readability denoted as qadj) were ≤ 0.05. Significant 4974 
trends in data were considered when Kruskal-Wallis p value was ≤ 0.5, padj value ≤ 4975 
0.1 and Dunn’s post hoc test value padj (for readability denoted as qadj) was ≤ 0.1. 4976 
Short Chain Fatty Acid Analysis: High performance liquid chromatography 4977 
(HPLC) was used in order to detect acetate, propionate and butyrate production, as 4978 
described before (Chapter 2; Ntemiri et al., 2017). Slurry retrieved from the 4979 
fermenter vessels was centrifuged for 30 min and the supernatant was filtered 4980 
through 0.2 μm filter. For the SCFA analysis 1 ml was loaded in an Agilent 1200 4981 
HPLC system with a refractive index detector. An Agilent Hi-Plex H 300x7.7mm 4982 
column was used with 0.01N H2SO4 elution fluid, at a flow rate of 0.6 mL/min and 4983 
column temperature at 65°C. For the visualization and analysis of SCFA levels, 4984 
Graph Pad Prism 5 Software was used. A Kruskal-Wallis non-parametric test and 4985 
Dunn’s post hoc test were applied in order to detect significant differences in SCFA 4986 
production per donor per substrate at 24 h. The same test was applied in order to 4987 
detect significant differences in combined SCFA production in the faecal microbiota 4988 
of all donors aggregated at 24 h.  4989 
4.4 Results 4990 
Blueberry responses of Bifidobacteriaceae, Bacteroidaceae and Lactobacillales 4991 
depend on baseline abundance 4992 
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We have previously described the compositional and phylogenetic differences in the 4993 
faecal microbiota of healthy or frail older subjects (COM type microbiota EM425 4994 
and EM278, and LS type microbiota EM297 and EM704, respectively) (Jeffery et 4995 
al., 2015; Ntemiri et al., 2017; Chapters 2 and 3 this thesis). Significant differences 4996 
between the two types of microbiota include the enrichment in Lachnospiraceae and 4997 
Ruminococcaceae in the COM type faecal microbiota composition and the 4998 
enrichment in Proteobacteria observed in LS type microbiota. The LS type 4999 
microbiota is also characterised by lower phylogenetic diversity compared to the 5000 
community type (S Table 10). Principal coordinates analysis (PCoA) of the 5001 
microbiotas at 0 h showed the differential clustering between COM and LS type (S 5002 
Figure 8).  5003 
Supplementation with the prebiotic MIX sustained the highest microbiota diversity 5004 
across all faecal microbiotas (S Figure 9 and 10). Principal coordinates analysis 5005 
(PCoA) of the microbiotas at the end of the fermentation (24 h) showed that the 5006 
microbiotas clustered predominantly by donor and microbiota type and to a lesser 5007 
extent by supplementation (S Figure 11 A and B).  5008 
At baseline, the COM type microbiota of donor EM278 was naturally abundant in 5009 
Bifidobacteriales/Bifidobacteriaceae and Bacteroidales/Bacteroidaceae; 5010 
approximately 25% combined relative abundance (Figures 21 and 22). Blueberry 5011 
supplementation (BB) resulted in increased Bifidobacteriaceae relative abundance in 5012 
the composition of the EM278 COM faecal microbiota whereas prebiotic MIX 5013 
supplementation increased the Bacteroidaceae abundance after 24 h fermentation. 5014 
Supplementation with combined blueberry and prebiotic mix (BB.MIX) resulted in 5015 
the concomitant increase of both Bifidobacteriaceae and Bacteroidaceae relative 5016 
262 
 
abundance; the combined relative abundance increased to approximately 67% 5017 
(Figure 22 and Table 9). The Bifidobacteriaceae were represented by 5018 
Bifidobacterium bifidum, Bifidobacterium longum and other unclassified 5019 
Bifidobacterium taxa whereas the major Bacteroidaceae representative taxa after 24 5020 
h MIX or BB.MIX supplementation were Bacteroides uniformis and Bacteroides 5021 
caccae (Species level information for COM type microbiota in S Table 13). Another 5022 
faecal microbiota enriched in Bifidobacteriacea and Bacteroidaceae was the LS 5023 
faecal microbiota from donor EM297 (approximately 20% combined abundance). 5024 
Bifidobacteriaceae in the EM297 LS type microbiota were not responsive to 5025 
blueberry supplementation and the baseline abundance (approximately 2%) 5026 
decreased across all supplementation regimes (Figure 22). Bacteroidaceae in the LS 5027 
microbiota EM297 were predominantly responsive to BB.MIX supplementation 5028 
whereas across the COM type microbiota EM425 and LS type microbiota EM704 5029 
the Bacteroidaceae were predominantly responsive to the prebiotic MIX 5030 
supplementation (Figure 22).  5031 
Lactobacillales were highly responsive to blueberry supplementation (BB or 5032 
BB.MIX) predominantly in the EM425 COM type faecal microbiota and in the 5033 
EM704 LS type microbiota whereas inclusion of the prebiotic MIX in the blueberry 5034 
supplemented medium (BB.MIX) promoted the growth of a wider array of taxa 5035 
resulting in a lower scale relative abundance of Lactobacillales after 24 h 5036 
fermentation (Figure 21). In the EM425 COM microbiota, BB supplementation 5037 
increased the Lactobacillales relative abundance from approximately 0.5% (0 h) to 5038 
33% (padj & qadj <0.1) at 24 h (comparison data at Order level for COM and LS 5039 
microbiota in S Table 11 and 12, respectively). In the EM704 LS microbiota the 5040 
Lactobacillales relative abundance increased after BB supplementation from 0.1 % at 5041 
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0 h to 72 % at 24 h (padj & qadj <0.1) (Figure 21). In both EM425 and EM704 the 5042 
taxon Streptococcus (unclassified) was the dominant representative of the 5043 
Lactobacillales (S Tables 13 and 14).  5044 
In the EM297 LS microbiota the Lactobacillales was represented by the taxon 5045 
Enterococcus (unclassified) (S Table 14). The taxon relative abundance was 5046 
significantly (trend) increased by both BB supplementation (0 h: 2.5%, 24 h: 9% padj 5047 
& qadj<0.1) and BB.MIX supplementation (0 h: 1.5%, 24 h: 9.6%, padj & qadj ≤0.1). 5048 
The responsiveness of enterococci to blueberry supplementation was of a lower scale 5049 
compared to the streptococci responsiveness, and prebiotic MIX supplementation 5050 
promoted a higher increase in the relative abundance of enterococci in the EM297 5051 
faecal microbiota (Figures 22).  5052 
Blueberry supplementation increased the abundance of Enterobacteriaceae 5053 
across all donors faecal microbiota 5054 
Blueberry supplementation (BB) increased the relative abundance of the 5055 
Proteobacteria/Enterobacteriaceae represented by Escherichia/Shigella taxa across 5056 
all donors faecal microbiotas whereas supplementation of fermentation medium with 5057 
prebiotic MIX (MIX or BB.MIX) balanced the overrepresentation of the 5058 
Enterobacteriaceae family observed with BB supplementation (Figure 22). The 5059 
increase in the enterobacteria was partly independent the baseline Proteobacteria 5060 
abundance. For example, in the COM type EM425 microbiota the low in abundance 5061 
Enterobacteriaceae increased from <0.05% to 40% at 24 h (Table 9) whereas in the 5062 
EM297 LS type faecal microbiota that was significantly enriched in Proteobacteria, 5063 
BB supplementation resulted in the highest Enterobacteriaceae relative abundance 5064 
increase from approximately 9% to 69% at 24 h (padj & qadj <0.1) (Table 10). A 5065 
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comparatively lower scale increase in the enterobacteria relative abundance was 5066 
observed in the EM704 LS type microbiota; combined BB and MIX supplementation 5067 
resulted in the highest abundance increase of the enterobacteria (Table 10).  5068 
The prebiotic MIX retained relatively higher Lachnospiraceae and 5069 
Ruminococcaceae combined abundance whereas Faecalibacterium prausnitzii 5070 
showed some responsiveness to BB supplementation 5071 
The high Lachnospiraceae and Ruminococcaceae relative abundance observed in the 5072 
COM type microbiotas (approximately 66% combined abundance in both EM278 5073 
and EM425) was not retained across any of the three supplementation regimes 5074 
(Figure 22). Supplementation with prebiotic MIX alone retained the highest portion 5075 
of the Lachnospiraceae abundance in COM type microbiotas EM278 and EM425 5076 
and LS type EM704, whereas supplementation with BB and MIX combined retained 5077 
the highest Lachnospiraceae abundance in the LS type microbiota EM297 (Tables 9 5078 
and 10). The taxon Anaerostipes hadrus was highly responsive to co-5079 
supplementation in both COM microbiotas (S Table 13). 5080 
Similarly, Ruminococcaceae abundance was partially retained with MIX and 5081 
BB.MIX supplementation in COM type EM425 and LS type EM704 microbiotas 5082 
(Tables 9 and 10), whereas the Ruminococcaceae in the COM microbiota EM278 5083 
were highly responsive to BB supplementation; the same responsiveness was not 5084 
observed after MIX or BB.MIX supplementation (Figure 22, TABLE 9).  5085 
Faecalibacterium prausnitzii was the predominant taxon of the Ruminococcaceae 5086 
family (approximately 13% relative abundance) in the EM278 microbiota after BB 5087 
supplementation (S Table 13). In EM425 microbiota, the taxon F. prausnitzii was 5088 
the predominant member of the Ruminococcaceae family after BB or MIX 5089 
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supplementation (2.5% and 5% relative abundance respectively), whereas the taxon 5090 
Gemmiger formicilis of the Ruminococcaceae was dominant after BB.MIX or MIX 5091 
supplementation (approximately 7% and 2% relative abundance respectively) (S 5092 
Table 13). In EM704 LS faecal microbiota, of unclassified taxa were the dominant 5093 
representatives of the Ruminococcaceae family (S Table 14).  5094 
Blueberry supplemented prebiotic medium promoted the abundance of 5095 
Peptostreptococcaceae and Clostridiaceae 1 when abundant at baseline and 5096 
irrespective of microbiota type. 5097 
In the EM425 COM type faecal microbiota where the Peptostreptococcaceae family 5098 
was present with approximately 3% relative abundance at baseline, BB and BB.MIX 5099 
but not MIX supplementation alone resulted in increased relative abundance during 5100 
the first 16 h of BB (4.5% relative abundance) and BB.MIX (3% relative 5101 
abundance); however, the abundance of the taxon was not retained until the 5102 
fermentation end (Figure 22, Table 9). In the LS type faecal microbiota EM704 5103 
where the Peptostreptococcaceae was present with approximately 11% relative 5104 
abundance at baseline, BB or MIX supplementation alone could not retain 5105 
Peptostreptococcaceae relative abundance whereas BB.MIX supplementation 5106 
resulted in increased relative abundance at 24 h (Figure 22, Table 10). Clostridium 5107 
glycolicum and other unclassified taxa were the dominant Clostridium cluster XI 5108 
representatives of the Peptostreptococcaceae at 24 h (S Table 14). Abundant 5109 
baseline Clostridiaceae 1 (represented by Clostridium sensu stricto taxa) increased in 5110 
abundance with BB.MIX and MIX supplementation in both the COM type 5111 
microbiota EM425 and the LS type EM704 microbiota whereas when non-abundant 5112 
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at baseline as in LS type EM297 microbiota, the abundance increased after MIX 5113 
supplementation (Figure 22, Tables 9 and 10).  5114 
 5115 
Figure 21 Order level development of the faecal microbiota from COM donors 5116 
(EM278, EM425) and LS donors (EM704, EM297). Orders present with relative 5117 
abundance ≥1% are shown. Substrate conditions are basal medium supplemented 5118 
with: BB: blueberry powder; BB.MIX: blueberry powder and prebiotic mix of 5119 
carbohydrates; MIX: mix of prebiotic carbohydrates. Time points: 0 h, 16 h and 24 h 5120 




Figure 22 Family level development of the faecal microbiota from COM donors 5123 
(EM278, EM425) and LS donors (EM704, EM297). Families present at ≥1% are 5124 
shown. Substrate conditions are basal medium supplemented with: BB: blueberry 5125 
powder; BB.MIX: blueberry and prebiotic mix of carbohydrates; MIX: mix of 5126 
prebiotic carbohydrates. Time points: 16 h and 24 h of fermentation.  5127 
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Table 9 Development of the composition and comparison between time points of 5128 
the relative abundance and comparison between time points of the relative 5129 
abundance of dominant families after 24 h fermentation with COM faecal 5130 
microbiota (EM278, EM425). BB: blueberry powder supplementation; BB.MIX: 5131 
blueberry powder and prebiotic carbohydrate mix supplementation; MIX: prebiotic 5132 
carbohydrate mix supplementation. Missing values indicate that the relevant taxon 5133 
had <1% abundance in all vessels (two or three) summed for mean abundance. The 5134 
mean value of the relative abundance per time point is shown. 5135 
 EM278 EM425 
 BB BB.MIX MIX BB BB.MIX MIX 
 
t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 
Bifidobacteriaceae 3.5 21.6 3.0 21.9 4.9 13.9a - - - - - - 
Bacteroidaceae 20.0 4.5 16.9 44.8 19.1 29.9a 5.8 3.7 4.6 10.6 6.8 26.1 
Porphyromonadaceae - - - - - - 2.7 0.3 - - 2.7 1.7 
Rikenellaceae 1.7 1.5 1.3 0.4 1.8 1.5 1.6 0.1 - - 1.6 0.6a 
Streptococcaceae 1.1 0.9 1.0 2.6 1.3 3.1 0.5 32.1a 0.4 39.1 0.4 8.5 
Clostridiaceae_1 0.1 0.2 - - 0.1 0.1 3.1 5.3 3.9 6.2 2.7 12.6a 
Lachnospiraceae 43.7 26.7 49.5 25.0 43.4 43.8 44.4 9.3a 42.8 13.0 46.4 29.0a 
Peptostreptococcaceae - - 0.3 0.6 - - 3.2 2.5 3.5 0.4 2.9 0.2 
Ruminococcaceae 20.1 15.7 19.2 0.8 21.0 2.9 21.2 3.2a 22.8 7.6 19.4 8.5a 
Clostridiales unclas. 2.7 0.1 2.5 0.1 2.5 0.2a 3.8 0.2a 4.0 0.1 3.6 0.2 
Erysipelotrichaceae 0.3 3.5 0.4 1.4 0.5 1.7a - - - - - - 
Acidaminococcaceae 0.4 2 - - 0.2 0.6a 2.6 0.7a 2.0 0.4 1.8 0.3a 
Firmicutes/unclassified 0.8 1 - - - - 2.6 0.2a 2.7 0.02 2.7 0.6a 
Enterobacteriaceae 0.01 20 - - 0.01 0.5 0.04 41.3 0.03 22.0 0.03 11.1a 
* Statistically significant result, Kruskal-Wallis test result p≤0.05, padj≤0.05 with Dunn’s test qadj j≤0.05 
a Statistical trend, Kruskal-Wallis test result p≤0.05, padj≤0.1, with Dunn’s test qadj ≤0.1. 
  5136 
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Table 10 Development of the composition and comparison between time points 5137 
of the relative abundance of dominant families after 24 h fermentation with LS 5138 
faecal microbiota (EM704, EM297). BB: blueberry powder supplementation; 5139 
BB.MIX: blueberry powder and prebiotic carbohydrate mix supplementation; MIX: 5140 
prebiotic carbohydrate mix supplementation. Missing values indicate that the 5141 
relevant taxon had <1% abundance in all vessels (two or three) summed for mean 5142 
abundance. The mean value of the relative abundance per time point is shown. 5143 
 EM704 EM297 
OTUU BB BB.MIX MIX BB BB.MIX MIX 
Classification t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 
Bifidobacteriaceae - - - - - - 2.3 0.02 - - - - 
Bacteroidaceae 6.0 3.5 6.4 12.9 5.4 29.9 12.9 1.8 13.9 18.5 15.1 14.6 
Porphyromonadaceae 3.2 0.1 - - 3.5 0.3 1.4 0.04 1.5 0.1a 2.7 0.02 
Rikenellaceae - - - - 1.0 0.04 1.2 0.02 1.3 0.02 1.5 0.01 
Enterococcaceae - - - - - - 1.1 8.6a 0.5 9.6a 1.6 28.1 
Streptococcaceae 0.1 72.0a 0.1 35.0 0.1 4.5a - - - - - - 
Clostridiaceae_1 10.1 11.8 11.1 21.7 9.2 37.3 - - 0.01 0.9a 0.01 17.9 
Lachnospiraceae 3.3 3.7 3.2 3.1 3.2 9.3 15.3 7.7 11.9 18.7 17.0 13.6 
Peptostreptococcaceae 11.7 4.0 13.4 15.1 10.3 4.3a - - - - - - 
Ruminococcaceae 3.6 1.6a 3.2 4.0 3.7 5.2aa 11.2 0.1 8.7 0.1 13.7 0.1 
Clostridiales unclas. 1.8 0.1 2.1 0.1 1.9 0.6a 2.0 0.5a 1.5 0.5a 2.3 1.4 
Acidaminococcaceae 2.3 0.3a - - 2.6 1.9a 0.3 1.1 0.2 1.3 - - 
Enterobacteriaceae 0.1 1.2 0.04 6.6 0.1 4.9 8.8 68.5a 6.6 44.3a 10.2 21.9 
* Statistically significant result, Kruskal-Wallis test result p≤0.05, padj≤0.05 with Dunn’s test qadj≤0.05 
a Statistical trend, Kruskal-Wallis test result p≤0.05, padj≤0.1, with Dunn’s test qadj≤0.1 
  5144 
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Blueberry supplemented prebiotic medium sustained high microbiota diversity 5145 
and Bacteroides taxa abundance in the artificial consortium MCC100 compared 5146 
to the other supplementation regimes 5147 
The artificial consortium MCC100 composition was designed in order to mimic the 5148 
faecal microbiota composition of a healthy adult. The analysis of the relatedness by 5149 
Weighted Principal Coordinates Analysis (PCoA) of the microbiota composition in 5150 
the bacterial consortium and faecal microbiotas showed that at 0 h the MCC100 5151 
grouped with the community type faecal microbiotas separating from the LS type 5152 
microbiotas (PCoA information in S Figure 8 A and B), as expected from its design. 5153 
The distance between PCoA positions of some MCC100 microbiota (S Figure 8 A) 5154 
was associated with the presence of OTUs assigned to chloroplasts deriving from the 5155 
blueberry supplementation. Therefore, it was not considered a true compositional 5156 
difference between the MCC100 preparations inoculated at 0 h. 5157 
Supplementation of fermentation medium with BB.MIX sustained similar or higher 5158 
levels of alpha diversity to the prebiotic MIX supplementation in the MCC100 5159 
microbiota (Table 11). The Shannon and Simpson indices were similar after 5160 
BB.MIX or MIX supplementation, whereas species richness indices (Chao1, 5161 
Observed species and PD whole tree) were higher after BB.MIX supplementation. 5162 
BB supplementation alone sustained the lowest diversity among the supplementation 5163 
regimes.  5164 
Supplementation of the MCC100 fermentation with BB.MIX was more effective in 5165 
sustaining the abundance of Bacteroidetes compared to prebiotic MIX 5166 
supplementation alone (Figure 23 A). Bacteroidetes relative abundance increased 5167 
from approximately 12% to 52% over the 24 h of BB.MIX fermentation (padj=0.05, 5168 
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qadj=0.02) whereas MIX supplementation resulted in a decrease in the relative 5169 
abundance of Bacteroidetes during the first 16 h; the relative abundance of the 5170 
phylum subsequently increased to an average of 45% (24 h, padj=0.04, qadj=0.1). The 5171 
Bacteroidaceae family were the main Bacteroidetes representatives (Figure 23 B). 5172 
The average relative abundance of the Bacteroidaceae increased from approximately 5173 
6% (16 h) to 46% (24 h) and from 6% (0 h) to 52% (24 h) after MIX and BB.MIX 5174 
supplementation respectively (Figure 23 B). Supplementation with BB had a 5175 
relatively lower scale impact on the Bacteroidaceae (Figure 23 B). Bacteroides 5176 
fragilis and Bacteroides thetaiotaomicron were the two most responsive taxa of the 5177 
Bacteroidaceae family across supplementation regimes (Table 12). After 24 h 5178 
BB.MIX supplementation B. fragilis relative abundance increased from 0.5% to 5179 
24%, (padj=0.04, qadj=0.01) whereas after MIX supplementation the abundance was 5180 
approximately 38%, (padj=0.05 qadj=0.01). The highest relative abundance increase 5181 
for B. thetaiotaomicron was observed after BB.MIX supplementation from 5182 
approximately 1% to 26% (padj=0.04, qadj=0.01). The taxon Bacteroides caccae was 5183 
responsive to BB.MIX supplementation and its average relative abundance had a 5184 
significant increasing trend from 0.4% to 1% after 24 h fermentation, (padj=0.04, 5185 
qadj=0.1).  5186 
Firmicutes tended to decrease across the three supplementation regimes whereas 5187 
MIX supplementation sustained a relatively higher portion of the Firmicutes 5188 
abundance (Figure 23 A). The differences in the relative abundance of Firmicutes 5189 
taxa observed at baseline (Table 12) between the three supplementation conditions 5190 
can be attributed to some variation introduced during the preparation of the 5191 
consortium; gDNA extraction and sequencing bias may have amplified this variation 5192 
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resulting in increased relative representation of the phylum at baseline of the MIX 5193 
supplementation regime.  5194 
Lachnospiraceae relative abundance showed a decreasing trend across all 5195 
supplementation regimes during the first 16 h of fermentations; the abundance of the 5196 
Lachnospiraceae tended to increase thereafter (Figure 23 B). Twenty-four h 5197 
BB.MIX supplementation retained a comparatively high Lachnospiraceae relative 5198 
abundance (14%) compared to MIX (11%) and BB supplementation (6%). The 5199 
relative abundance of Lachnospiraceae taxon Clostridium symbosium reached its 5200 
highest abundance after BB supplementation followed by BB.MIX supplementation 5201 
whereas Coprococcus comes retained the highest abundance after BB.MIX 5202 
supplementation (approximately 8 %) (Table 12). Other dominant Firmicutes taxa 5203 
responsive to blueberry supplementation belonged to the Clostridium cluster XI of 5204 
the Peptostreptococcaceae family (Table 12). The Lactobacillales were more 5205 
responsive to the MIX supplementation. The taxon Enterococcus was the main 5206 
representative of the Lactobacillales and increased in relative abundance from <0.1% 5207 
(0 h) to approximately 21% (padj=0.05, qadj=0.01) during the first 16 h of MIX 5208 
supplementation; a similar but to a lesser scale response was observed with BB and 5209 
BB.MIX supplementation (Table 12).  5210 
The Proteobacteria relative abundance increased over the first 16 h across all 5211 
supplementation regimes and tended to decrease thereafter; the highest relative 5212 
abundance was observed after BB supplementation (60% average relative abundance 5213 
at 24 h; padj=0.09, qadj=0.08) (Figure 23 A). Supplementation with prebiotic MIX or 5214 
BB.MIX had a similar effect on the abundance of the main Proteobacteria taxa that 5215 
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belonged to the Escherichia/Shigella group, i.e., approximately 20% relative 5216 
abundance after 24 h fermentation (Table 12).  5217 
Table 11 MCC100 alpha diversity indices after 24 h fermentation with the 5218 
selected substrates. BB: blueberry powder supplementation; BB.MIX: blueberry 5219 
powder and prebiotic carbohydrate mix supplementation; MIX: prebiotic 5220 
carbohydrate mix supplementation. 5221 
 Mean alpha diversity value at 24 h with indicated substrate 
Alpha Diversity Indices BB BB.MIX MIX 
Shannon 2.0 2.9 2.7 
Simpson 0.6 0.8 0.8 
PD whole tree 3.3 4.4 3.7 
Chao1 34.8 68.2 45.4 
Observed species 32.0 43.0 35.0 
  5222 
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Table 12 Development of the relative abundance at species level in the MCC100 5223 
after 24 h fermentation and comparison by time point. BB: blueberry powder 5224 
supplementation; BB.MIX: blueberry powder and prebiotic carbohydrate mix 5225 
supplementation; MIX: prebiotic carbohydrate mix supplementation. Missing values 5226 
indicate that the relevant taxon had <1% abundance in all vessels (two or three) 5227 









OTU Classification t0 t16 t24 t0 t16 t24 t0 t16 t24 
Bacteroides/Bacteroides 
caccae - - - 0.4 0.1 1.0* - - - 
Bacteroides/Bacteroides 
dorei 4.1 0.01* 0.1 - - - - - - 
Bacteroides/Bacteroides 
fragilis 1.0 5.9 37.8* 0.5 14.7 24.3* 0.5 0.9 2.1 
Bacteroides/Bacteroides 
thetaiotaomicron 1.81 0.1 7.5* 1.0 6.4 26.3* 1.0 4.5 15.4 
Odoribacter/Odoribacter 
splanchnicus - - - 2.9 0.004a 0.01 - - - 
Enterococcus/unclassified 0.1 20.8* 7.6 0.01 2.8 2.2 0.02 1.7 1.9 
Clostridium sensu stricto/ 
Clostridium baratii 0.03 1.9 1.0 0.04 1.2 1.3 0.01 0.1 1.3a 
Clostridium XlVa/ 
Clostridium hathewayi 0.3 0.2 2.1 - - - - - - 
Anaerostipes/Anaerostipes 
hadrus - - - - - - 6.5 0.02 0.2 
Clostridium 
XlVa/Clostridium 
symbiosum 0.1 1.0 2.4* 0.04 0.8 3.4* 0.04 1.5 5.0a 
Clostridium 
XlVa/unclassified 0.1 0.03 0.6* - - - - - - 
Coprococcus/Coprococcus 
comes 25.5 0.5* 1.2a 13.5 3.0* 7.8a 9.6 0.1 0.1 
Roseburia/Eubacterium 
rectale - - - 2.7 0.02 0.1 1.9 0.0 0.01 
Lachnospiraceae/ 
unclassified 5.3 1.6 4.9 3.1 0.1* 0.7 2.6 0.02* 0.1 
Clostridium 
XI/unclassified - - - 0.01 18.2* 6.2 0.0 16.8 11.2 
Veillonella/Veillonella 
dispar 0.03 16.0 12.7 0.01 0.1 2.2 - - - 
Escherichia/Shigella/ 
unclassified 2.6 51.3* 21.2 0.8 51.5* 21.0 1.1 71.4a 59.5 
*Statistically significant result, Kruskal-Wallis test result p≤0.05, padj≤0.05 with Dunn’s test qadj≤0.05.
 




Figure 23 Development of the MCC100 composition after 24 h fermentation. 5230 
The relative abundance of the dominant phyla Bacteroidetes, Firmicutes and 5231 
Proteobacteria (A) and the relevant families (B) is shown for time points 0 h, 16 h 5232 
and 24 h. BB: blueberry powder supplementation; BB.MIX: blueberry powder and 5233 
prebiotic carbohydrate mix supplementation; MIX: prebiotic carbohydrate mix 5234 
supplementation. Only families present with ≥1% relative abundance are shown. “*” 5235 
statistically significant: Kruskal-Wallis test result p≤0.05, padj≤0.05, Dunn’s test 5236 
qadj≤0.05. “a” statistical trend: Kruskal-Wallis test result p≤0.05, padj≤0.1, Dunn’s 5237 
test qadj≤0.1. 5238 
Blueberry supplemented prebiotic medium resulted in increased short chain 5239 
fatty acid production across the four faecal microbiotas and MCC100.  5240 
The production levels of the SCFAs acetate, propionate and butyrate levels in the 5241 
community type faecal microbiotas (EM278, EM425) and the longstay type 5242 
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(EM297, EM704) after 24 h fermentation are shown in Figure 25 A and B 5243 
respectively. Combined supplementation of fermentation medium with blueberry 5244 
powder and prebiotic carbohydrates (BB.MIX) resulted in increased SCFA 5245 
production across all donors faecal microbiota irrespective of community or longstay 5246 
type and in comparison to prebiotic (MIX) or blueberry (BB) supplementation alone. 5247 
The effect of substrate supplementation on combined SCFA levels in the aggregated 5248 
across the four donors faecal microbiota is shown in Figure 25 C. BB.MIX 5249 
supplementation resulted in significantly higher SCFA levels (mean 210 μmol mean 5250 
SCFA per g of faecal pellet) compared to BB (mean 124 μmol per g of faecal pellet, 5251 
p<0.005) and MIX (mean 150 μmol per g of faecal pellet, p<0.0005). Similarly, in 5252 
the MCC100 microbiota BB.MIX supplementation resulted in higher SCFA levels 5253 
after 24 h fermentation compared to the other supplementation regimes (Figure 25 5254 
D). Acetate and butyrate production were significantly higher after BB.MIX 5255 
supplementation (mean 66 μmol per g of bacterial pellet, p<0.05 and 14 μmol per g 5256 
of bacterial pellet, p<0.05 respectively) compared to MIX supplementation (5.5 and 5257 




Figure 24 Short chain fatty acid (SCFA) production by the faecal microbiota 5260 
and artificial consortium MCC100 after 24 h fermentation with selected 5261 
substrates. The concentration (μmol/g of faecal pellet) of acetate, propionate and 5262 
butyrate in the fermentation fluid from the COM type (EM278 and EM425) and LS 5263 
type (EM297, EM704) faecal microbiotas and consortium MCC100 is shown in A, B 5264 
and D respectively. The combined SCFA production in the aggregated (i.e. across all 5265 
donors faecal microbiotas) is shown in panel C. Kruskal-Wallis test with Dunn’s 5266 
post hoc test was applied to compare the SCFA levels at 24 h. *** p≤0.0005, ** 5267 
p≤0.005, * p≤0.05. BB: blueberry powder supplementation; BB.MIX: blueberry 5268 
powder and prebiotic supplementation; MIX: prebiotic carbohydrate mix 5269 
supplementation.  5270 
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4.5 Discussion 5271 
Baseline-dependent prebiotic effect of whole blueberry extract on the gut 5272 
microbiota of older donors 5273 
In this study we explored the modulatory effect of the rich in polyphenols and 5274 
dietary fibre whole blueberry powder in vitro on the faecal microbiota of older 5275 
subjects. Blueberry powder was used either as the sole fermentation substrate or in 5276 
combination with prebiotics. By testing the supplementation regimes and analysing 5277 
its effect on individual faecal microbiotas we observed the differential prebiotic 5278 
potential of blueberries that was broadly determined by the baseline microbiota 5279 
composition. Differential responsiveness to prebiotic treatment due to inter-5280 
individual compositional differences in the gut microbiota has been repeatedly 5281 
reported calling for personalized strategies towards restoring the dysbiotic gut 5282 
microbiota and retaining health (Duncan and Flint, 2013). Notwithstanding, due to 5283 
the increasing understanding of the ecological forces that assemble the gut 5284 
microbiota communities and the role of certain health-related taxa in disease, 5285 
prebiotics remain a promising generic therapeutic approach (Scott et al., 2015; 5286 
Bashan et al., 2016).  5287 
The presence of a dominant Bifidobacterium and Bacteroides population responsive 5288 
to blueberry supplementation differentiated the EM278 community type microbiota 5289 
from the other community type and the longstay type microbiotas. In the case of the 5290 
community type EM278 bifidobacteria and F. prausnitzii relative abundance 5291 
increased when blueberries were the sole fermentation substrate whereas 5292 
bifidobacteria and Bacteroides increased after co-supplementation with blueberries 5293 
and prebiotics suggesting extensive cross-feeding between bifidobacteria and either 5294 
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butyrate-producers like F. prausnitzii or Bacteroides taxa. Cross-feeding between 5295 
butyrate-producing bacteria like F. prausnitzii and acetate-producing bifidobacteria 5296 
have been extensively described before (Moens et al., 2016). Strain-dependent cross-5297 
feeding phenomena between Bifidobacterium and Bacteroides taxa have also been 5298 
described (Rios-Covian et al., 2013). In vitro responsiveness of bifidobacteria 5299 
predominantly and to a lesser extent of F. prausnitzii to polyphenols-rich extracts 5300 
from fruits like blueberries, pomegranate and apple, has been reported before (Molan 5301 
et al., 2009; Balionska et al., 2010; Guergoletto et al., 2016; Koutsos et al., 2017). 5302 
There are well-documented health-claims for bifidobacteria, F. prausnitzii and 5303 
Bacteroides taxa. Decreased relative abundance of F. prausnitzii population 5304 
associates to IBD whereas bifidobacteria abundance decreases with ageing (Miquel 5305 
et al., 2013; Arboleya et al., 2016). Various Bacteroides are next generation 5306 
probiotic candidates (El Hage et al., 2017). Interestingly, although the combined 5307 
supplementation favoured other dominant bacterial groups and inhibited F. 5308 
prausnitzii from accessing the blueberries substrate, the resulting SCFA production 5309 
was the highest among supplementation regimes, including the highest production of 5310 
butyrate indicating that although F. prausnitzii population was not sustained other 5311 
butyrate producing Lachnospiraceae like A. hadrus may have benefitted from cross-5312 
feeding phenomena with bifidobacteria as reported before (Belenguer et al., 2006).  5313 
Increased SCFA production was observed across all faecal microbiotas and MC100 5314 
after co-supplementation compared to prebiotics supplementation alone. Although 5315 
acetate and propionate were the major SCFAs, butyrate production profile was 5316 
promoted by the co-supplementation. In animal trials diet combining strawberry 5317 
polyphenols-rich extracts with fructooligosaccharides (FOS) resulted in increased 5318 
caecal SCFA production especially butyrate suggesting a synergistic beneficial effect 5319 
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of the two substrates on the GIT health (Singh et al., 2017). Others have reported 5320 
beneficial metabolic effects of similar co-supplementation in murine models but not 5321 
increased SCFA production (Fotschki et al., 2016). The SCFA propionate and 5322 
butyrate are strongly associated to host health produced mostly by Bacteroidetes and 5323 
certain Clostridiales respectively, whereas acetate is an abundant SCFA by-product 5324 
of the colonic bacteria fermentation activity (Louis and Flint, 2017).   5325 
Co-supplementation supported a greater production of SCFA which was 5326 
accompanied by a concomitant increase in alpha diversity indices only in MCC100. 5327 
Due to its wide repertoire of carbohydrate utilization (Flint et al., 2012) Bacteroides 5328 
were among the taxa that increased in abundance after co-supplementation across the 5329 
faecal microbiotas and especially in MCC100. The Clostridium cluster XIVa taxa 5330 
Clostridium symbosium and Coprococcus comes were identified as highly responsive 5331 
to co-supplementation in MCC100. Members of the Clostridium cluster XIVa are 5332 
major butyrate producers and potential candidates for probiotic consortium design 5333 
(El Hage et al., 2017). The synthetic community MCC100 has allowed monitoring 5334 
the responsive behaviour of selected dominant faecal bacteria to supplementation 5335 
potentially through what Clavel et al. (2017) has described as “functional enrichment 5336 
via community reduction”.  5337 
Importantly, Lactobacillales represented here by Streptococcus taxa were highly 5338 
responsive to blueberry supplementation whereas Enterococcus taxa demonstrated 5339 
lower responsiveness. Others have reported in vitro responsiveness of 5340 
Lactobacillales (measured with Lactobacillus/Enterococcus FISH and qPCR probes) 5341 
to supplementation with various polyphenols rich extracts (Balionska et al., 2010; 5342 
Cueva et al., 2013; Zhang et al., 2016; Gil-Sanchez et al., 2017). Importantly, Lee et 5343 
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al. (2018) reported that in mice fed high-fat diet blueberry powder administration 5344 
resulted in amelioration of the GIT physiology and inflammation that correlated to 5345 
an increase in Lactobacillales and Proteobacteria abundance. The Lactobacillales is a 5346 
prominent member of the human gut microbiota; the order harbours probiotic strains 5347 
but also potential pathobionts (Rajilic-Stojanovic and de Vos, 2014). Enterococci 5348 
and streptococci have been identified to be involved in polyphenols metabolism 5349 
(Rowland et al., 2018). Streptococci may have readily responded to both the 5350 
blueberry fruit sugars and the polyphenol content.  5351 
Effect of whole blueberry extract on the abundance of Enterobacteriaceae 5352 
We observed a relatively high increase in the Gammaproteobacteria with the 5353 
blueberry supplementation. It has been reported before that Enterobacteriaceae may 5354 
play a role in polyphenols metabolism (Couteau et al., 2001) and increase in 5355 
Enterobacteriaceae population with a concomitant increase in Bacteroides was 5356 
observed due to tannin-rich diets in murine models (Smith and Mackie, 2004). 5357 
Recently, Lee et al. (2018) reported that in the faecal microbiota of rats fed high-fat 5358 
diet supplemented with whole blueberry extract the abundance of 5359 
Gammaproteobacteria, mainly Pasteurellaceae, Fusobacteriaceae and 5360 
Porphyromonadaceae was increased compared to feeding with high-fat diet or low-5361 
fat diet. Proliferation of Proteobacteria and Fusobacteria in the gut microbiota is 5362 
associated with dysbiosis (Gevers et al., 2014; Eklof et al., 2017; Litvak et al., 5363 
2017). In the Lee et al. (2018) study the seemingly dysbiotic modulation of the 5364 
murine faecal microbiota after blueberry supplementation was accompanied with 5365 
improved GIT function and lowered inflammation markers. Increase in 5366 
Proteobacteria abundance was observed in the faecal microbiota of rats after Roux-5367 
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en Y gastric bypasses and was correlated to postoperative weight loss (Shao et al., 5368 
2017).  5369 
4.6 Conclusion 5370 
Importantly, dietary polyphenolic compounds may be bound to dietary fibre 5371 
impacting the bioavailability and the metabolism of the substrates by the colonic 5372 
microbiota (Edwards et al., 2017). Dietary fibre in polyphenols rich substrates may 5373 
better support the growth of various taxa such as Bacteroides taxa as observed in in 5374 
vitro and in human trials (Eid et al., 2014; Henning et al., 2017) and is more relevant 5375 
to human diet. Here, we reported that rich in polyphenols and dietary fibre whole 5376 
blueberry supplementation can affect certain health-relevant taxa and drive an 5377 
increased SCFA production in the faecal microbiota of elderly. Blueberries 5378 
potentially promote elderly health by contributing fibre to the fibrolytic colonic 5379 
bacterial community thus, increasing the SCFA production that is known to decline 5380 
with ageing (Duncan and Flint, 2013) and also by contributing phenolic metabolites. 5381 
The lack of compartmentalisation and the reduction in diversity of the faecal 5382 
microbiota under in vitro conditions significantly impact on microbiota 5383 
responsiveness to supplementation tests (Guerra et al., 2012). The awaited phenolic 5384 
compound analysis will reveal bioconversion of these compounds by the microbiota 5385 
during the 24 h fermentation. Follow-up in vitro trials with isolated phenolic 5386 
compounds will elucidate the role of blueberry extracts on gut microbiota 5387 
modulation. In vivo trials will leverage the in vitro bias and further elucidate the 5388 
microbiota modulatory potential of whole blueberries allowing for safe dietary 5389 
recommendations for the elderly.   5390 
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S Figure 5 Principal Coordinates Analysis (PCoA) of the faecal microbiota and 5626 
MCC100 at baseline (t0 h). A: Weighted UniFrac distances; B: Unweighted 5627 
UniFrac distances. “●” Community (COM) type microbiota; “▲” Longstay (LS) 5628 
type microbiota; red: BB supplementation; blue: BB.MIX supplementation; green: 5629 
MIX supplementation.  5630 
S Table 10 Alpha diversity indices for the faecal microbiotas and MCC100 at 5631 
baseline (0 h).  5632 
Alpha Diversity Index 




EM278 5.5 0.9 25.3 298 387 
EM425 5.5 0.9 29.6 332 404 
MCC100 3.8 0.8 10.2 90 109 
EM297 4.4 0.9 16.0 165 242 
EM704 3.9 0.9 19.0 169 220 




S Figure 6 Alpha diversity of the community (COM) type faecal microbiota at 5635 
24 h. The results refer to the aggregated faecal microbiotas EM278 and EM425. BB: 5636 
blueberry supplementation; BB_MIX: blueberry and prebiotic carbohydrate mix 5637 




S Figure 7 Alpha diversity of the longstay (LS) type faecal microbiota at 24 h. 5640 
The results refer to the aggregated faecal microbiotas EM704 and EM297. BB: 5641 
blueberry supplementation; BB_MIX: blueberry and prebiotic carbohydrate mix 5642 
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S Figure 8 Principal Coordinates Analysis (PCoA) of the faecal microbiota and 5645 
MCC100 at 24 h. A. Weighted UniFrac distances; B. Unweighted UniFrac distances. 5646 
“●” Community (COM) type microbiota and MCC100; “▲” Longstay (LS) type 5647 
microbiota; red: BB supplementation; blue: BB.MIX supplementation; green: MIX 5648 
supplementation.  5649 
S Table 11 Development of the composition and comparison between time 5650 
points of the relative abundance of orders after 24 h fermentation with 5651 
community (COM) type faecal microbiota (EM278, EM425). BB: blueberry 5652 
powder supplementation; BB.MIX: blueberry powder and prebiotic carbohydrate 5653 
mix supplementation; MIX: prebiotic carbohydrate mix supplementation. Missing 5654 
values indicate that the relevant taxon had <1% abundance in all vessels (two or 5655 
three) summed for mean abundance. The mean value of the relative abundance per 5656 
time point is shown. 5657 
  EM278   EM425  
OTU BB BB.MIX MIX BB BB.MIX MIX 
Classification t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 
Bifidobacteriales 3.5 21.6 3.0 21.9 4.9 13.9a - - - - - - 
Bacteroidales 23.3 6.3 19.4 45.5 22.3 31.8a 10.1 4.1 8.7 10.6 11.2 28.6 
Lactobacillales 1.1 0.9 1.0 2.6 1.4 3.1a 0.5 32.8a 0.4 39.2 0.4 8.5 
Clostridiales 67.0 42.9 71.5 26.8 67.6 47.1 75.6 20.5 76.9 27.3 75.0 50.5* 
Erysipelotrichales 0.3 3.5 0.4 1.4 0.5 1.7a - - - - - - 
Selenomonadales 1.0 2.2 - - 0.4 0.6a 2.7 0.7a 2.1 0.4 1.8 0.3a 
Firmicutes/unclassified 0.8 1.0 - - - - 2.6 0.2a 2.7 0.02 2.7 0.6 
Burkholderiales 0.8 1.1 0.9 0.5 1.0 0.7 - - - - - - 
Enterobacteriales 0.0 20.0 - - 0.01 0.5 0.04 41.3 0.03 22.0 0.03 11.1* 
*Statistically significant result, Kruskal Wallis test result p≤0.05, padj≤0.05 with Dunn’s test qadj≤0.05. 
a Statistical trend, Kruskal Wallis test result p≤0.05, padj≤0.1, with Dunn’s test qadj≤0.1. 
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S Table 12 Development of the composition and comparison between time 5659 
points of the relative abundance of orders after 24 h fermentation with longstay 5660 
(LS) type faecal microbiota (EM704, EM297). BB: blueberry powder 5661 
supplementation; BB.MIX: blueberry powder and prebiotic carbohydrate mix 5662 
supplementation; MIX: prebiotic carbohydrate mix supplementation. Missing values 5663 
indicate that the relevant taxon had <1% abundance in all vessels (two or three) 5664 
summed for mean abundance. The mean value of the relative abundance per time 5665 
point is shown. 5666 
 EM704 EM297 
OTU BB BB.MIX MIX BB BB.MIX MIX 
Classification t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 
Bifidobacteriales - - - - - - 2.3 0.02 - - - - 
Bacteroidales 10.2 3.6 10.1 13.0 10.0 30.3 15.5 1.9 16.7 18.7 19.3 14.8 
Lactobacillales 0.1 72.1a 0.1 35.1 0.1 4.5a 2.5 8.6a 1.5 9.6a 4.7 28.2 
Clostridiales 31.1 21.4 33.6 44.2 28.8 56.7 28.5 18.9a 22.1 20.2 33.1 33.2 
Selenomonadales 2.3 0.3a - - 2.6 1.9a 0.3 1.1 0.2 1.3 - - 
Enterobacteriales 0.1 1.2 0.04 6.6 0.1 4.9 8.8 68.5a 6.6 44.3a 10.2 21.9 
Synergistales 10.5 0.1 9.2 0.02 13.8 0.1a 23.3 0.1 21.0 0.04 7.6 0.09 
*Statistically significant result, Kruskal-Wallis test result p≤0.05, padj≤0.05 with Dunn’s test qadj≤0.05. 
a Statistical trend, Kruskal-Wallis test result p≤0.05, padj≤0.1, with Dunn’s test qadj≤0.1. 
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S Table 13 Development of the composition and comparison between time points of the relative abundance of species after 24 h 5667 
fermentation with community (COM) type faecal microbiota (EM278, EM425). BB: blueberry powder supplementation; BB.MIX: 5668 
blueberry powder and prebiotic carbohydrate mix supplementation; MIX: prebiotic carbohydrate mix supplementation. Missing values indicate 5669 
that the relevant taxon had <1% abundance in all vessels (two or three) summed for mean abundance. The mean value of the relative abundance 5670 
per time point is shown. 5671 
 EM278 EM425 
OTU  BB BB.MIX MIX BB BB.MIX MIX 
Classif ication t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 
Bif idobacterium bif idum 0.05 1.8 0.03 0.8 0.1 0.6a - - - - - - 
Bifidobacterium longum 0.2 2.3 0.1 2.5 0.4 1.2 - - - - - - 
Bifidobacteriumu  2.7 15.5 2.2 16.3 3.6 9.6a - - - - - - 
Bifidobacte-riaceaeu  0.6 2.0 0.6 2.3 0.7 2.5a - - - - - - 
Bacteroides caccae 0.9 0.4 0.7 3.2 0.8 5.7a - - - - - - 
Bacteroides dorei  7.5 0.7 6.4 0.4 7.2 1.4a - - - - - - 
Bacteroides eggerthii  1.9 0.2 1.7 0.8 2.0 0.5a - - - - - - 
Bacteroides fragil is  - - - - - - 0.8 0.6 0.6 10.1 0.8 15.2 
Bacteroides thetaiotaomicron  0.6 0.3 - - 0.4 0.4 - - - - 0.1 1.1a 
Bacteroides uniformis  7.8 2.1 6.7 38.3 7.4 19.2a 4.5 2.5 3.6 0.1 5.5 8.2 
Bacteroides u - - - - 0.5 1.8 - - - - 0.1 1.1a 
Alistipes u  1.1 1.3 - - 1.2 1.4 - - - - - - 
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 EM278 EM425 
OTU  BB BB.MIX MIX BB BB.MIX MIX 
Classif ication t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 
Streptococcus u  1.1 0.9 1.0 2.6 1.3 3.1 0.4 32.1a 0.2 39.1 0.2 8.5 
Clostridium sensu stricto u  - - - - - 0.5 7.8 5.0a 0.6 5.7 0.4 12.3a 
Anaerostipes hadrus  2.3 11.2 2.6 11.3 2.5 7.8 - - 0.7 6.7 0.8 8.1 
Blautia faecis 2.3 0.5 2.7 2.0 2.0 4.3 - - - - - - 
Blautia luti  2.0 3.0 2.4 0.7 2.2 2.3 - - - - - - 
Blautia u  4.5 1.9 5.9 0.9 4.2 2.1 2.6 0.1 2.8 1.6 2.4 3.4 
Clostridium XlVa u  - - - - 0.1 0.8a 0.1 0.5 - - - - 
Coprococcus catus  - - 0.3 1.2 - - 0.2 1.1a 0.2 0.8 - - 
Coprococcus comes  0.6 1.3 - - 0.8 4.3a 0.2 0.6 0.2 0.9 - - 
Eubacterium rectale  15.1 0.5 16.3 2.7 16.6 10.2 - - - - - - 
Lachnospiraceae u  13.6 5.8 15.4 5.2 11.9 9.8a 35.4 3.7a 34.3 1.4 38.3 12.0a 
Clostridium XI u  - - - - - - 0.2 1.4 0.1 0.1 - - 
Faecalibacterium prausnitzi i  9.9 12.7 8.8 0.2 10.1 1.4 7.9 2.5 8.8 0.1 7.9 5.3a 
Gemmiger formicil is  - - - - 1.4 0.1 2.0 0.1 2.7 7.4 1.8 2.0 
Ruminococcaceae u 2.2 1.7 2.3 0.2 2.1 0.5a 7.6 0.2 7.8 0.1 6.2 0.7a 
Clostridiales u  2.7 0.1 2.5 0.1 2.5 0.2a 3.8 0.2a 4.0 0.1 3.6 0.2 
Clostridium XVIII u  0.1 3.2 0.2 1.3 0.3 1.4 - - - - - - 
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 EM278 EM425 
OTU  BB BB.MIX MIX BB BB.MIX MIX 
Classif ication t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 
Phascolarctobacterium faecium 0.4 2.0 - - 0.2 0.6a - - - - - - 
Firmicutes u  0.8 1.0 - - - - 2.6 0.2a 2.7 0.02 2.7 0.6a 
Shigella u 0.02 9.3 - - - - 0.04 40.8 0.03 21.8 0.03 11.1a 
*Statistically significant result, Kruskal-Wallis test result p≤0.05, padj≤0.05 with Dunn’s test qadj≤0.05 
aStatistical trend, Kruskal-Wallis test result p≤0.05, padj≤0.1, with Dunn’s test qadj≤0.1 
uUnclassified: not classified at a finer phylogenetic level than the indicated 
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S Table 14 Development of the composition and comparison between time points of the relative abundance of species after 24 h 5673 
fermentation with longstay (LS) type faecal microbiota (EM704, EM297). BB: blueberry powder supplementation; BB.MIX: blueberry 5674 
powder and prebiotic carbohydrate mix supplementation; MIX: prebiotic carbohydrate mix supplementation. Missing values indicate that the 5675 
relevant taxon had <1% abundance in all vessels (two or three) summed for mean abundance. The mean value of the relative abundance per time 5676 
point is shown. 5677 
 EM704 EM297 
OTU BB BB.MIX MIX BB BB.MIX MIX 
Classification t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 
Bifidobacteriumu - - - - - - 1.6 0.01 - - - - 
Bacteroides caccae - - - - 0.4 1.4 - - - - - - 
Bacteroides cellulosilyticus - - - - 0.6 1.3 - - - - - - 
Bacteroides dorei 1.5 0.4a 1.0 0.7 1.1 0.9 4.0 0.2a 4.8 0.7a 4.1 1.1 
Bacteroides fragilis        7.5 0.3a 7.4 8.8 8.9 8.5 
Bacteroides thetaiotaomicron 3.3 2.8 4.4 11.9 3.3 25.8 0.3 1.1 0.4 5.1 0.5 2.7 
Bacteroidesu - - - - - - 0.8 0.2 0.9 3.9 1.2 2.4 
Methanobrevibacter smithii 10.4 0.04 - - 7.5 0.03a - - - - 20.7 0.003 
Enterococcusu - - - - - - 1.1 8.6a 0.5 9.6a 1.6 28.1 
Streptococcusu 0.1 72.0a 0.1 35.0 0.1 4.5a - - - - - - 
Clostridium baratii - - 0.7 2.8 0.7 1.7a - - - - - - 
Clostridium disporicum 9.4 0.8 10.3 4.6 8.4 4.4 - - - - - - 
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 EM704 EM297 
OTU BB BB.MIX MIX BB BB.MIX MIX 
Classification t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 t0 t24 
Clostridium sensu strictou 0.1 6.9 0.1 10.3 0.1 25.5 - - 0.003 0.8a - - 
Blautiau 0.2 1.7a 0.1 2.1 0.1 5.0a 0.2 1.0 0.2 1.1 0.2 2.7 
Clostridium hathewayi - - - - - - 1.6 2.4 1.2 7.0 1.9 4.7 
Clostridium XlVau - - - - 0.2 1.4a 2.7 0.8 2.3 0.9a 3.4 1.6 
Ruminococcus torques 1.4 0.1 1.4 0.05 1.2 0.3a 6.1 0.1a 4.7 2.4 7.0 0.03 
Eubacterium eligens - - - - - - 0.1 0.5 0.1 3.0 - - 
Lachnospiraceaeu 1.4 0.1a 1.4 0.03 - - 2.5 2.3 2.0 3.6a 3.5 3.1 
Clostridium glycolicum 0.1 1.4 0.1 3.5 - - - - - - - - 
Clostridium XIu 0.2 1.9a 0.2 11.0 0.2 3.9a - - - - - - 
Ruminococcaceaeu 2.7 1.5a 2.5 4.0 2.9 5.1a 5.4 0.02 4.7 0.03 5.4 0.02 
Clostridialesu 1.8 0.1 2.1 0.1 1.9 0.6a 2.0 0.5a 1.5 0.5a 2.3 1.4 
Phascolarctobacterium faecium 2.3 0.3a - - 2.6 1.9a 0.3 1.1 0.2 1.3 - - 
Escherichia/Shigellau 0.01 0.9 0.01 6.5 0.02 4.8 7.0 66.8a 5.4 44.3a 9.0 20.3 
Klebsiellau - - - - - - 1.8 1.6 - - 1.2 1.1 
Cloacibacillus evryensis 10.3 0.1 9.0 0.02 13.7 0.1a 23.2 0.1 20.9 0.04 7.6 0.1 
Akkermansia muciniphila 30.2 0.03 - - 34.7 0.2 - - - - - - 
*Statistically significant result, Kruskal-Wallis test result p≤0.05, padj≤0.05 with Dunn’s test qadj≤0.05 
aStatistical trend, Kruskal-Wallis test result p≤0.05, padj≤0.1, with Dunn’s test qadj≤0.1 
uUnclassified: not classified at a finer phylogenetic level than the indicated 
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5 Chapter 5- General discussion 
Chapter 5 5678 
General Discussion  5679 
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Considerations for advancing gut microbiota modulation research for older 5680 
people 5681 
The population over 60 yrs old is growing fast and people over 80 yrs are expected 5682 
to comprise 13% of the European population by 2080 (http://ec.europa.eu/eurostat/ 5683 
statistics-explained/index.php/Population_structure_and_ageing). The extension of 5684 
human life expectancy comes with increased risk of age-related conditions such as 5685 
cognitive decline and non-communicable disease (metabolic disease, CVD, cancer), 5686 
which places national economies and health care systems under significant stress 5687 
(Divo et al., 2016). While habitual diet can be the major source of key nutrients that 5688 
could prevent or at least, ameliorate age-related conditions, the high prevalence of 5689 
malnutrition in both community- and long term care unit- dwelling older people has 5690 
increased the need for innovative nutritional recommendations and strategies, and 5691 
the design of novel functional food products targeting the specific nutritional needs 5692 
of the elderly population (de Groot et al., 2016; Hill et al., 2016; Moore et al., 2018).  5693 
There is an increasing effort to develop general or targeted gut microbiota 5694 
therapeutics for the older population, similar to the efforts aimed at diseases in which 5695 
the associated microbiota dysbiosis could be treated with prebiotics, probiotics or 5696 
bacteriotherapy (reviewed in Chapter 1; Salazar et al., 2017). While Salazar et al. 5697 
(2017) in their recent review pointed out that more intervention studies on older 5698 
population using a wide range of probiotics and prebiotics are needed, I have also 5699 
emphasised in Chapter 1.2 the fact that there is a scarcity of studies using faecal 5700 
microbiota from older subjects (≥65 yrs) in in vitro and also in in vivo preclinical 5701 
experiments. Furthermore, there is a lack of preclinical trials using microbiota from 5702 
non-healthy older subjects (reviewed in Chapter 1.2).  5703 
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In vitro screening of the “elderly” gut microbiota against an array of potential 5704 
microbiota modulators (e.g. prebiotics, probiotics, LBT), could be an important 5705 
stepping stone to advance the preclinical research of microbiota therapeutics 5706 
targeting the older population. Outcomes of in vitro screens can lead to the design of 5707 
in vivo preclinical trials and subsequently, to human interventions (O’Toole et al., 5708 
2017; Schmidt et al., 2018). In this research thesis, faecal microbiota from healthy 5709 
and non-healthy (frail) older subjects were used in the preclinical trials described in 5710 
Chapters 2, 3 and 4. The use of both “healthy” and “non-healthy” microbiota from 5711 
elderly people reflects the current scientific interest to develop both preventive and 5712 
therapeutic approaches for gut microbiota modulation (Derrien and Veiga, 2016).  5713 
The choice between aiming at a general or a more precise gut microbiota modulation 5714 
depends on the context of what is considered the healthy or normal state of the 5715 
microbiota, and whether whole community or specific taxon perturbations are 5716 
associated with the non-healthy state of interest. Targeted and untargeted microbiota 5717 
modulations can be achieved through the use of pre/pro-biotics and LBT, or through 5718 
FMT (reviewed in Chapter 1.2; Schmidt et al., 2018). Importantly, under the current 5719 
updated concept of prebiotics, (potential) prebiotics can serve in untargeted 5720 
microbiota modulation approaches because retention of the phylogenetic diversity of 5721 
the whole microbiota community in combination with increased SCFA production 5722 
especially butyrate, is emerging as a desirable outcome of prebiotic administration 5723 
(reviewed in Chapter 1.2; Gibson et al., 2017).  5724 
Examples of precision approaches targeting a certain microbiota component include 5725 
the following: F. prausnitzii is proposed as a therapeutic target for Crohn’s disease 5726 
(Sokol et al., 2008; Pascal et al., 2017), therefore, the taxon could be supplemented 5727 
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in patients or targeted with prebiotics. The discovery of CRC biomarker bacterial 5728 
clusters (Flemer et al., 2017) may call for a targeted approach that will aim at a wide 5729 
but defined portion of the microbiota community of patients. Importantly, for the 5730 
rational design of precision gut microbiota therapeutics, some degree of causation 5731 
beyond mere associations, between biomarker taxa and disease needs to be 5732 
established before aiming at specific microbiota interventions (Schmidt et al., 2018).  5733 
It is also important not to overstate the beneficial effects of certain gut bacteria or 5734 
“incriminate” others for deleterious effects based solely on association studies and 5735 
without placing the effect in an ecological context (e.g. diet, immunity, cross-talk 5736 
with other microbiota members), as the examples of the LBT based on the 5737 
“beneficial” taxon A. muciniphila and P. copri have shown (Cani, 2018; Cirstea et 5738 
al., 2018). Another example is the normalisation of dysbiosis and inflammation by 5739 
precision tailoring of the expanded Enterobacteriaceae population during the 5740 
inflamed stage of colitis in mice (Zhu et al., 2018). This potentially pathobiont taxon 5741 
which is a common member of the gut microbiota was not eradicated but its 5742 
abundance was restored to pre-inflammation levels. 5743 
While some conditions may require the targeting of certain taxa or clusters, others 5744 
will require a general effect on the whole microbiota community. For example, the 5745 
association of metabolic disease with low diversity and low gene counts in the gut 5746 
microbiota (Le Chatelier et al., 2013) indicates the need for general modulations, i.e. 5747 
to target of the whole community for the increase of the phylogenetic diversity, in 5748 
order to decrease the risk for metabolic conditions. Interestingly, boost of the 5749 
phylogenetic diversity of the gut microbiota of “westernised/industrialised” cohorts 5750 
in which decreased phylogenetic diversity is a potential risk factor for various 5751 
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“modern” diseases such as metabolic disease and IBD, could be key for general 5752 
approaches towards maintaining health and lowering the risk of disease in the 5753 
general population (Moeller et al., 2017).  5754 
Identifying the “healthy adult” microbiota has been challenging (Lloyd-Price et al., 5755 
2016). A “functional healthy core” in which different microbial lineages confer a 5756 
similar metabolic activity due to metabolic redundancy in the gut microbiota has 5757 
been proposed as a more relevant notion compared to a core of taxa for which 5758 
consensus across cohorts is often prevented by inter-individual compositional 5759 
variations (Lloyd-Price et al., 2016). Compositional patterns, i.e. enterotypes 5760 
(discussed in Chapter 1.1), in spite of the controversy with which the concept was 5761 
initially met, may offer a useful way to stratify “healthy” microbiota compositional 5762 
profiles across subjects (Costea et al., 2018).  5763 
In depth understanding of microbiota assembly dynamics can be key to general 5764 
microbiota modulatory strategies. In spite of inter-individual species/strain level 5765 
differences, and especially for “healthy” microbiomes, these dynamics are most 5766 
likely governed by “universality” reflected in the pathways of inter-species cross-talk, 5767 
resilience to stressors and in the combination of compositional adaptiveness and 5768 
longitudinal robustness (Bashan et al., 2016; Gilbert et al., 2018). Dysbiotic 5769 
microbiota dynamics are more difficult to predict because this “universality” may be 5770 
interrupted and some authors argue for “stochastic” changes in the dysbiotic 5771 
microbiota (Bashan et al., 2016; Zaneveld et al., 2017).  5772 
The wide distance observed in β-diversity analysis among patients (e.g. Crohn’s 5773 
disease) compared to the close clustering of healthy controls, indicates that the 5774 
underlying dysbiosis may in some conditions, lead to an unstable microbiota state 5775 
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and unpredictable (stochastic) shifts from the healthy microbiota profile (Zaneveld et 5776 
al., 2017). The deregulated dynamics of the “dysbiotic microbiota” which is most 5777 
likely characterised by unpredictable responsiveness to stressors, may also be 5778 
hampering responsiveness to therapeutics. In depth profiling of the gut microbiota 5779 
compositional changes in “perturb-to-predict” experiments (e.g. in in vitro and in 5780 
vivo colon models), offer valuable insight to microbiota dynamics because they can 5781 
help typify shifts of the microbiota from baseline as being stochastic or reproducible 5782 
as a response to the experimentally imposed challenge (e.g. response to diet) 5783 
(Zaneveld et al., 2017; Schmidt et al., 2018).  5784 
The re-evaluated concept of the enterotypes in the analysis of microbiota 5785 
composition could further refine the identification of predictable and stochastic 5786 
microbiota responses (Costea et al., 2108). Furthermore, many studies have reported 5787 
responders and non-responders to prebiotic intervention, underlying the importance 5788 
of the baseline microbiota composition in “perturb-to-predict” approaches (Duncan 5789 
and Flint, 2013; Zhao et al., 2018). To date, Bacteroides and Prevotella have been 5790 
identified as key taxa that define major enterotype profiles among individuals, and 5791 
responsiveness variations, for example as demonstrated in an in vitro colon system 5792 
after dietary fibre supplementation (Chen et al., 2017; Costea et al., 2018).  5793 
Taken together, efforts to categorise microbiota responses to extrinsic challenges (e.g. 5794 
diet, antibiotics, LBT, pathogens) in predictable or stochastic manners, overcoming 5795 
the inter-individual variations by stratifying responses according to enterotypes and 5796 
baseline microbiota characteristics, may facilitate generalised and at the same time 5797 
precision approaches in health-maintenance and therapeutic strategies, overcoming 5798 
the need for personalised therapeutics (Sonnenburg and Backhed, 2016).  5799 
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In order to extend our definition of the “healthy” microbiota, an interesting question 5800 
to ask is how different is the responsiveness of the “healthy older” from the “healthy 5801 
younger” gut microbiota to perturbations. The “healthy older” may not significantly 5802 
differ in composition from the “healthy younger adult” microbiota as observed in 5803 
principal coordinates (PCoA) analysis in various studies (Claesson et al., 2012; Bian 5804 
et al., 2017). In the in vitro experiments described in Chapters 2 and 4, microbiota 5805 
from younger adults was not used. However, it would be interesting to examine in 5806 
future preclinical in vitro studies the comparative responsiveness of healthy “young” 5807 
and “old” microbiota to substrate supplementation/perturbation, both in taxa and 5808 
SCFA production.  5809 
In vitro microbiota perturbation tests (e.g. challenge of the microbiota with candidate 5810 
pre/pro-biotic substrate, LBT, pathobionts), in which simulation of the host factors 5811 
that affect the microbiota composition (e.g. lower immune regulation in the elderly; 5812 
Kundu et al., 2017) cannot be achieved, apart perhaps from the slower retention time 5813 
in the elderly colon (e.g. in Fehlaub et al., 2015), may allow for a better 5814 
understanding of the “intrinsic” potential of the “young” and “old” healthy 5815 
microbiota to respond to challenges. The potential differences could be associated to 5816 
different strains being differentially enriched in the two types of microbiota (Zhu et 5817 
al., 2015). Strain level differences between microbiotas are often underestimated 5818 
because it is difficult to discern them based on phylogenetic gene markers such as 5819 
16S rRNA gene (Zhu et al., 2015); however, strain level analysis will refine our 5820 
understanding of the microbiota dynamics and functionality. Identification of such 5821 
fine strain-level differences may improve the outcome of gut microbiota modulation 5822 
strategies (De Filippis et al., 2016) and open a window for preventive modulations 5823 
targeting the progression of ageing in the microbiota. 5824 
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The use of synthetic minimal microbial communities (reviewed in Chapter 1.2,; 5825 
experiments in Chapter 4), can be a valuable tool for studying how key microbiota 5826 
members respond to dietary substrates, and especially in in vitro systems, and they 5827 
offer the potential to study the microbiota down to strain level properties. Rationally 5828 
assembled artificial microbiota communities that are designed to resemble ”healthy” 5829 
or “dysbiotic” gut microbiota or microbiotas of certain enterotypes, will allow for 5830 
controlled and reproducible experiments through which associations, function, 5831 
metabolism, cross-feeding and other parameters can be studied in a reduced in 5832 
complexity ecosystem (de Roy et al., 2013). Importantly, in vitro studies employing 5833 
artificial microbiota communities can be the basis for the design of LBT intervention 5834 
in which microbiota consortia and dietary context (i.e. substrates that can sustain the 5835 
viability and diversity of the consortium) can be matched in order to achieve the 5836 
desired response (e.g. increased butyrate production by increasing the fibrolytic 5837 
bacteria in the colon) in microbiotas that otherwise may fail to respond due to 5838 
missing responsive members (Makki et al., 2018).  5839 
The reproducibility within studies and the comparability across studies that can now 5840 
be achieved by thorough documentation of protocols from the wet lab to the data 5841 
analysis, can maximise the information extracted from microbiome studies, leading 5842 
to improved translatability and rationally designed clinical applications (Knight et 5843 
al., 2018). While next generation 16S rRNA amplicon sequencing has been a major 5844 
analysis method in the microbiota studies to date, it is apparent that in order to refine 5845 
the microbiota taxonomic and functionality analysis, a combination of –omics 5846 
methods should be employed (e.g. metagenomics, metatranscriptomics) when 5847 
economic resources, sample availability and time constrains allow for it (Knight et 5848 
al., 2018). Especially the metagenomics approach, allows for high taxonomic 5849 
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resolution of both the bacterial component of the microbiota community and the 5850 
whole microbial component, i.e. fungi, yeasts, archaea and viruses and phages, 5851 
which although underrepresented in most microbiota studies, still impacts health and 5852 
disease (Cani, 2018). Furthermore, accurate profiling of the microbiota composition 5853 
could benefit from a combination of qualitative (16S rRNA gene amplicon 5854 
sequencing) and quantitative methods (e.g. quantitative PCR) in order to detect true 5855 
changes in cell counts in combination to relative abundance changes (Vandeputte et 5856 
al., 2017; Knight et al., 2018).  5857 
Any prediction that is generated in in vitro studies requires validation in in vivo 5858 
systems and ultimately in “real life” clinical trials, before scientific advances in the 5859 
field of gut microbiota research can be responsibly disseminated to the public (Cani, 5860 
2018; Schmidt et al., 2018). Importantly, some advances in gut microbiota research 5861 
are already reaching the public and health authorities are promoting science-backed 5862 
dietary recommendations (Derrien and Veiga, 2016). Dietary recommendations 5863 
represent low-cost health-improving strategies but require careful dissemination 5864 
strategies from the laboratories to society and adherence by the public. Cohort 5865 
studies show that adherence to international and national dietary guidelines may 5866 
significantly improve public health (Batis et al., 2016; Biesbroek et al., 2017) and 5867 
even increase the life expectancy of the older population (Jankovic et al., 2014; 5868 
Jankovic et al., 2015).  5869 
In spite of the importance of dietary guidelines, adherence is often challenging. 5870 
Functional foods supplemented with next generation prebiotics and/or probiotics or 5871 
microbial products potentially regulated as food products (Derrien and Veiga, 2016; 5872 
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Brodman et al., 2017) are expected to play a significant role in the amelioration of 5873 
health across all ages and in particularly in the elderly population.  5874 
Widely used plant- and animal- derived dietary substrates as a source for novel 5875 
prebiotics 5876 
Plants (fruits, vegetables, legumes) are the main source of substrates with potential 5877 
prebiotic activity, e.g. dietary fibre (reviewed in. Makki et al., 2018) and in the 5878 
search for new prebiotics, dietary substrates of plant origin are being investigated. 5879 
There is increasing interest in the study of the effect of dietary polyphenols in the gut 5880 
microbiota, found in fruits, vegetables and legumes (Derrien and Veiga, 2016). The 5881 
health relevance of polyphenol consumption is associated with the gut microbiota 5882 
metabolism of unabsorbed polyphenols and the subsequent release of bioactive 5883 
phenolic compounds (Marchesi et al., 2015). Furthermore, some recent studies have 5884 
focused on the cumulative prebiotic effect of polyphenols and dietary fibre, because 5885 
apart from the documented health benefits of these two food components, the 5886 
binding of polyphenols to dietary fibre (e.g. the case of plant cell wall) may increase 5887 
the bioavailability of the polyphenols in the distal colon (discussed in Chapter 4). 5888 
Another less investigated source of potentially prebiotic substrates is milk. As 5889 
reviewed in Chapter 1.3, milk and its carbohydrate components are drawing 5890 
scientific attention due to BMOs having complex structures similar to HMOs. The 5891 
structural complexity of HMOs is associated to the HMOs prebiotic activity 5892 
(reviewed in Chapter 1.2). A similar to HMOs structural complexity has not been 5893 
identified in the plant derived prebiotic candidates investigated to date (Chapter 1.2). 5894 
The large-scale isolation (or production) of HMOs has been challenging and 5895 
therefore, there are limitations in the use of HMOs for study purposes or for food 5896 
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supplementation (Bode et al., 2016). Should prebiotic activity of BMOs be 5897 
documented (as recent studies are indicating; see Chapters 1.3 and 3), they could 5898 
replace HMOs in various large-scale in vitro, in vivo and importantly, in clinical 5899 
studies, thus, extending our knowledge on the effect of these non-plant derived OS 5900 
on the gut microbiota.  5901 
The studies on the effect of isolated milk components such as BMOs or GMP 5902 
(Chapter 2) on the gut microbiota can reveal new opportunities for functional foods 5903 
design (https://www.nutrition.org.uk/nutritionscience/foodfacts/functional-5904 
foods.html?limitstart=0) and give new perspectives for the industrial and commercial 5905 
exploitation of dairy industry residual by-products. Isolation of BMOs, and GMP, 5906 
from whey concentrates may present a productive way for the dairy industry to 5907 
resolve the challenging whey surplus problem while also extracting valuable 5908 
compounds for foods supplementation (Oliveira et al., 2015; Bode et al., 2016).  5909 
To my knowledge (reviewed in Chapter 1.3), research has yet to thoroughly assess 5910 
the effect of regular milk consumption on the microbiota composition, an area of 5911 
study which could complement the array of health benefits known for milk 5912 
consumption. Evidence on the prebiotic potential of (whole, unfermented) milk, such 5913 
as those presented in Chapter 3, in combination with large cohort data and meta-5914 
analysis (reviewed in Chapter 1) showing that milk consumption does not correlate 5915 
with detrimental health effects, would add compelling scientific evidence towards 5916 
milk inclusion in a balanced diet. The inclusion of milk in the diet of the elderly 5917 
population is of particular relevance because milk is a source of the vitamins B and 5918 
D among others, and of protein and micronutrients such as calcium, the dietary 5919 
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deficiency of which is associated with degenerative disease in older age (de Groot, 5920 
2016). 5921 
Research thesis contribution to current literature and future work 5922 
In this research thesis I investigated the modulatory effect on the human gut 5923 
microbiota of selected food ingredients, i.e. milk and milk-derived GMP, and berry 5924 
fruit, focusing on older subjects. The aim was to provide scientific evidence for the 5925 
prebiotic potential of these products and therefore, evidence to warrant the design of 5926 
informed future clinical trials in order to establish the effect of the selected products 5927 
on GIT health.  5928 
In Chapter 1.3, I have reviewed the existing evidence on the potential of the selected 5929 
dairy food ingredients to be used in approaches to modulate the gut microbiota; I 5930 
have also reviewed the existing knowledge on the health benefits associated with the 5931 
consumption of these products. In Chapter 1.2, I reviewed the major experimental 5932 
models that can be used in the study of gut microbiota modulation. Chapter 2 5933 
provides experimental evidence for the potential of GMP to modulate in vitro the gut 5934 
microbiota of older subjects by promoting the growth of several health-relevant taxa 5935 
and by sustaining the microbiota diversity close to baseline starting point. As I 5936 
reviewed in Chapter 1.3, previous in vitro studies yielded controversial evidence on 5937 
the prebiotic potential of GMP. One possible reason for this is the fact that they did 5938 
not examine the whole microbiota community changes that GMP can promote, but 5939 
rather they focused on identifying changes in specific taxa such as Lactobacillus and 5940 
Bifidobacterium, measured by quantitative molecular methods such as FISH (Bruck 5941 
et al., 2002; Hernandez-Hernndez et al., 2011). In Chapter 2, I profiled the changes 5942 
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in the whole community and identified affected taxa beyond the “traditional” targets 5943 
of prebiotics.  5944 
Importantly, in the in vitro experiments I used faecal samples from subjects in which 5945 
low phylogenetic diversity correlated with poor health and frailty. As reviewed in 5946 
Chapter 1, frailty is associated to dysbiosis, it is prevalent in the elderly population 5947 
and it is a risk factor for morbidity. Apart from examining the potential of GMP to 5948 
sustain the phylogenetic diversity of the “frail” microbiota, we exposed a major 5949 
limitation in the use of low-diversity faecal samples in in vitro models. Reduced 5950 
diversity can lead to reduced responsiveness of the microbiota, translating into fewer 5951 
competent taxa being overrepresented in the compositional profile after fermentation, 5952 
as seen in Chapter 2 figures.  5953 
This observation could be reflecting “real life” observations from other studies: low 5954 
richness faecal microbiota (measured by alpha diversity, species diversity indexes 5955 
and gene counts) in obese subjects, was not only predictive of disease but also of low 5956 
responsiveness to dietary intervention (Cotillard et al., 2013; Le Chatelier et al., 5957 
2013). Some restoration of microbiota dysbiosis was achieved by dietary 5958 
intervention but the underlying low-grade inflammation was not significantly 5959 
ameliorated (Cotillard et al., 2013), implying that low species richness leads to low 5960 
metabolic potential (e.g. SCFA production) through limited functional redundancy in 5961 
the microbiota.  5962 
In spite of the limitations, in vitro colon models can be a valuable tool for the study 5963 
of the modulation of the “frail” microbiota. One improvement for future studies is 5964 
the use of a rich basal medium which can be supplemented with the test substrate 5965 
(similar to the one used in Chapter 4). The adaptation of the faecal microbiota in in 5966 
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vitro systems comes with the reduction of the alpha diversity (discussed in Chapters 5967 
1.2 and 2); a rich basal medium may be necessary when using microbiota with 5968 
reduced diversity in order to sustain the maximum portion of the baseline diversity 5969 
and therefore, its dynamics and functionality.  5970 
In Chapter 2, I discussed the choice not to pool the faecal samples that were used. An 5971 
interesting adjustment in the study design for future experiments, would be the 5972 
pooling of “frail” microbiotas following the rationale of Zaneveld et al. (2017). The 5973 
comparative analysis of the responsiveness of the pooled “frail” faecal microbiota 5974 
against single-donor “frail” microbiotas could reveal whether the observed changes 5975 
are reproducible or stochastic because in the pooled microbiota the stochastic 5976 
responses may be minimised (Zaneveld et al. 2017).  5977 
In Chapter 3, I described the preclinical trial where the potential of milk and GMP to 5978 
modulate the gut microbiota was examined in an in vivo colon model of humanised 5979 
mice. With the preclinical trial we aimed at evaluating the findings of the in vitro 5980 
trial with regard to GMP prebiotic activity, and at performing an in-depth profiling 5981 
of the changes that milk confers on the gut microbiota and thus, to provide evidence 5982 
for health benefits of milk consumption through its potential prebiotic activity.  5983 
In the mouse model used here, we found that lactose free milk was the most efficient 5984 
in retaining gut microbiota diversity equally to or followed by soy-protein control 5985 
diet. Although whole milk retained higher microbiota diversity compared to GMP, 5986 
no significant differences were detected between the two feeding regimes. 5987 
Importantly, both milk diets positively affected the relative abundance of health-5988 
relevant taxa such as R. bromii, in a gender-dependent manner. Same gender mice 5989 
are often used in microbiome studies in order to obtain more homogenous results. 5990 
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However, it is important to address gender variations not only in murine studies 5991 
(Wang et al., 2016; Fransen et al., 2017) but also in human studies in order to 5992 
identify the extent of the impact of the endocrine system on the gut microbiota inter-5993 
individual variation and therefore, illuminate another aspect of the gut microbiota 5994 
dynamics (Neuman et al., 2015). 5995 
The inherent limitations of the mouse model used in Chapter 3 experiments 5996 
(analysed in Chapters 1.2, 3), generated some questions that may be reducing the 5997 
translatability of the results. For example, the murine gut favours the establishment 5998 
and prevalence of xenomicrobiota Bacteroidetes including Bacteroidaceae and 5999 
Porphyromonadaceae, whereas it is refractory to Firmicutes / Lachnospiraceae 6000 
xenomicrobiota colonisation (reviewed in Chapter 1.2). Glycomacropeptide contains 6001 
a high portion of sialic acid that, as discussed in Chapter 3, may promote the growth 6002 
of Bacteroidetes taxa. Therefore, testing a potentially Bacteroidetes promoting 6003 
substrate in a gut microbiota model that is “biased” towards Bacteroidetes 6004 
enrichment, may not have been the most useful approach for identifying the prebiotic 6005 
potential of GMP. Importantly, it was the milk diets that led to the smallest 6006 
Bacteroidetes/Firmicutes ratio, tipping the scale towards an increased Firmicutes 6007 
relative abundance. However, because of the poor Lachnospiraceae colonisation (e.g. 6008 
Figures 18 and 21) we could not identify effects on a wide range of Lachnospiraceae 6009 
taxa. 6010 
It has been proposed that for the investigation of the effect of diet on the gut 6011 
microbiota, the use of conventional mice with their intact indigenous gut microbiota 6012 
and full-range taxonomic representation may be a more informative approach 6013 
compared to conventionalisation or humanisation (Arrieta et al., 2016). In spite of 6014 
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limitations of the study model, the promising findings of our pre-clinical trial 6015 
coupled with the fact that most of the cohort studies indicate the health benefits of 6016 
moderate milk consumption, warrant a human trial searching for microbiota effects. 6017 
Importantly, mice like other rodents, may not fully tolerate lactose (de Heijning et al., 6018 
2015) and it can be inferred that the differential effect of the two types of milk on the 6019 
gut microbiota described in Chapter 3, is due to the presence or absence of residual 6020 
lactose reaching the colon. In LP humans, lactose is fully digested and absorbed in 6021 
the small intestine. Whether or not this means that lactose free milk and whole milk 6022 
have similar gut microbiota modulatory effect in LP humans, remains to be 6023 
investigated in a clinical trial. Furthermore, because LNP subjects can tolerate an 6024 
average of 1 glass of whole milk per day, it would be also interesting to further 6025 
investigate the prebiotic potential of whole milk in LNP subjects.  6026 
Another interesting question in the search of the effect of milk on the gut microbiota 6027 
is if different lactose free milk preparations have the same effect on the human gut 6028 
microbiota composition. The lactose-free milk used in Chapter 3 was prepared after 6029 
lactose was filtered and the remaining lactose was hydrolysed 6030 
(https://www.valio.com/articles/lactose-intolerance-is-real-and-common/). Other 6031 
preparations involve only lactose hydrolysation to glucose and galactose. Potentially, 6032 
low load of simple sugar (e.g. the case of filtered lactose free milk preparations) 6033 
reaching the small intestine microbiota that competes with the human host for the 6034 
uptake of these compounds, can affect the downstream microbiota dynamics 6035 
differentially to higher simple sugar load (Zoetendal et al., 2012; Marinez-Guryn et 6036 
al., 2018).  6037 
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In Chapter 4, I described the exploratory experiments towards identifying the in vitro 6038 
effect of the blueberry powder on the gut microbiota of elderly subjects and the 6039 
bacterial consortium MCC100. We hypothesised that the high sugar content (e.g. 6040 
fructose) of the blueberry powder, resulted in enrichment of the microbiota in 6041 
streptococci as these organisms are known to be fast utilisers of simple sugars 6042 
(Zoetendal et al., 2018). Only the presence of bifidobacteria outcompeted 6043 
streptococci in the utilisation of the provided substrates, showing the importance of 6044 
the baseline microbiota in the responsiveness to the dietary substrates. Interestingly, 6045 
bifidobacteria taxa were present at baseline in one of the two LS microbiotas used; 6046 
however, they failed to respond to supplementation similarly to what observed when 6047 
present in the COM type microbiota. If this is an indication of deregulated 6048 
microbiota “universality” remains to be further examined in future experiments in 6049 
vitro experiments using both faecal and artificial microbiotas.  6050 
A multi-stage fermenter involving compartmentalisation of interconnected vessels 6051 
with different pH mimicking parts of the GIT might have allowed for fastidiously 6052 
growing fibre utilisers to grow; under in vivo conditions, simple sugars would have 6053 
been digested or absorbed in the upper parts of the GIT. Results of the phenolic 6054 
compound chemical analysis are awaited. In future experiments that will complete 6055 
this exploratory work, isolated phenolic compounds will be used in in vitro 6056 
fermentation experiments in order to identify specific microbiota changes caused by 6057 
selected phenolic compound supplementation free of complicating sugars being 6058 
present.  6059 
The artificial consortium was assembled by our laboratory in order to mimic the 6060 
faecal microbiota of a healthy adult. The 100 selected strains belong to the laboratory 6061 
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microbiome collection of faecal bacteria isolated from healthy donors; the isolation 6062 
work was part of this PhD research. A manuscript with details on consortium 6063 
assembly and relevant further work is in preparation as mentioned in Chapter 4 6064 
(Materials and Methods). As discussed before (Chapters 1, 5), the use of minimal 6065 
synthetic microbiotas is expected to facilitate diet-microbiota research. To my 6066 
knowledge, this is a first attempt to use a minimal “healthy” faecal microbiota in the 6067 
study of the effect of diet on the microbiota. Future experiments with isolated 6068 
phenolic compounds and potentially with consortia that will mimic microbiotas of 6069 
different enterotypes are expected to elucidate the role and associations of various 6070 
gut microbiota members in the metabolism of dietary polyphenols and other dietary 6071 
components with potential prebiotic activity.   6072 
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